#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Gray matter morphological anomalies in the cerebellar vermis in first-episode schizophrenia patients with cognitive deficits
#Text=Background
#Text=Cognitive deficits are a core feature of early schizophrenia.
1-1	0-4	Gray	_
1-2	5-11	matter	_
1-3	12-25	morphological	_
1-4	26-35	anomalies	_
1-5	36-38	in	_
1-6	39-42	the	_
1-7	43-53	cerebellar	_
1-8	54-60	vermis	_
1-9	61-63	in	_
1-10	64-77	first-episode	_
1-11	78-91	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-12	92-100	patients	_
1-13	101-105	with	_
1-14	106-115	cognitive	_
1-15	116-124	deficits	_
1-16	125-135	Background	_
1-17	136-145	Cognitive	_
1-18	146-154	deficits	_
1-19	155-158	are	_
1-20	159-160	a	_
1-21	161-165	core	_
1-22	166-173	feature	_
1-23	174-176	of	_
1-24	177-182	early	_
1-25	183-196	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-26	196-197	.	_

#Text=However, the pathological foundations underlying cognitive deficits are still unknown.
2-1	198-205	However	_
2-2	205-206	,	_
2-3	207-210	the	_
2-4	211-223	pathological	_
2-5	224-235	foundations	_
2-6	236-246	underlying	_
2-7	247-256	cognitive	_
2-8	257-265	deficits	_
2-9	266-269	are	_
2-10	270-275	still	_
2-11	276-283	unknown	_
2-12	283-284	.	_

#Text=The present study examined the association between gray matter density and cognitive deficits in first-episode schizophrenia.
3-1	285-288	The	_
3-2	289-296	present	_
3-3	297-302	study	_
3-4	303-311	examined	_
3-5	312-315	the	_
3-6	316-327	association	_
3-7	328-335	between	_
3-8	336-340	gray	_
3-9	341-347	matter	_
3-10	348-355	density	_
3-11	356-359	and	_
3-12	360-369	cognitive	_
3-13	370-378	deficits	_
3-14	379-381	in	_
3-15	382-395	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[1]
3-16	396-409	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[1]
3-17	409-410	.	_

#Text=Method
#Text=Structural magnetic resonance imaging of the brain was performed in 34 first-episode schizophrenia patients and 21 healthy controls.
4-1	411-417	Method	_
4-2	418-428	Structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[2]
4-3	429-437	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[2]
4-4	438-447	resonance	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[2]
4-5	448-455	imaging	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[2]
4-6	456-458	of	_
4-7	459-462	the	_
4-8	463-468	brain	_
4-9	469-472	was	_
4-10	473-482	performed	_
4-11	483-485	in	_
4-12	486-488	34	_
4-13	489-502	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]
4-14	503-516	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]
4-15	517-525	patients	_
4-16	526-529	and	_
4-17	530-532	21	_
4-18	533-540	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]
4-19	541-549	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]
4-20	549-550	.	_

#Text=Patients were divided into two subgroups according to working memory task performance.
5-1	551-559	Patients	_
5-2	560-564	were	_
5-3	565-572	divided	_
5-4	573-577	into	_
5-5	578-581	two	_
5-6	582-591	subgroups	_
5-7	592-601	according	_
5-8	602-604	to	_
5-9	605-612	working	_
5-10	613-619	memory	_
5-11	620-624	task	_
5-12	625-636	performance	_
5-13	636-637	.	_

#Text=The three groups were well matched for age, gender, and education, and the two patient groups were also further matched for diagnosis, duration of illness, and antipsychotic treatment.
6-1	638-641	The	_
6-2	642-647	three	_
6-3	648-654	groups	_
6-4	655-659	were	_
6-5	660-664	well	_
6-6	665-672	matched	_
6-7	673-676	for	_
6-8	677-680	age	_
6-9	680-681	,	_
6-10	682-688	gender	_
6-11	688-689	,	_
6-12	690-693	and	_
6-13	694-703	education	_
6-14	703-704	,	_
6-15	705-708	and	_
6-16	709-712	the	_
6-17	713-716	two	_
6-18	717-724	patient	_
6-19	725-731	groups	_
6-20	732-736	were	_
6-21	737-741	also	_
6-22	742-749	further	_
6-23	750-757	matched	_
6-24	758-761	for	_
6-25	762-771	diagnosis	_
6-26	771-772	,	_
6-27	773-781	duration	_
6-28	782-784	of	_
6-29	785-792	illness	_
6-30	792-793	,	_
6-31	794-797	and	_
6-32	798-811	antipsychotic	_
6-33	812-821	treatment	_
6-34	821-822	.	_

#Text=Voxel-based morphometric analysis was performed to estimate changes in gray matter density in first-episode schizophrenia patients with cognitive deficits.
7-1	823-834	Voxel-based	_
7-2	835-847	morphometric	_
7-3	848-856	analysis	_
7-4	857-860	was	_
7-5	861-870	performed	_
7-6	871-873	to	_
7-7	874-882	estimate	_
7-8	883-890	changes	_
7-9	891-893	in	_
7-10	894-898	gray	_
7-11	899-905	matter	_
7-12	906-913	density	_
7-13	914-916	in	_
7-14	917-930	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[5]
7-15	931-944	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[5]
7-16	945-953	patients	_
7-17	954-958	with	_
7-18	959-968	cognitive	_
7-19	969-977	deficits	_
7-20	977-978	.	_

#Text=The relationships between gray matter density and clinical outcomes were explored.
8-1	979-982	The	_
8-2	983-996	relationships	_
8-3	997-1004	between	_
8-4	1005-1009	gray	_
8-5	1010-1016	matter	_
8-6	1017-1024	density	_
8-7	1025-1028	and	_
8-8	1029-1037	clinical	_
8-9	1038-1046	outcomes	_
8-10	1047-1051	were	_
8-11	1052-1060	explored	_
8-12	1060-1061	.	_

#Text=Results
#Text=Patients with cognitive deficits were found to have reduced gray matter density in the vermis and tonsil of cerebellum compared with patients without cognitive deficits and healthy controls, decreased gray matter density in left supplementary motor area, bilateral precentral gyrus compared with patients without cognitive deficits.
9-1	1062-1069	Results	_
9-2	1070-1078	Patients	_
9-3	1079-1083	with	_
9-4	1084-1093	cognitive	_
9-5	1094-1102	deficits	_
9-6	1103-1107	were	_
9-7	1108-1113	found	_
9-8	1114-1116	to	_
9-9	1117-1121	have	_
9-10	1122-1129	reduced	_
9-11	1130-1134	gray	_
9-12	1135-1141	matter	_
9-13	1142-1149	density	_
9-14	1150-1152	in	_
9-15	1153-1156	the	_
9-16	1157-1163	vermis	_
9-17	1164-1167	and	_
9-18	1168-1174	tonsil	_
9-19	1175-1177	of	_
9-20	1178-1188	cerebellum	_
9-21	1189-1197	compared	_
9-22	1198-1202	with	_
9-23	1203-1211	patients	_
9-24	1212-1219	without	_
9-25	1220-1229	cognitive	_
9-26	1230-1238	deficits	_
9-27	1239-1242	and	_
9-28	1243-1250	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]
9-29	1251-1259	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]
9-30	1259-1260	,	_
9-31	1261-1270	decreased	_
9-32	1271-1275	gray	_
9-33	1276-1282	matter	_
9-34	1283-1290	density	_
9-35	1291-1293	in	_
9-36	1294-1298	left	_
9-37	1299-1312	supplementary	_
9-38	1313-1318	motor	_
9-39	1319-1323	area	_
9-40	1323-1324	,	_
9-41	1325-1334	bilateral	_
9-42	1335-1345	precentral	_
9-43	1346-1351	gyrus	_
9-44	1352-1360	compared	_
9-45	1361-1365	with	_
9-46	1366-1374	patients	_
9-47	1375-1382	without	_
9-48	1383-1392	cognitive	_
9-49	1393-1401	deficits	_
9-50	1401-1402	.	_

#Text=Classifier results showed GMD in cerebellar vermis tonsil cluster could differentiate SZ-CD from controls, left supplementary motor area cluster could differentiate SZ-CD from SZ-NCD.
10-1	1403-1413	Classifier	_
10-2	1414-1421	results	_
10-3	1422-1428	showed	_
10-4	1429-1432	GMD	_
10-5	1433-1435	in	_
10-6	1436-1446	cerebellar	_
10-7	1447-1453	vermis	_
10-8	1454-1460	tonsil	_
10-9	1461-1468	cluster	_
10-10	1469-1474	could	_
10-11	1475-1488	differentiate	_
10-12	1489-1494	SZ-CD	_
10-13	1495-1499	from	_
10-14	1500-1508	controls	_
10-15	1508-1509	,	_
10-16	1510-1514	left	_
10-17	1515-1528	supplementary	_
10-18	1529-1534	motor	_
10-19	1535-1539	area	_
10-20	1540-1547	cluster	_
10-21	1548-1553	could	_
10-22	1554-1567	differentiate	_
10-23	1568-1573	SZ-CD	_
10-24	1574-1578	from	_
10-25	1579-1585	SZ-NCD	_
10-26	1585-1586	.	_

#Text=Gray matter density values of the cerebellar vermis cluster in patients groups were positively correlated with cognitive severity.
11-1	1587-1591	Gray	_
11-2	1592-1598	matter	_
11-3	1599-1606	density	_
11-4	1607-1613	values	_
11-5	1614-1616	of	_
11-6	1617-1620	the	_
11-7	1621-1631	cerebellar	_
11-8	1632-1638	vermis	_
11-9	1639-1646	cluster	_
11-10	1647-1649	in	_
11-11	1650-1658	patients	_
11-12	1659-1665	groups	_
11-13	1666-1670	were	_
11-14	1671-1681	positively	_
11-15	1682-1692	correlated	_
11-16	1693-1697	with	_
11-17	1698-1707	cognitive	_
11-18	1708-1716	severity	_
11-19	1716-1717	.	_

#Text=Conclusions
#Text=Decreased gray matter density in the vermis and tonsil of cerebellum may underlie early psychosis and serve as a candidate biomarker for schizophrenia with cognitive deficits.
12-1	1718-1729	Conclusions	_
12-2	1730-1739	Decreased	_
12-3	1740-1744	gray	_
12-4	1745-1751	matter	_
12-5	1752-1759	density	_
12-6	1760-1762	in	_
12-7	1763-1766	the	_
12-8	1767-1773	vermis	_
12-9	1774-1777	and	_
12-10	1778-1784	tonsil	_
12-11	1785-1787	of	_
12-12	1788-1798	cerebellum	_
12-13	1799-1802	may	_
12-14	1803-1811	underlie	_
12-15	1812-1817	early	_
12-16	1818-1827	psychosis	_
12-17	1828-1831	and	_
12-18	1832-1837	serve	_
12-19	1838-1840	as	_
12-20	1841-1842	a	_
12-21	1843-1852	candidate	_
12-22	1853-1862	biomarker	_
12-23	1863-1866	for	_
12-24	1867-1880	schizophrenia	_
12-25	1881-1885	with	_
12-26	1886-1895	cognitive	_
12-27	1896-1904	deficits	_
12-28	1904-1905	.	_

#Text=Background
#Text=Cognitive deficits are one of the main symptoms in early schizophrenia and are especially marked in sustained attention, learning, processing speed, language, motor skills, and working memory.
13-1	1906-1916	Background	_
13-2	1917-1926	Cognitive	_
13-3	1927-1935	deficits	_
13-4	1936-1939	are	_
13-5	1940-1943	one	_
13-6	1944-1946	of	_
13-7	1947-1950	the	_
13-8	1951-1955	main	_
13-9	1956-1964	symptoms	_
13-10	1965-1967	in	_
13-11	1968-1973	early	_
13-12	1974-1987	schizophrenia	_
13-13	1988-1991	and	_
13-14	1992-1995	are	_
13-15	1996-2006	especially	_
13-16	2007-2013	marked	_
13-17	2014-2016	in	_
13-18	2017-2026	sustained	_
13-19	2027-2036	attention	_
13-20	2036-2037	,	_
13-21	2038-2046	learning	_
13-22	2046-2047	,	_
13-23	2048-2058	processing	_
13-24	2059-2064	speed	_
13-25	2064-2065	,	_
13-26	2066-2074	language	_
13-27	2074-2075	,	_
13-28	2076-2081	motor	_
13-29	2082-2088	skills	_
13-30	2088-2089	,	_
13-31	2090-2093	and	_
13-32	2094-2101	working	_
13-33	2102-2108	memory	_
13-34	2108-2109	.	_

#Text=Based on the limited impact of conventional antipsychotics on cognitive symptoms, there has been an interest in developing pharmacological treatments to target cognitive deficits.
14-1	2110-2115	Based	_
14-2	2116-2118	on	_
14-3	2119-2122	the	_
14-4	2123-2130	limited	_
14-5	2131-2137	impact	_
14-6	2138-2140	of	_
14-7	2141-2153	conventional	_
14-8	2154-2168	antipsychotics	_
14-9	2169-2171	on	_
14-10	2172-2181	cognitive	_
14-11	2182-2190	symptoms	_
14-12	2190-2191	,	_
14-13	2192-2197	there	_
14-14	2198-2201	has	_
14-15	2202-2206	been	_
14-16	2207-2209	an	_
14-17	2210-2218	interest	_
14-18	2219-2221	in	_
14-19	2222-2232	developing	_
14-20	2233-2248	pharmacological	_
14-21	2249-2259	treatments	_
14-22	2260-2262	to	_
14-23	2263-2269	target	_
14-24	2270-2279	cognitive	_
14-25	2280-2288	deficits	_
14-26	2288-2289	.	_

#Text=In addition, studies have shown that differences across abnormal types might be generated by different mechanisms.
15-1	2290-2292	In	_
15-2	2293-2301	addition	_
15-3	2301-2302	,	_
15-4	2303-2310	studies	_
15-5	2311-2315	have	_
15-6	2316-2321	shown	_
15-7	2322-2326	that	_
15-8	2327-2338	differences	_
15-9	2339-2345	across	_
15-10	2346-2354	abnormal	_
15-11	2355-2360	types	_
15-12	2361-2366	might	_
15-13	2367-2369	be	_
15-14	2370-2379	generated	_
15-15	2380-2382	by	_
15-16	2383-2392	different	_
15-17	2393-2403	mechanisms	_
15-18	2403-2404	.	_

#Text=Investigating the neural substrates of cognitive deficits is a clinically important endeavor that would provide insight into understanding cognitive deficits and new therapeutic targets.
16-1	2405-2418	Investigating	_
16-2	2419-2422	the	_
16-3	2423-2429	neural	_
16-4	2430-2440	substrates	_
16-5	2441-2443	of	_
16-6	2444-2453	cognitive	_
16-7	2454-2462	deficits	_
16-8	2463-2465	is	_
16-9	2466-2467	a	_
16-10	2468-2478	clinically	_
16-11	2479-2488	important	_
16-12	2489-2497	endeavor	_
16-13	2498-2502	that	_
16-14	2503-2508	would	_
16-15	2509-2516	provide	_
16-16	2517-2524	insight	_
16-17	2525-2529	into	_
16-18	2530-2543	understanding	_
16-19	2544-2553	cognitive	_
16-20	2554-2562	deficits	_
16-21	2563-2566	and	_
16-22	2567-2570	new	_
16-23	2571-2582	therapeutic	_
16-24	2583-2590	targets	_
16-25	2590-2591	.	_

#Text=Across multiple studies, patients who have relatively intact cognition comprise 20–25% of schizophrenia patients.
17-1	2592-2598	Across	_
17-2	2599-2607	multiple	_
17-3	2608-2615	studies	_
17-4	2615-2616	,	_
17-5	2617-2625	patients	_
17-6	2626-2629	who	_
17-7	2630-2634	have	_
17-8	2635-2645	relatively	_
17-9	2646-2652	intact	_
17-10	2653-2662	cognition	_
17-11	2663-2671	comprise	_
17-12	2672-2674	20	_
17-13	2674-2675	–	_
17-14	2675-2678	25%	_
17-15	2679-2681	of	_
17-16	2682-2695	schizophrenia	_
17-17	2696-2704	patients	_
17-18	2704-2705	.	_

#Text=However, the wide heterogeneity of schizophrenia patients could partially confuse the final conclusions of such studies.
18-1	2706-2713	However	_
18-2	2713-2714	,	_
18-3	2715-2718	the	_
18-4	2719-2723	wide	_
18-5	2724-2737	heterogeneity	_
18-6	2738-2740	of	_
18-7	2741-2754	schizophrenia	_
18-8	2755-2763	patients	_
18-9	2764-2769	could	_
18-10	2770-2779	partially	_
18-11	2780-2787	confuse	_
18-12	2788-2791	the	_
18-13	2792-2797	final	_
18-14	2798-2809	conclusions	_
18-15	2810-2812	of	_
18-16	2813-2817	such	_
18-17	2818-2825	studies	_
18-18	2825-2826	.	_

#Text=Some related studies have focused on cognitive deficits in schizophrenia.
19-1	2827-2831	Some	_
19-2	2832-2839	related	_
19-3	2840-2847	studies	_
19-4	2848-2852	have	_
19-5	2853-2860	focused	_
19-6	2861-2863	on	_
19-7	2864-2873	cognitive	_
19-8	2874-2882	deficits	_
19-9	2883-2885	in	_
19-10	2886-2899	schizophrenia	_
19-11	2899-2900	.	_

#Text=Based on a simplified comparison of brain regions, significantly smaller white matter volumes and larger lateral ventricle volumes have been found in schizophrenia patients with cognitive deficits relative to healthy subjects, but not in patients without cognitive deficits.
20-1	2901-2906	Based	_
20-2	2907-2909	on	_
20-3	2910-2911	a	_
20-4	2912-2922	simplified	_
20-5	2923-2933	comparison	_
20-6	2934-2936	of	_
20-7	2937-2942	brain	_
20-8	2943-2950	regions	_
20-9	2950-2951	,	_
20-10	2952-2965	significantly	_
20-11	2966-2973	smaller	_
20-12	2974-2979	white	_
20-13	2980-2986	matter	_
20-14	2987-2994	volumes	_
20-15	2995-2998	and	_
20-16	2999-3005	larger	_
20-17	3006-3013	lateral	_
20-18	3014-3023	ventricle	_
20-19	3024-3031	volumes	_
20-20	3032-3036	have	_
20-21	3037-3041	been	_
20-22	3042-3047	found	_
20-23	3048-3050	in	_
20-24	3051-3064	schizophrenia	_
20-25	3065-3073	patients	_
20-26	3074-3078	with	_
20-27	3079-3088	cognitive	_
20-28	3089-3097	deficits	_
20-29	3098-3106	relative	_
20-30	3107-3109	to	_
20-31	3110-3117	healthy	_
20-32	3118-3126	subjects	_
20-33	3126-3127	,	_
20-34	3128-3131	but	_
20-35	3132-3135	not	_
20-36	3136-3138	in	_
20-37	3139-3147	patients	_
20-38	3148-3155	without	_
20-39	3156-3165	cognitive	_
20-40	3166-3174	deficits	_
20-41	3174-3175	.	_

#Text=However, whole-brain voxel-based morphometry (VBM) failed to reveal a significant difference in gray and white matter volume between two subgroups of schizophrenia patients with 23 years of illness who were divided by cognitive ability.
21-1	3176-3183	However	_
21-2	3183-3184	,	_
21-3	3185-3196	whole-brain	_
21-4	3197-3208	voxel-based	_
21-5	3209-3220	morphometry	_
21-6	3221-3222	(	_
21-7	3222-3225	VBM	_
21-8	3225-3226	)	_
21-9	3227-3233	failed	_
21-10	3234-3236	to	_
21-11	3237-3243	reveal	_
21-12	3244-3245	a	_
21-13	3246-3257	significant	_
21-14	3258-3268	difference	_
21-15	3269-3271	in	_
21-16	3272-3276	gray	_
21-17	3277-3280	and	_
21-18	3281-3286	white	_
21-19	3287-3293	matter	_
21-20	3294-3300	volume	_
21-21	3301-3308	between	_
21-22	3309-3312	two	_
21-23	3313-3322	subgroups	_
21-24	3323-3325	of	_
21-25	3326-3339	schizophrenia	_
21-26	3340-3348	patients	_
21-27	3349-3353	with	_
21-28	3354-3356	23	_
21-29	3356-3357	 	_
21-30	3357-3362	years	_
21-31	3363-3365	of	_
21-32	3366-3373	illness	_
21-33	3374-3377	who	_
21-34	3378-3382	were	_
21-35	3383-3390	divided	_
21-36	3391-3393	by	_
21-37	3394-3403	cognitive	_
21-38	3404-3411	ability	_
21-39	3411-3412	.	_

#Text=Furthermore no significant difference was found in white matter integrity between schizophrenia patients with and without cognitive deficits based on diffusion tensor imaging.
22-1	3413-3424	Furthermore	_
22-2	3425-3427	no	_
22-3	3428-3439	significant	_
22-4	3440-3450	difference	_
22-5	3451-3454	was	_
22-6	3455-3460	found	_
22-7	3461-3463	in	_
22-8	3464-3469	white	_
22-9	3470-3476	matter	_
22-10	3477-3486	integrity	_
22-11	3487-3494	between	_
22-12	3495-3508	schizophrenia	_
22-13	3509-3517	patients	_
22-14	3518-3522	with	_
22-15	3523-3526	and	_
22-16	3527-3534	without	_
22-17	3535-3544	cognitive	_
22-18	3545-3553	deficits	_
22-19	3554-3559	based	_
22-20	3560-3562	on	_
22-21	3563-3572	diffusion	_
22-22	3573-3579	tensor	_
22-23	3580-3587	imaging	_
22-24	3587-3588	.	_

#Text=Although prior studies have considered symptom diversity as an influential factor, there has been inconsistency among findings.
23-1	3589-3597	Although	_
23-2	3598-3603	prior	_
23-3	3604-3611	studies	_
23-4	3612-3616	have	_
23-5	3617-3627	considered	_
23-6	3628-3635	symptom	_
23-7	3636-3645	diversity	_
23-8	3646-3648	as	_
23-9	3649-3651	an	_
23-10	3652-3663	influential	_
23-11	3664-3670	factor	_
23-12	3670-3671	,	_
23-13	3672-3677	there	_
23-14	3678-3681	has	_
23-15	3682-3686	been	_
23-16	3687-3700	inconsistency	_
23-17	3701-3706	among	_
23-18	3707-3715	findings	_
23-19	3715-3716	.	_

#Text=To obtain more reliable results, we made improvements in the study design from two aspects.
24-1	3717-3719	To	_
24-2	3720-3726	obtain	_
24-3	3727-3731	more	_
24-4	3732-3740	reliable	_
24-5	3741-3748	results	_
24-6	3748-3749	,	_
24-7	3750-3752	we	_
24-8	3753-3757	made	_
24-9	3758-3770	improvements	_
24-10	3771-3773	in	_
24-11	3774-3777	the	_
24-12	3778-3783	study	_
24-13	3784-3790	design	_
24-14	3791-3795	from	_
24-15	3796-3799	two	_
24-16	3800-3807	aspects	_
24-17	3807-3808	.	_

#Text=First, the subgroup derivation rules were updated.
25-1	3809-3814	First	_
25-2	3814-3815	,	_
25-3	3816-3819	the	_
25-4	3820-3828	subgroup	_
25-5	3829-3839	derivation	_
25-6	3840-3845	rules	_
25-7	3846-3850	were	_
25-8	3851-3858	updated	_
25-9	3858-3859	.	_

#Text=Based on task accuracy, patients were divided into two subgroups: 1) schizophrenia patients with cognitive deficits (SZ-CD); 2) schizophrenia patients with no cognitive deficits (SZ-NCD).
26-1	3860-3865	Based	_
26-2	3866-3868	on	_
26-3	3869-3873	task	_
26-4	3874-3882	accuracy	_
26-5	3882-3883	,	_
26-6	3884-3892	patients	_
26-7	3893-3897	were	_
26-8	3898-3905	divided	_
26-9	3906-3910	into	_
26-10	3911-3914	two	_
26-11	3915-3924	subgroups	_
26-12	3924-3925	:	_
26-13	3926-3927	1	_
26-14	3927-3928	)	_
26-15	3929-3942	schizophrenia	_
26-16	3943-3951	patients	_
26-17	3952-3956	with	_
26-18	3957-3966	cognitive	_
26-19	3967-3975	deficits	_
26-20	3976-3977	(	_
26-21	3977-3982	SZ-CD	_
26-22	3982-3983	)	_
26-23	3983-3984	;	_
26-24	3985-3986	2	_
26-25	3986-3987	)	_
26-26	3988-4001	schizophrenia	_
26-27	4002-4010	patients	_
26-28	4011-4015	with	_
26-29	4016-4018	no	_
26-30	4019-4028	cognitive	_
26-31	4029-4037	deficits	_
26-32	4038-4039	(	_
26-33	4039-4045	SZ-NCD	_
26-34	4045-4046	)	_
26-35	4046-4047	.	_

#Text=In addition, we also validated the results using other clinical assessments.
27-1	4048-4050	In	_
27-2	4051-4059	addition	_
27-3	4059-4060	,	_
27-4	4061-4063	we	_
27-5	4064-4068	also	_
27-6	4069-4078	validated	_
27-7	4079-4082	the	_
27-8	4083-4090	results	_
27-9	4091-4096	using	_
27-10	4097-4102	other	_
27-11	4103-4111	clinical	_
27-12	4112-4123	assessments	_
27-13	4123-4124	.	_

#Text=Second, we recruited first-episode schizophrenia patients to minimize the confounding factor of illness course and antipsychotic medication use.
28-1	4125-4131	Second	_
28-2	4131-4132	,	_
28-3	4133-4135	we	_
28-4	4136-4145	recruited	_
28-5	4146-4159	first-episode	_
28-6	4160-4173	schizophrenia	_
28-7	4174-4182	patients	_
28-8	4183-4185	to	_
28-9	4186-4194	minimize	_
28-10	4195-4198	the	_
28-11	4199-4210	confounding	_
28-12	4211-4217	factor	_
28-13	4218-4220	of	_
28-14	4221-4228	illness	_
28-15	4229-4235	course	_
28-16	4236-4239	and	_
28-17	4240-4253	antipsychotic	_
28-18	4254-4264	medication	_
28-19	4265-4268	use	_
28-20	4268-4269	.	_

#Text=In the present study, we modified the subgroup derivation rules to recruit eighteen first-episode SZ-CD patients, sixteen first-episode SZ-NCD patients, and twenty-one healthy controls (HCs).
29-1	4270-4272	In	_
29-2	4273-4276	the	_
29-3	4277-4284	present	_
29-4	4285-4290	study	_
29-5	4290-4291	,	_
29-6	4292-4294	we	_
29-7	4295-4303	modified	_
29-8	4304-4307	the	_
29-9	4308-4316	subgroup	_
29-10	4317-4327	derivation	_
29-11	4328-4333	rules	_
29-12	4334-4336	to	_
29-13	4337-4344	recruit	_
29-14	4345-4353	eighteen	_
29-15	4354-4367	first-episode	_
29-16	4368-4373	SZ-CD	_
29-17	4374-4382	patients	_
29-18	4382-4383	,	_
29-19	4384-4391	sixteen	_
29-20	4392-4405	first-episode	_
29-21	4406-4412	SZ-NCD	_
29-22	4413-4421	patients	_
29-23	4421-4422	,	_
29-24	4423-4426	and	_
29-25	4427-4437	twenty-one	_
29-26	4438-4445	healthy	_
29-27	4446-4454	controls	_
29-28	4455-4456	(	_
29-29	4456-4459	HCs	_
29-30	4459-4460	)	_
29-31	4460-4461	.	_

#Text=Gray matter density (GMD) had been reported to be more consistent and sensitive in the schizophrenia patients and characterized as brain structure biomarkers for the psychosis biotypes.
30-1	4462-4466	Gray	_
30-2	4467-4473	matter	_
30-3	4474-4481	density	_
30-4	4482-4483	(	_
30-5	4483-4486	GMD	_
30-6	4486-4487	)	_
30-7	4488-4491	had	_
30-8	4492-4496	been	_
30-9	4497-4505	reported	_
30-10	4506-4508	to	_
30-11	4509-4511	be	_
30-12	4512-4516	more	_
30-13	4517-4527	consistent	_
30-14	4528-4531	and	_
30-15	4532-4541	sensitive	_
30-16	4542-4544	in	_
30-17	4545-4548	the	_
30-18	4549-4562	schizophrenia	_
30-19	4563-4571	patients	_
30-20	4572-4575	and	_
30-21	4576-4589	characterized	_
30-22	4590-4592	as	_
30-23	4593-4598	brain	_
30-24	4599-4608	structure	_
30-25	4609-4619	biomarkers	_
30-26	4620-4623	for	_
30-27	4624-4627	the	_
30-28	4628-4637	psychosis	_
30-29	4638-4646	biotypes	_
30-30	4646-4647	.	_

#Text=We focused on characterizing changes in GMD in first-episode schizophrenia patients with and without cognitive deficits.
31-1	4648-4650	We	_
31-2	4651-4658	focused	_
31-3	4659-4661	on	_
31-4	4662-4676	characterizing	_
31-5	4677-4684	changes	_
31-6	4685-4687	in	_
31-7	4688-4691	GMD	_
31-8	4692-4694	in	_
31-9	4695-4708	first-episode	_
31-10	4709-4722	schizophrenia	_
31-11	4723-4731	patients	_
31-12	4732-4736	with	_
31-13	4737-4740	and	_
31-14	4741-4748	without	_
31-15	4749-4758	cognitive	_
31-16	4759-4767	deficits	_
31-17	4767-4768	.	_

#Text=Methods
#Text=Subjects
#Text=We recruited fifty-eight right-handed participants.
32-1	4769-4776	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod
32-2	4777-4785	Subjects	_
32-3	4786-4788	We	_
32-4	4789-4798	recruited	_
32-5	4799-4810	fifty-eight	_
32-6	4811-4823	right-handed	_
32-7	4824-4836	participants	_
32-8	4836-4837	.	_

#Text=Among them, thirty-seven first-episode patients determined by the Structured Clinical Interview for Diagnostic and Statistical Manual for Mental Disorders Fourth Edition (DSM-IV) Axis I Disorders, Patient Edition (SCID-I/P), were recruited from the Department of Psychiatry, Second Xiangya Hospital of Central South University, Changsha, China.
33-1	4838-4843	Among	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
33-2	4844-4848	them	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
33-3	4848-4849	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
33-4	4850-4862	thirty-seven	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
33-5	4863-4876	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[8]
33-6	4877-4885	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[8]
33-7	4886-4896	determined	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
33-8	4897-4899	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
33-9	4900-4903	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
33-10	4904-4914	Structured	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[9]
33-11	4915-4923	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[9]
33-12	4924-4933	Interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[9]
33-13	4934-4937	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[9]
33-14	4938-4948	Diagnostic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[9]
33-15	4949-4952	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[9]
33-16	4953-4964	Statistical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[9]
33-17	4965-4971	Manual	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[9]
33-18	4972-4975	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[9]
33-19	4976-4982	Mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[9]
33-20	4983-4992	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[9]
33-21	4993-4999	Fourth	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[9]
33-22	5000-5007	Edition	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[9]
33-23	5008-5009	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[9]
33-24	5009-5015	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[9]
33-25	5015-5016	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[9]
33-26	5017-5021	Axis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[9]
33-27	5022-5023	I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[9]
33-28	5024-5033	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[9]
33-29	5033-5034	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[9]
33-30	5035-5042	Patient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[9]
33-31	5043-5050	Edition	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[9]
33-32	5051-5052	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[9]
33-33	5052-5058	SCID-I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[9]
33-34	5058-5059	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[9]
33-35	5059-5060	P	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[9]
33-36	5060-5061	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[9]
33-37	5061-5062	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
33-38	5063-5067	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
33-39	5068-5077	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
33-40	5078-5082	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
33-41	5083-5086	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
33-42	5087-5097	Department	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
33-43	5098-5100	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
33-44	5101-5111	Psychiatry	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
33-45	5111-5112	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
33-46	5113-5119	Second	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
33-47	5120-5127	Xiangya	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
33-48	5128-5136	Hospital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
33-49	5137-5139	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
33-50	5140-5147	Central	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
33-51	5148-5153	South	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
33-52	5154-5164	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
33-53	5164-5165	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
33-54	5166-5174	Changsha	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
33-55	5174-5175	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
33-56	5176-5181	China	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
33-57	5181-5182	.	_

#Text=We required all patients to have at least 9 years of education, to have been diagnosed with schizophrenia within the past 18 months, and to have no history of chronic neurological disease, substance abuse, electroconvulsive therapy, severe medical disorder or antidepressant.
34-1	5183-5185	We	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-2	5186-5194	required	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-3	5195-5198	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-4	5199-5207	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-5	5208-5210	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-6	5211-5215	have	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-7	5216-5218	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-8	5219-5224	least	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-9	5225-5226	9	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-10	5226-5227	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-11	5227-5232	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-12	5233-5235	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-13	5236-5245	education	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-14	5245-5246	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-15	5247-5249	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-16	5250-5254	have	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-17	5255-5259	been	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-18	5260-5269	diagnosed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-19	5270-5274	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-20	5275-5288	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-21	5289-5295	within	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-22	5296-5299	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-23	5300-5304	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-24	5305-5307	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-25	5307-5308	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-26	5308-5314	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-27	5314-5315	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-28	5316-5319	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-29	5320-5322	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-30	5323-5327	have	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-31	5328-5330	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-32	5331-5338	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-33	5339-5341	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-34	5342-5349	chronic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-35	5350-5362	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-36	5363-5370	disease	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-37	5370-5371	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-38	5372-5381	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-39	5382-5387	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-40	5387-5388	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-41	5389-5406	electroconvulsive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-42	5407-5414	therapy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-43	5414-5415	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-44	5416-5422	severe	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-45	5423-5430	medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-46	5431-5439	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-47	5440-5442	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-48	5443-5457	antidepressant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
34-49	5457-5458	.	_

#Text=In the month before functional Magnetic Resonance Imaging (fMRI), the positive and negative symptoms of each patient were independently assessed using the Scale for Assessment of Positive Symptoms (SAPS) and the Scale for the Assessment of Negative Symptoms (SANS).
35-1	5459-5461	In	_
35-2	5462-5465	the	_
35-3	5466-5471	month	_
35-4	5472-5478	before	_
35-5	5479-5489	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[11]
35-6	5490-5498	Magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[11]
35-7	5499-5508	Resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[11]
35-8	5509-5516	Imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[11]
35-9	5517-5518	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[11]
35-10	5518-5522	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[11]
35-11	5522-5523	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[11]
35-12	5523-5524	,	_
35-13	5525-5528	the	_
35-14	5529-5537	positive	_
35-15	5538-5541	and	_
35-16	5542-5550	negative	_
35-17	5551-5559	symptoms	_
35-18	5560-5562	of	_
35-19	5563-5567	each	_
35-20	5568-5575	patient	_
35-21	5576-5580	were	_
35-22	5581-5594	independently	_
35-23	5595-5603	assessed	_
35-24	5604-5609	using	_
35-25	5610-5613	the	_
35-26	5614-5619	Scale	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[12]
35-27	5620-5623	for	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[12]
35-28	5624-5634	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[12]
35-29	5635-5637	of	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[12]
35-30	5638-5646	Positive	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[12]
35-31	5647-5655	Symptoms	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[12]
35-32	5656-5657	(	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[12]
35-33	5657-5661	SAPS	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[12]
35-34	5661-5662	)	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[12]
35-35	5663-5666	and	_
35-36	5667-5670	the	_
35-37	5671-5676	Scale	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[13]
35-38	5677-5680	for	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[13]
35-39	5681-5684	the	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[13]
35-40	5685-5695	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[13]
35-41	5696-5698	of	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[13]
35-42	5699-5707	Negative	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[13]
35-43	5708-5716	Symptoms	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[13]
35-44	5717-5718	(	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[13]
35-45	5718-5722	SANS	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[13]
35-46	5722-5723	)	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[13]
35-47	5723-5724	.	_

#Text=Additionally, we also evaluated the cognitive function of all participants by using a parametric n-back task during the fMRI scan.
36-1	5725-5737	Additionally	_
36-2	5737-5738	,	_
36-3	5739-5741	we	_
36-4	5742-5746	also	_
36-5	5747-5756	evaluated	_
36-6	5757-5760	the	_
36-7	5761-5770	cognitive	_
36-8	5771-5779	function	_
36-9	5780-5782	of	_
36-10	5783-5786	all	_
36-11	5787-5799	participants	_
36-12	5800-5802	by	_
36-13	5803-5808	using	_
36-14	5809-5810	a	_
36-15	5811-5821	parametric	_
36-16	5822-5828	n-back	http://maven.renci.org/NeuroBridge/neurobridge#N-BackTaskTest[14]
36-17	5829-5833	task	http://maven.renci.org/NeuroBridge/neurobridge#N-BackTaskTest[14]
36-18	5834-5840	during	_
36-19	5841-5844	the	_
36-20	5845-5849	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
36-21	5850-5854	scan	_
36-22	5854-5855	.	_

#Text=Demographic and clinical characteristics of three groups
#Text=Demographics\tHCs\tSZ-NCD\tSZ-CD\tP\t \t10 M:11 F\t7 M:11 F\t11 M:5 F\t0.205\t \tMean ± SD\tMean ± SD\tMean ± SD\t\t \tAge(years)\t22.38 ± 3.94\t24.5 ± 6.70\t22.63 ± 6.71\t0.71\t \tEducation(years)\t13.33 ± 1.83\t12.39 ± 2.06\t12.16 ± 2.64\t0.78\t \tWAIS-Digital\t–\t71.53 ± 1.61\t58.69 ± 12.32\t0.02*\t \tWAIS-Information\t–\t18.92 ± 5.13\t15.1 ± 4.26\t0.03*\t \tDuration of illness (months)\t–\t8.25 ± 5.69\t8.27 ± 4.31\t0.83\t \tCPZ equivalents\t–\t238.89 ± 104.16\t375.12 ± 328.43\t0.14\t \tSAPS total\t–\t18.06 ± 8.62\t16.23 ± 8.46\t0.11\t \tSANS total\t–\t21.11 ± 23.74\t30.26 ± 2.54\t0.28\t \tAccuracy (%)a\t \t 2back\t84.60 ± 8.2875~94\t73.61 ± 7.6264~96\t54.78 ± 9.2640~72\t-\t \t 0back\t97.31 ± 1.8592~100\t95.89 ± 5.5278~100\t77.36 ± 8.3564~98\t\t \tReaction time (ms)b\t \t 2back\t625.60 ± 120.14427.72~911.41\t692.35 ± 119.49549.6~944.74\t729.35 ± 205.07581.02~1056.8\t-\t \t 0back\t482.29 ± 50.22383.46~585.06\t529.27 ± 76.18429.37~719.65\t553.11 ± 114.04466.47~857.02\t\t \t
#Text=
#Text=SD standard deviation, WAIS-Digital the Digit Symbol Substitution Test of the Wechsler Adult Intelligence Scale, WAIS-Information the information subscale of the Wechsler Adult Intelligence Scale, CPZ chlorpromazine, SAPS Scale for Assessment of Positive Symptoms, SANS, Scale for the Assessment of Negative Symptoms
#Text=*p<0.05 significant difference was found
#Text=
#Text=aThe raw cognitive scores were calculated as the average of the Target and Non-target accuracies in N back tasks
#Text=
#Text=bReaction time was calculated as the average of the Target and Non-target reaction time in N back tasks
#Text=Twenty-one right-handed HCs matched for age, sex, and years of education were recruited from the city of Changsha and were without past or present psychiatric, neurological, or other neurological disorders, as determined by an abbreviated version of the Comprehensive Assessment of Symptoms and History.
37-1	5856-5867	Demographic	_
37-2	5868-5871	and	_
37-3	5872-5880	clinical	_
37-4	5881-5896	characteristics	_
37-5	5897-5899	of	_
37-6	5900-5905	three	_
37-7	5906-5912	groups	_
37-8	5913-5925	Demographics	_
37-9	5926-5929	HCs	_
37-10	5930-5936	SZ-NCD	_
37-11	5937-5942	SZ-CD	_
37-12	5943-5944	P	_
37-13	5947-5949	10	_
37-14	5949-5950	 	_
37-15	5950-5951	M	_
37-16	5951-5952	:	_
37-17	5952-5954	11	_
37-18	5954-5955	 	_
37-19	5955-5956	F	_
37-20	5957-5958	7	_
37-21	5958-5959	 	_
37-22	5959-5960	M	_
37-23	5960-5961	:	_
37-24	5961-5963	11	_
37-25	5963-5964	 	_
37-26	5964-5965	F	_
37-27	5966-5968	11	_
37-28	5968-5969	 	_
37-29	5969-5970	M	_
37-30	5970-5971	:	_
37-31	5971-5972	5	_
37-32	5972-5973	 	_
37-33	5973-5974	F	_
37-34	5975-5980	0.205	_
37-35	5983-5987	Mean	_
37-36	5988-5989	±	_
37-37	5990-5992	SD	_
37-38	5993-5997	Mean	_
37-39	5998-5999	±	_
37-40	6000-6002	SD	_
37-41	6003-6007	Mean	_
37-42	6008-6009	±	_
37-43	6010-6012	SD	_
37-44	6016-6019	Age	_
37-45	6019-6020	(	_
37-46	6020-6025	years	_
37-47	6025-6026	)	_
37-48	6027-6032	22.38	_
37-49	6033-6034	±	_
37-50	6035-6039	3.94	_
37-51	6040-6044	24.5	_
37-52	6045-6046	±	_
37-53	6047-6051	6.70	_
37-54	6052-6057	22.63	_
37-55	6058-6059	±	_
37-56	6060-6064	6.71	_
37-57	6065-6069	0.71	_
37-58	6072-6081	Education	_
37-59	6081-6082	(	_
37-60	6082-6087	years	_
37-61	6087-6088	)	_
37-62	6089-6094	13.33	_
37-63	6095-6096	±	_
37-64	6097-6101	1.83	_
37-65	6102-6107	12.39	_
37-66	6108-6109	±	_
37-67	6110-6114	2.06	_
37-68	6115-6120	12.16	_
37-69	6121-6122	±	_
37-70	6123-6127	2.64	_
37-71	6128-6132	0.78	_
37-72	6135-6147	WAIS-Digital	_
37-73	6148-6149	–	_
37-74	6150-6155	71.53	_
37-75	6156-6157	±	_
37-76	6158-6162	1.61	_
37-77	6163-6168	58.69	_
37-78	6169-6170	±	_
37-79	6171-6176	12.32	_
37-80	6177-6181	0.02	_
37-81	6181-6182	*	_
37-82	6185-6201	WAIS-Information	_
37-83	6202-6203	–	_
37-84	6204-6209	18.92	_
37-85	6210-6211	±	_
37-86	6212-6216	5.13	_
37-87	6217-6221	15.1	_
37-88	6222-6223	±	_
37-89	6224-6228	4.26	_
37-90	6229-6233	0.03	_
37-91	6233-6234	*	_
37-92	6237-6245	Duration	_
37-93	6246-6248	of	_
37-94	6249-6256	illness	_
37-95	6257-6258	(	_
37-96	6258-6264	months	_
37-97	6264-6265	)	_
37-98	6266-6267	–	_
37-99	6268-6272	8.25	_
37-100	6273-6274	±	_
37-101	6275-6279	5.69	_
37-102	6280-6284	8.27	_
37-103	6285-6286	±	_
37-104	6287-6291	4.31	_
37-105	6292-6296	0.83	_
37-106	6299-6302	CPZ	_
37-107	6303-6314	equivalents	_
37-108	6315-6316	–	_
37-109	6317-6323	238.89	_
37-110	6324-6325	±	_
37-111	6326-6332	104.16	_
37-112	6333-6339	375.12	_
37-113	6340-6341	±	_
37-114	6342-6348	328.43	_
37-115	6349-6353	0.14	_
37-116	6356-6360	SAPS	_
37-117	6361-6366	total	_
37-118	6367-6368	–	_
37-119	6369-6374	18.06	_
37-120	6375-6376	±	_
37-121	6377-6381	8.62	_
37-122	6382-6387	16.23	_
37-123	6388-6389	±	_
37-124	6390-6394	8.46	_
37-125	6395-6399	0.11	_
37-126	6402-6406	SANS	_
37-127	6407-6412	total	_
37-128	6413-6414	–	_
37-129	6415-6420	21.11	_
37-130	6421-6422	±	_
37-131	6423-6428	23.74	_
37-132	6429-6434	30.26	_
37-133	6435-6436	±	_
37-134	6437-6441	2.54	_
37-135	6442-6446	0.28	_
37-136	6449-6457	Accuracy	_
37-137	6458-6459	(	_
37-138	6459-6460	%	_
37-139	6460-6461	)	_
37-140	6461-6462	a	_
37-141	6466-6471	2back	_
37-142	6472-6477	84.60	_
37-143	6478-6479	±	_
37-144	6480-6486	8.2875	_
37-145	6486-6487	~	_
37-146	6487-6489	94	_
37-147	6490-6495	73.61	_
37-148	6496-6497	±	_
37-149	6498-6504	7.6264	_
37-150	6504-6505	~	_
37-151	6505-6507	96	_
37-152	6508-6513	54.78	_
37-153	6514-6515	±	_
37-154	6516-6522	9.2640	_
37-155	6522-6523	~	_
37-156	6523-6525	72	_
37-157	6526-6527	-	_
37-158	6531-6536	0back	_
37-159	6537-6542	97.31	_
37-160	6543-6544	±	_
37-161	6545-6551	1.8592	_
37-162	6551-6552	~	_
37-163	6552-6555	100	_
37-164	6556-6561	95.89	_
37-165	6562-6563	±	_
37-166	6564-6570	5.5278	_
37-167	6570-6571	~	_
37-168	6571-6574	100	_
37-169	6575-6580	77.36	_
37-170	6581-6582	±	_
37-171	6583-6589	8.3564	_
37-172	6589-6590	~	_
37-173	6590-6592	98	_
37-174	6596-6604	Reaction	_
37-175	6605-6609	time	_
37-176	6610-6611	(	_
37-177	6611-6613	ms	_
37-178	6613-6614	)	_
37-179	6614-6615	b	_
37-180	6619-6624	2back	_
37-181	6625-6631	625.60	_
37-182	6632-6633	±	_
37-183	6634-6646	120.14427.72	_
37-184	6646-6647	~	_
37-185	6647-6653	911.41	_
37-186	6654-6660	692.35	_
37-187	6661-6662	±	_
37-188	6663-6674	119.49549.6	_
37-189	6674-6675	~	_
37-190	6675-6681	944.74	_
37-191	6682-6688	729.35	_
37-192	6689-6690	±	_
37-193	6691-6703	205.07581.02	_
37-194	6703-6704	~	_
37-195	6704-6710	1056.8	_
37-196	6711-6712	-	_
37-197	6716-6721	0back	_
37-198	6722-6728	482.29	_
37-199	6729-6730	±	_
37-200	6731-6742	50.22383.46	_
37-201	6742-6743	~	_
37-202	6743-6749	585.06	_
37-203	6750-6756	529.27	_
37-204	6757-6758	±	_
37-205	6759-6770	76.18429.37	_
37-206	6770-6771	~	_
37-207	6771-6777	719.65	_
37-208	6778-6784	553.11	_
37-209	6785-6786	±	_
37-210	6787-6799	114.04466.47	_
37-211	6799-6800	~	_
37-212	6800-6806	857.02	_
37-213	6812-6814	SD	_
37-214	6815-6823	standard	_
37-215	6824-6833	deviation	_
37-216	6833-6834	,	_
37-217	6835-6847	WAIS-Digital	_
37-218	6848-6851	the	_
37-219	6852-6857	Digit	_
37-220	6858-6864	Symbol	_
37-221	6865-6877	Substitution	_
37-222	6878-6882	Test	_
37-223	6883-6885	of	_
37-224	6886-6889	the	_
37-225	6890-6898	Wechsler	_
37-226	6899-6904	Adult	_
37-227	6905-6917	Intelligence	_
37-228	6918-6923	Scale	_
37-229	6923-6924	,	_
37-230	6925-6941	WAIS-Information	_
37-231	6942-6945	the	_
37-232	6946-6957	information	_
37-233	6958-6966	subscale	_
37-234	6967-6969	of	_
37-235	6970-6973	the	_
37-236	6974-6982	Wechsler	_
37-237	6983-6988	Adult	_
37-238	6989-7001	Intelligence	_
37-239	7002-7007	Scale	_
37-240	7007-7008	,	_
37-241	7009-7012	CPZ	_
37-242	7013-7027	chlorpromazine	_
37-243	7027-7028	,	_
37-244	7029-7033	SAPS	_
37-245	7034-7039	Scale	_
37-246	7040-7043	for	_
37-247	7044-7054	Assessment	_
37-248	7055-7057	of	_
37-249	7058-7066	Positive	_
37-250	7067-7075	Symptoms	_
37-251	7075-7076	,	_
37-252	7077-7081	SANS	_
37-253	7081-7082	,	_
37-254	7083-7088	Scale	_
37-255	7089-7092	for	_
37-256	7093-7096	the	_
37-257	7097-7107	Assessment	_
37-258	7108-7110	of	_
37-259	7111-7119	Negative	_
37-260	7120-7128	Symptoms	_
37-261	7129-7130	*	_
37-262	7130-7131	p	_
37-263	7131-7132	<	_
37-264	7132-7136	0.05	_
37-265	7137-7148	significant	_
37-266	7149-7159	difference	_
37-267	7160-7163	was	_
37-268	7164-7169	found	_
37-269	7171-7175	aThe	_
37-270	7176-7179	raw	_
37-271	7180-7189	cognitive	_
37-272	7190-7196	scores	_
37-273	7197-7201	were	_
37-274	7202-7212	calculated	_
37-275	7213-7215	as	_
37-276	7216-7219	the	_
37-277	7220-7227	average	_
37-278	7228-7230	of	_
37-279	7231-7234	the	_
37-280	7235-7241	Target	_
37-281	7242-7245	and	_
37-282	7246-7256	Non-target	_
37-283	7257-7267	accuracies	_
37-284	7268-7270	in	_
37-285	7271-7272	N	_
37-286	7273-7277	back	_
37-287	7278-7283	tasks	_
37-288	7285-7294	bReaction	_
37-289	7295-7299	time	_
37-290	7300-7303	was	_
37-291	7304-7314	calculated	_
37-292	7315-7317	as	_
37-293	7318-7321	the	_
37-294	7322-7329	average	_
37-295	7330-7332	of	_
37-296	7333-7336	the	_
37-297	7337-7343	Target	_
37-298	7344-7347	and	_
37-299	7348-7358	Non-target	_
37-300	7359-7367	reaction	_
37-301	7368-7372	time	_
37-302	7373-7375	in	_
37-303	7376-7377	N	_
37-304	7378-7382	back	_
37-305	7383-7388	tasks	_
37-306	7389-7399	Twenty-one	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-307	7400-7412	right-handed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-308	7413-7416	HCs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-309	7417-7424	matched	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-310	7425-7428	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-311	7429-7432	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-312	7432-7433	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-313	7434-7437	sex	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-314	7437-7438	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-315	7439-7442	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-316	7443-7448	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-317	7449-7451	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-318	7452-7461	education	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-319	7462-7466	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-320	7467-7476	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-321	7477-7481	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-322	7482-7485	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-323	7486-7490	city	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-324	7491-7493	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-325	7494-7502	Changsha	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-326	7503-7506	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-327	7507-7511	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-328	7512-7519	without	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-329	7520-7524	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-330	7525-7527	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-331	7528-7535	present	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-332	7536-7547	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-333	7547-7548	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-334	7549-7561	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-335	7561-7562	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-336	7563-7565	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-337	7566-7571	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-338	7572-7584	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-339	7585-7594	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-340	7594-7595	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-341	7596-7598	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-342	7599-7609	determined	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-343	7610-7612	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-344	7613-7615	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-345	7616-7627	abbreviated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-346	7628-7635	version	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-347	7636-7638	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-348	7639-7642	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-349	7643-7656	Comprehensive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-350	7657-7667	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-351	7668-7670	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-352	7671-7679	Symptoms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-353	7680-7683	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-354	7684-7691	History	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
37-355	7691-7692	.	_

#Text=Informed consent was fully explained to each participant, who then each gave written informed consent.
38-1	7693-7701	Informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-2	7702-7709	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-3	7710-7713	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-4	7714-7719	fully	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-5	7720-7729	explained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-6	7730-7732	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-7	7733-7737	each	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-8	7738-7749	participant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-9	7749-7750	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-10	7751-7754	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-11	7755-7759	then	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-12	7760-7764	each	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-13	7765-7769	gave	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-14	7770-7777	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-15	7778-7786	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-16	7787-7794	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-17	7794-7795	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]

#Text=Demographics and clinical characteristics of all participants are shown in Table 1.
39-1	7796-7808	Demographics	_
39-2	7809-7812	and	_
39-3	7813-7821	clinical	_
39-4	7822-7837	characteristics	_
39-5	7838-7840	of	_
39-6	7841-7844	all	_
39-7	7845-7857	participants	_
39-8	7858-7861	are	_
39-9	7862-7867	shown	_
39-10	7868-7870	in	_
39-11	7871-7876	Table	_
39-12	7876-7877	 	_
39-13	7877-7878	1	_
39-14	7878-7879	.	_

#Text=Part of patients and healthy controls have been choose to investigate disrupted effective connectivity in schizophrenia patients,while Zhou et al. have choose other part of patients to provide evidence for inefficient default mode network (DMN) suppression in schizophrenia with cognitive deficits.
40-1	7881-7885	Part	_
40-2	7886-7888	of	_
40-3	7889-7897	patients	_
40-4	7898-7901	and	_
40-5	7902-7909	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[17]
40-6	7910-7918	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[17]
40-7	7919-7923	have	_
40-8	7924-7928	been	_
40-9	7929-7935	choose	_
40-10	7936-7938	to	_
40-11	7939-7950	investigate	_
40-12	7951-7960	disrupted	_
40-13	7961-7970	effective	_
40-14	7971-7983	connectivity	_
40-15	7984-7986	in	_
40-16	7987-8000	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[18]
40-17	8001-8009	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[18]
40-18	8009-8010	,	_
40-19	8010-8015	while	_
40-20	8016-8020	Zhou	_
40-21	8021-8023	et	_
40-22	8024-8026	al	_
40-23	8026-8027	.	_
40-24	8028-8032	have	_
40-25	8033-8039	choose	_
40-26	8040-8045	other	_
40-27	8046-8050	part	_
40-28	8051-8053	of	_
40-29	8054-8062	patients	_
40-30	8063-8065	to	_
40-31	8066-8073	provide	_
40-32	8074-8082	evidence	_
40-33	8083-8086	for	_
40-34	8087-8098	inefficient	_
40-35	8099-8106	default	_
40-36	8107-8111	mode	_
40-37	8112-8119	network	_
40-38	8120-8121	(	_
40-39	8121-8124	DMN	_
40-40	8124-8125	)	_
40-41	8126-8137	suppression	_
40-42	8138-8140	in	_
40-43	8141-8154	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
40-44	8155-8159	with	_
40-45	8160-8169	cognitive	_
40-46	8170-8178	deficits	_
40-47	8178-8179	.	_

#Text=This study was approved by the Ethics Committee of the Second Xiangya Hospital, Central South University, Hunan, China.
41-1	8180-8184	This	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
41-2	8185-8190	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
41-3	8191-8194	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
41-4	8195-8203	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
41-5	8204-8206	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
41-6	8207-8210	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
41-7	8211-8217	Ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
41-8	8218-8227	Committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
41-9	8228-8230	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
41-10	8231-8234	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
41-11	8235-8241	Second	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
41-12	8242-8249	Xiangya	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
41-13	8250-8258	Hospital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
41-14	8258-8259	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
41-15	8260-8267	Central	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
41-16	8268-8273	South	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
41-17	8274-8284	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
41-18	8284-8285	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
41-19	8286-8291	Hunan	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
41-20	8291-8292	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
41-21	8293-8298	China	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
41-22	8298-8299	.	_

#Text=N-back task
#Text=A letter n-back task was performed on NordicNeurolab’s fMRI hardware system as previously described.
42-1	8300-8306	N-back	_
42-2	8307-8311	task	_
42-3	8312-8313	A	_
42-4	8314-8320	letter	_
42-5	8321-8327	n-back	http://maven.renci.org/NeuroBridge/neurobridge#N-BackTaskTest[20]
42-6	8328-8332	task	http://maven.renci.org/NeuroBridge/neurobridge#N-BackTaskTest[20]
42-7	8333-8336	was	_
42-8	8337-8346	performed	_
42-9	8347-8349	on	_
42-10	8350-8364	NordicNeurolab	_
42-11	8364-8365	’	_
42-12	8365-8366	s	_
42-13	8367-8371	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
42-14	8372-8380	hardware	_
42-15	8381-8387	system	_
42-16	8388-8390	as	_
42-17	8391-8401	previously	_
42-18	8402-8411	described	_
42-19	8411-8412	.	_

#Text=Briefly, the task included two alternating conditions: the ‘0-back’ condition and the ‘2-back’ condition.
43-1	8413-8420	Briefly	_
43-2	8420-8421	,	_
43-3	8422-8425	the	_
43-4	8426-8430	task	_
43-5	8431-8439	included	_
43-6	8440-8443	two	_
43-7	8444-8455	alternating	_
43-8	8456-8466	conditions	_
43-9	8466-8467	:	_
43-10	8468-8471	the	_
43-11	8472-8473	‘	_
43-12	8473-8474	0	_
43-13	8474-8475	-	_
43-14	8475-8479	back	_
43-15	8479-8480	’	_
43-16	8481-8490	condition	_
43-17	8491-8494	and	_
43-18	8495-8498	the	_
43-19	8499-8500	‘	_
43-20	8500-8501	2	_
43-21	8501-8502	-	_
43-22	8502-8506	back	_
43-23	8506-8507	’	_
43-24	8508-8517	condition	_
43-25	8517-8518	.	_

#Text=In the 0-back condition, subjects pressed the right button if the letter x appeared; otherwise, the left button was pressed.
44-1	8519-8521	In	_
44-2	8522-8525	the	_
44-3	8526-8527	0	_
44-4	8527-8528	-	_
44-5	8528-8532	back	_
44-6	8533-8542	condition	_
44-7	8542-8543	,	_
44-8	8544-8552	subjects	_
44-9	8553-8560	pressed	_
44-10	8561-8564	the	_
44-11	8565-8570	right	_
44-12	8571-8577	button	_
44-13	8578-8580	if	_
44-14	8581-8584	the	_
44-15	8585-8591	letter	_
44-16	8592-8593	x	_
44-17	8594-8602	appeared	_
44-18	8602-8603	;	_
44-19	8604-8613	otherwise	_
44-20	8613-8614	,	_
44-21	8615-8618	the	_
44-22	8619-8623	left	_
44-23	8624-8630	button	_
44-24	8631-8634	was	_
44-25	8635-8642	pressed	_
44-26	8642-8643	.	_

#Text=In the 2-back condition, subjects pressed the right button when the letter was identical to the one presented two trials previously; otherwise, the left button was pressed.
45-1	8644-8646	In	_
45-2	8647-8650	the	_
45-3	8651-8652	2	_
45-4	8652-8653	-	_
45-5	8653-8657	back	_
45-6	8658-8667	condition	_
45-7	8667-8668	,	_
45-8	8669-8677	subjects	_
45-9	8678-8685	pressed	_
45-10	8686-8689	the	_
45-11	8690-8695	right	_
45-12	8696-8702	button	_
45-13	8703-8707	when	_
45-14	8708-8711	the	_
45-15	8712-8718	letter	_
45-16	8719-8722	was	_
45-17	8723-8732	identical	_
45-18	8733-8735	to	_
45-19	8736-8739	the	_
45-20	8740-8743	one	_
45-21	8744-8753	presented	_
45-22	8754-8757	two	_
45-23	8758-8764	trials	_
45-24	8765-8775	previously	_
45-25	8775-8776	;	_
45-26	8777-8786	otherwise	_
45-27	8786-8787	,	_
45-28	8788-8791	the	_
45-29	8792-8796	left	_
45-30	8797-8803	button	_
45-31	8804-8807	was	_
45-32	8808-8815	pressed	_
45-33	8815-8816	.	_

#Text=The scan session comprised four 2-back and four 0-back blocks for 8 min and 20 s.
46-1	8817-8820	The	_
46-2	8821-8825	scan	_
46-3	8826-8833	session	_
46-4	8834-8843	comprised	_
46-5	8844-8848	four	_
46-6	8849-8850	2	_
46-7	8850-8851	-	_
46-8	8851-8855	back	_
46-9	8856-8859	and	_
46-10	8860-8864	four	_
46-11	8865-8866	0	_
46-12	8866-8867	-	_
46-13	8867-8871	back	_
46-14	8872-8878	blocks	_
46-15	8879-8882	for	_
46-16	8883-8884	8	_
46-17	8884-8885	 	_
46-18	8885-8888	min	_
46-19	8889-8892	and	_
46-20	8893-8895	20	_
46-21	8895-8896	 	_
46-22	8896-8897	s	_
46-23	8897-8898	.	_

#Text=Each block was preceded by a text instruction shown for 2 s; participants were then shown 20 trials, of which 7 trials were the target trials.
47-1	8899-8903	Each	_
47-2	8904-8909	block	_
47-3	8910-8913	was	_
47-4	8914-8922	preceded	_
47-5	8923-8925	by	_
47-6	8926-8927	a	_
47-7	8928-8932	text	_
47-8	8933-8944	instruction	_
47-9	8945-8950	shown	_
47-10	8951-8954	for	_
47-11	8955-8956	2	_
47-12	8956-8957	 	_
47-13	8957-8958	s	_
47-14	8958-8959	;	_
47-15	8960-8972	participants	_
47-16	8973-8977	were	_
47-17	8978-8982	then	_
47-18	8983-8988	shown	_
47-19	8989-8991	20	_
47-20	8992-8998	trials	_
47-21	8998-8999	,	_
47-22	9000-9002	of	_
47-23	9003-9008	which	_
47-24	9009-9010	7	_
47-25	9011-9017	trials	_
47-26	9018-9022	were	_
47-27	9023-9026	the	_
47-28	9027-9033	target	_
47-29	9034-9040	trials	_
47-30	9040-9041	.	_

#Text=Each trial was presented for 500 ms, followed by an inter-letter interval of 1500 ms.
48-1	9042-9046	Each	_
48-2	9047-9052	trial	_
48-3	9053-9056	was	_
48-4	9057-9066	presented	_
48-5	9067-9070	for	_
48-6	9071-9074	500	_
48-7	9074-9075	 	_
48-8	9075-9077	ms	_
48-9	9077-9078	,	_
48-10	9079-9087	followed	_
48-11	9088-9090	by	_
48-12	9091-9093	an	_
48-13	9094-9106	inter-letter	_
48-14	9107-9115	interval	_
48-15	9116-9118	of	_
48-16	9119-9123	1500	_
48-17	9123-9124	 	_
48-18	9124-9126	ms	_
48-19	9126-9127	.	_

#Text=Before the real task, all participants needed practice to reach the required accuracy of correct responses 80%.
49-1	9128-9134	Before	_
49-2	9135-9138	the	_
49-3	9139-9143	real	_
49-4	9144-9148	task	_
49-5	9148-9149	,	_
49-6	9150-9153	all	_
49-7	9154-9166	participants	_
49-8	9167-9173	needed	_
49-9	9174-9182	practice	_
49-10	9183-9185	to	_
49-11	9186-9191	reach	_
49-12	9192-9195	the	_
49-13	9196-9204	required	_
49-14	9205-9213	accuracy	_
49-15	9214-9216	of	_
49-16	9217-9224	correct	_
49-17	9225-9234	responses	_
49-18	9235-9238	80%	_
49-19	9238-9239	.	_

#Text=Statistical analysis
#Text=Three patients with significant head motion (maximum motion larger than 2° or 2 mm) or other artifacts were discarded.
50-1	9240-9251	Statistical	_
50-2	9252-9260	analysis	_
50-3	9261-9266	Three	_
50-4	9267-9275	patients	_
50-5	9276-9280	with	_
50-6	9281-9292	significant	_
50-7	9293-9297	head	_
50-8	9298-9304	motion	_
50-9	9305-9306	(	_
50-10	9306-9313	maximum	_
50-11	9314-9320	motion	_
50-12	9321-9327	larger	_
50-13	9328-9332	than	_
50-14	9333-9334	2	_
50-15	9334-9335	°	_
50-16	9336-9338	or	_
50-17	9339-9340	2	_
50-18	9340-9341	 	_
50-19	9341-9343	mm	_
50-20	9343-9344	)	_
50-21	9345-9347	or	_
50-22	9348-9353	other	_
50-23	9354-9363	artifacts	_
50-24	9364-9368	were	_
50-25	9369-9378	discarded	_
50-26	9378-9379	.	_

#Text=The remaining patients were placed into either the SZ-CD group or the SZ-NCD group on the basis of their accuracy in the 2-back task.
51-1	9380-9383	The	_
51-2	9384-9393	remaining	_
51-3	9394-9402	patients	_
51-4	9403-9407	were	_
51-5	9408-9414	placed	_
51-6	9415-9419	into	_
51-7	9420-9426	either	_
51-8	9427-9430	the	_
51-9	9431-9436	SZ-CD	_
51-10	9437-9442	group	_
51-11	9443-9445	or	_
51-12	9446-9449	the	_
51-13	9450-9456	SZ-NCD	_
51-14	9457-9462	group	_
51-15	9463-9465	on	_
51-16	9466-9469	the	_
51-17	9470-9475	basis	_
51-18	9476-9478	of	_
51-19	9479-9484	their	_
51-20	9485-9493	accuracy	_
51-21	9494-9496	in	_
51-22	9497-9500	the	_
51-23	9501-9502	2	_
51-24	9502-9503	-	_
51-25	9503-9507	back	_
51-26	9508-9512	task	_
51-27	9512-9513	.	_

#Text=The raw cognitive scores were calculated as the average of the Target and Non-target accuracies in the 2-back task.
52-1	9514-9517	The	_
52-2	9518-9521	raw	_
52-3	9522-9531	cognitive	_
52-4	9532-9538	scores	_
52-5	9539-9543	were	_
52-6	9544-9554	calculated	_
52-7	9555-9557	as	_
52-8	9558-9561	the	_
52-9	9562-9569	average	_
52-10	9570-9572	of	_
52-11	9573-9576	the	_
52-12	9577-9583	Target	_
52-13	9584-9587	and	_
52-14	9588-9598	Non-target	_
52-15	9599-9609	accuracies	_
52-16	9610-9612	in	_
52-17	9613-9616	the	_
52-18	9617-9618	2	_
52-19	9618-9619	-	_
52-20	9619-9623	back	_
52-21	9624-9628	task	_
52-22	9628-9629	.	_

#Text=Then, each raw cognitive score was normally distributed with a mean of 0 and a standard deviation of 1.
53-1	9630-9634	Then	_
53-2	9634-9635	,	_
53-3	9636-9640	each	_
53-4	9641-9644	raw	_
53-5	9645-9654	cognitive	_
53-6	9655-9660	score	_
53-7	9661-9664	was	_
53-8	9665-9673	normally	_
53-9	9674-9685	distributed	_
53-10	9686-9690	with	_
53-11	9691-9692	a	_
53-12	9693-9697	mean	_
53-13	9698-9700	of	_
53-14	9701-9702	0	_
53-15	9703-9706	and	_
53-16	9707-9708	a	_
53-17	9709-9717	standard	_
53-18	9718-9727	deviation	_
53-19	9728-9730	of	_
53-20	9731-9732	1	_
53-21	9732-9733	.	_

#Text=Patients were placed in the SZ-CD group if their normalized cognitive score was more than 1 SD below the normative mean.
54-1	9734-9742	Patients	_
54-2	9743-9747	were	_
54-3	9748-9754	placed	_
54-4	9755-9757	in	_
54-5	9758-9761	the	_
54-6	9762-9767	SZ-CD	_
54-7	9768-9773	group	_
54-8	9774-9776	if	_
54-9	9777-9782	their	_
54-10	9783-9793	normalized	_
54-11	9794-9803	cognitive	_
54-12	9804-9809	score	_
54-13	9810-9813	was	_
54-14	9814-9818	more	_
54-15	9819-9823	than	_
54-16	9824-9825	1	_
54-17	9826-9828	SD	_
54-18	9829-9834	below	_
54-19	9835-9838	the	_
54-20	9839-9848	normative	_
54-21	9849-9853	mean	_
54-22	9853-9854	.	_

#Text=The approach resulted in eighteen patients assigned to the SZ-CD group and sixteen patients to the SZ-NCD group.
55-1	9855-9858	The	_
55-2	9859-9867	approach	_
55-3	9868-9876	resulted	_
55-4	9877-9879	in	_
55-5	9880-9888	eighteen	_
55-6	9889-9897	patients	_
55-7	9898-9906	assigned	_
55-8	9907-9909	to	_
55-9	9910-9913	the	_
55-10	9914-9919	SZ-CD	_
55-11	9920-9925	group	_
55-12	9926-9929	and	_
55-13	9930-9937	sixteen	_
55-14	9938-9946	patients	_
55-15	9947-9949	to	_
55-16	9950-9953	the	_
55-17	9954-9960	SZ-NCD	_
55-18	9961-9966	group	_
55-19	9966-9967	.	_

#Text=Furthermore, the Digital Symbol Substitution Test (DSST) and the Information Subscale of Wechsler Adult Intelligence Scale Chinese Revised (WAIS-CR) (Table 1) were used to measure two other important cognitive functions, information processing speed and verbal comprehension, respectively.
56-1	9968-9979	Furthermore	_
56-2	9979-9980	,	_
56-3	9981-9984	the	_
56-4	9985-9992	Digital	_
56-5	9993-9999	Symbol	_
56-6	10000-10012	Substitution	_
56-7	10013-10017	Test	_
56-8	10018-10019	(	_
56-9	10019-10023	DSST	_
56-10	10023-10024	)	_
56-11	10025-10028	and	_
56-12	10029-10032	the	_
56-13	10033-10044	Information	_
56-14	10045-10053	Subscale	_
56-15	10054-10056	of	_
56-16	10057-10065	Wechsler	_
56-17	10066-10071	Adult	_
56-18	10072-10084	Intelligence	_
56-19	10085-10090	Scale	_
56-20	10091-10098	Chinese	_
56-21	10099-10106	Revised	_
56-22	10107-10108	(	_
56-23	10108-10115	WAIS-CR	_
56-24	10115-10116	)	_
56-25	10117-10118	(	_
56-26	10118-10123	Table	_
56-27	10124-10125	1	_
56-28	10125-10126	)	_
56-29	10127-10131	were	_
56-30	10132-10136	used	_
56-31	10137-10139	to	_
56-32	10140-10147	measure	_
56-33	10148-10151	two	_
56-34	10152-10157	other	_
56-35	10158-10167	important	_
56-36	10168-10177	cognitive	_
56-37	10178-10187	functions	_
56-38	10187-10188	,	_
56-39	10189-10200	information	_
56-40	10201-10211	processing	_
56-41	10212-10217	speed	_
56-42	10218-10221	and	_
56-43	10222-10228	verbal	_
56-44	10229-10242	comprehension	_
56-45	10242-10243	,	_
56-46	10244-10256	respectively	_
56-47	10256-10257	.	_

#Text=There were significant differences between the SZ-CD and SZ-NCD groups in information processing speed and verbal comprehension as assessed by a two-sample t-test using IBM SPSS statistics (version 20.0), providing further support for our criteria.
57-1	10258-10263	There	_
57-2	10264-10268	were	_
57-3	10269-10280	significant	_
57-4	10281-10292	differences	_
57-5	10293-10300	between	_
57-6	10301-10304	the	_
57-7	10305-10310	SZ-CD	_
57-8	10311-10314	and	_
57-9	10315-10321	SZ-NCD	_
57-10	10322-10328	groups	_
57-11	10329-10331	in	_
57-12	10332-10343	information	_
57-13	10344-10354	processing	_
57-14	10355-10360	speed	_
57-15	10361-10364	and	_
57-16	10365-10371	verbal	_
57-17	10372-10385	comprehension	_
57-18	10386-10388	as	_
57-19	10389-10397	assessed	_
57-20	10398-10400	by	_
57-21	10401-10402	a	_
57-22	10403-10413	two-sample	_
57-23	10414-10420	t-test	_
57-24	10421-10426	using	_
57-25	10427-10430	IBM	_
57-26	10431-10435	SPSS	_
57-27	10436-10446	statistics	_
57-28	10447-10448	(	_
57-29	10448-10455	version	_
57-30	10456-10460	20.0	_
57-31	10460-10461	)	_
57-32	10461-10462	,	_
57-33	10463-10472	providing	_
57-34	10473-10480	further	_
57-35	10481-10488	support	_
57-36	10489-10492	for	_
57-37	10493-10496	our	_
57-38	10497-10505	criteria	_
57-39	10505-10506	.	_

#Text=Image acquisition
#Text=All high-resolution T1-weighted images were acquired in the Department of Psychiatry, Second Xiangya Hospital of Central South University, Changsha, China, using a T1-weighted 3D turbo field echo on a Philips Gyroscan Achieva 3.0 Tesla MRI scanner with the following parameters: repetition time = 7.5 ms, echo time = 3.7 ms, flip angle = 8°, field of view = 240 × 240 mm2, acquisition matrix =256 × 200, voxel resolution 1.0 × 1.0 × 1.0 mm3,slice thickness = 1 mm, gap = 0, and number of slices = 180.
58-1	10507-10512	Image	_
58-2	10513-10524	acquisition	_
58-3	10525-10528	All	_
58-4	10529-10544	high-resolution	_
58-5	10545-10547	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[21]
58-6	10547-10548	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[21]
58-7	10548-10556	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[21]
58-8	10557-10563	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[21]
58-9	10564-10568	were	_
58-10	10569-10577	acquired	_
58-11	10578-10580	in	_
58-12	10581-10584	the	_
58-13	10585-10595	Department	_
58-14	10596-10598	of	_
58-15	10599-10609	Psychiatry	_
58-16	10609-10610	,	_
58-17	10611-10617	Second	_
58-18	10618-10625	Xiangya	_
58-19	10626-10634	Hospital	_
58-20	10635-10637	of	_
58-21	10638-10645	Central	_
58-22	10646-10651	South	_
58-23	10652-10662	University	_
58-24	10662-10663	,	_
58-25	10664-10672	Changsha	_
58-26	10672-10673	,	_
58-27	10674-10679	China	_
58-28	10679-10680	,	_
58-29	10681-10686	using	_
58-30	10687-10688	a	_
58-31	10689-10691	T1	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[22]
58-32	10691-10692	-	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[22]
58-33	10692-10700	weighted	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[22]
58-34	10701-10703	3D	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[22]
58-35	10704-10709	turbo	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[22]
58-36	10710-10715	field	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[22]
58-37	10716-10720	echo	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[22]
58-38	10721-10723	on	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[22]
58-39	10724-10725	a	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[22]
58-40	10726-10733	Philips	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[22]
58-41	10734-10742	Gyroscan	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[22]
58-42	10743-10750	Achieva	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[22]
58-43	10751-10754	3.0	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[22]
58-44	10755-10760	Tesla	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[22]
58-45	10761-10764	MRI	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[22]
58-46	10765-10772	scanner	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[22]
58-47	10773-10777	with	_
58-48	10778-10781	the	_
58-49	10782-10791	following	_
58-50	10792-10802	parameters	_
58-51	10802-10803	:	_
58-52	10804-10814	repetition	_
58-53	10815-10819	time	_
58-54	10820-10821	=	_
58-55	10822-10825	7.5	_
58-56	10825-10826	 	_
58-57	10826-10828	ms	_
58-58	10828-10829	,	_
58-59	10830-10834	echo	_
58-60	10835-10839	time	_
58-61	10840-10841	=	_
58-62	10842-10845	3.7	_
58-63	10845-10846	 	_
58-64	10846-10848	ms	_
58-65	10848-10849	,	_
58-66	10850-10854	flip	_
58-67	10855-10860	angle	_
58-68	10861-10862	=	_
58-69	10863-10864	8	_
58-70	10864-10865	°	_
58-71	10865-10866	,	_
58-72	10867-10872	field	_
58-73	10873-10875	of	_
58-74	10876-10880	view	_
58-75	10881-10882	=	_
58-76	10883-10886	240	_
58-77	10887-10888	×	_
58-78	10889-10892	240	_
58-79	10892-10893	 	_
58-80	10893-10896	mm2	_
58-81	10896-10897	,	_
58-82	10898-10909	acquisition	_
58-83	10910-10916	matrix	_
58-84	10917-10918	=	_
58-85	10918-10921	256	_
58-86	10922-10923	×	_
58-87	10924-10927	200	_
58-88	10927-10928	,	_
58-89	10929-10934	voxel	_
58-90	10935-10945	resolution	_
58-91	10946-10949	1.0	_
58-92	10950-10951	×	_
58-93	10952-10955	1.0	_
58-94	10956-10957	×	_
58-95	10958-10961	1.0	_
58-96	10961-10962	 	_
58-97	10962-10965	mm3	_
58-98	10965-10966	,	_
58-99	10966-10971	slice	_
58-100	10972-10981	thickness	_
58-101	10982-10983	=	_
58-102	10984-10985	1	_
58-103	10985-10986	 	_
58-104	10986-10988	mm	_
58-105	10988-10989	,	_
58-106	10990-10993	gap	_
58-107	10994-10995	=	_
58-108	10996-10997	0	_
58-109	10997-10998	,	_
58-110	10999-11002	and	_
58-111	11003-11009	number	_
58-112	11010-11012	of	_
58-113	11013-11019	slices	_
58-114	11020-11021	=	_
58-115	11022-11025	180	_
58-116	11025-11026	.	_

#Text=Functional MRI images were collected in the axial direction, using a gradient-echo echo planar imaging (EPI) sequence: repetition time (TR) = 2000 ms, echo time (TE) = 30 ms, matrix = 64 × 64, slices = 36, slice thickness = 4 mm, gap =0 mm, flip angle = 90°, FOV 24 × 24 cm, 250 time points.
59-1	11027-11037	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[23]
59-2	11038-11041	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[23]
59-3	11042-11048	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[23]
59-4	11049-11053	were	_
59-5	11054-11063	collected	_
59-6	11064-11066	in	_
59-7	11067-11070	the	_
59-8	11071-11076	axial	_
59-9	11077-11086	direction	_
59-10	11086-11087	,	_
59-11	11088-11093	using	_
59-12	11094-11095	a	_
59-13	11096-11109	gradient-echo	_
59-14	11110-11114	echo	_
59-15	11115-11121	planar	_
59-16	11122-11129	imaging	_
59-17	11130-11131	(	_
59-18	11131-11134	EPI	_
59-19	11134-11135	)	_
59-20	11136-11144	sequence	_
59-21	11144-11145	:	_
59-22	11146-11156	repetition	_
59-23	11157-11161	time	_
59-24	11162-11163	(	_
59-25	11163-11165	TR	_
59-26	11165-11166	)	_
59-27	11167-11168	=	_
59-28	11169-11173	2000	_
59-29	11173-11174	 	_
59-30	11174-11176	ms	_
59-31	11176-11177	,	_
59-32	11178-11182	echo	_
59-33	11183-11187	time	_
59-34	11188-11189	(	_
59-35	11189-11191	TE	_
59-36	11191-11192	)	_
59-37	11193-11194	=	_
59-38	11195-11197	30	_
59-39	11197-11198	 	_
59-40	11198-11200	ms	_
59-41	11200-11201	,	_
59-42	11202-11208	matrix	_
59-43	11209-11210	=	_
59-44	11211-11213	64	_
59-45	11214-11215	×	_
59-46	11216-11218	64	_
59-47	11218-11219	,	_
59-48	11220-11226	slices	_
59-49	11227-11228	=	_
59-50	11229-11231	36	_
59-51	11231-11232	,	_
59-52	11233-11238	slice	_
59-53	11239-11248	thickness	_
59-54	11249-11250	=	_
59-55	11251-11252	4	_
59-56	11252-11253	 	_
59-57	11253-11255	mm	_
59-58	11255-11256	,	_
59-59	11257-11260	gap	_
59-60	11261-11262	=	_
59-61	11262-11263	0	_
59-62	11263-11264	 	_
59-63	11264-11266	mm	_
59-64	11266-11267	,	_
59-65	11268-11272	flip	_
59-66	11273-11278	angle	_
59-67	11279-11280	=	_
59-68	11281-11283	90	_
59-69	11283-11284	°	_
59-70	11284-11285	,	_
59-71	11286-11289	FOV	_
59-72	11290-11292	24	_
59-73	11293-11294	×	_
59-74	11295-11297	24	_
59-75	11297-11298	 	_
59-76	11298-11300	cm	_
59-77	11300-11301	,	_
59-78	11302-11305	250	_
59-79	11306-11310	time	_
59-80	11311-11317	points	_
59-81	11317-11318	.	_

#Text=The scan lasted for 8min20s.Foam pads and earplugs were used to minimize head motion and scanner noise.
60-1	11319-11322	The	_
60-2	11323-11327	scan	_
60-3	11328-11334	lasted	_
60-4	11335-11338	for	_
60-5	11339-11351	8min20s.Foam	_
60-6	11352-11356	pads	_
60-7	11357-11360	and	_
60-8	11361-11369	earplugs	_
60-9	11370-11374	were	_
60-10	11375-11379	used	_
60-11	11380-11382	to	_
60-12	11383-11391	minimize	_
60-13	11392-11396	head	_
60-14	11397-11403	motion	_
60-15	11404-11407	and	_
60-16	11408-11415	scanner	_
60-17	11416-11421	noise	_
60-18	11421-11422	.	_

#Text=All scans were inspected for quality control.
61-1	11423-11426	All	_
61-2	11427-11432	scans	_
61-3	11433-11437	were	_
61-4	11438-11447	inspected	_
61-5	11448-11451	for	_
61-6	11452-11459	quality	_
61-7	11460-11467	control	_
61-8	11467-11468	.	_

#Text=Image processing
#Text=Structural images analysis was performed using the VBM8 toolbox version 1.19, an extension of the Statistical Parametric Mapping 8 (SPM8) software package.
62-1	11469-11474	Image	_
62-2	11475-11485	processing	_
62-3	11486-11496	Structural	_
62-4	11497-11503	images	_
62-5	11504-11512	analysis	_
62-6	11513-11516	was	_
62-7	11517-11526	performed	_
62-8	11527-11532	using	_
62-9	11533-11536	the	_
62-10	11537-11541	VBM8	_
62-11	11542-11549	toolbox	_
62-12	11550-11557	version	_
62-13	11558-11562	1.19	_
62-14	11562-11563	,	_
62-15	11564-11566	an	_
62-16	11567-11576	extension	_
62-17	11577-11579	of	_
62-18	11580-11583	the	_
62-19	11584-11595	Statistical	_
62-20	11596-11606	Parametric	_
62-21	11607-11614	Mapping	_
62-22	11615-11616	8	_
62-23	11617-11618	(	_
62-24	11618-11622	SPM8	_
62-25	11622-11623	)	_
62-26	11624-11632	software	_
62-27	11633-11640	package	_
62-28	11640-11641	.	_

#Text=The main procedure included the following steps: 1) checking for scanner artifacts and gross anatomical abnormalities for each subject; 2) setting the image origin to the anterior commissure; 3) segmenting the images into gray matter and white matter images; 4) using the DARTEL toolbox on SPM8 to produce a high-dimensional normalization protocol; and 5) smoothing the unmodulated gray matter images with a Gaussian kernel of 8-mm full-width at half-maximum (FWHM).
63-1	11642-11645	The	_
63-2	11646-11650	main	_
63-3	11651-11660	procedure	_
63-4	11661-11669	included	_
63-5	11670-11673	the	_
63-6	11674-11683	following	_
63-7	11684-11689	steps	_
63-8	11689-11690	:	_
63-9	11691-11692	1	_
63-10	11692-11693	)	_
63-11	11694-11702	checking	_
63-12	11703-11706	for	_
63-13	11707-11714	scanner	_
63-14	11715-11724	artifacts	_
63-15	11725-11728	and	_
63-16	11729-11734	gross	_
63-17	11735-11745	anatomical	_
63-18	11746-11759	abnormalities	_
63-19	11760-11763	for	_
63-20	11764-11768	each	_
63-21	11769-11776	subject	_
63-22	11776-11777	;	_
63-23	11778-11779	2	_
63-24	11779-11780	)	_
63-25	11781-11788	setting	_
63-26	11789-11792	the	_
63-27	11793-11798	image	_
63-28	11799-11805	origin	_
63-29	11806-11808	to	_
63-30	11809-11812	the	_
63-31	11813-11821	anterior	_
63-32	11822-11832	commissure	_
63-33	11832-11833	;	_
63-34	11834-11835	3	_
63-35	11835-11836	)	_
63-36	11837-11847	segmenting	_
63-37	11848-11851	the	_
63-38	11852-11858	images	_
63-39	11859-11863	into	_
63-40	11864-11868	gray	_
63-41	11869-11875	matter	_
63-42	11876-11879	and	_
63-43	11880-11885	white	_
63-44	11886-11892	matter	_
63-45	11893-11899	images	_
63-46	11899-11900	;	_
63-47	11901-11902	4	_
63-48	11902-11903	)	_
63-49	11904-11909	using	_
63-50	11910-11913	the	_
63-51	11914-11920	DARTEL	_
63-52	11921-11928	toolbox	_
63-53	11929-11931	on	_
63-54	11932-11936	SPM8	_
63-55	11937-11939	to	_
63-56	11940-11947	produce	_
63-57	11948-11949	a	_
63-58	11950-11966	high-dimensional	_
63-59	11967-11980	normalization	_
63-60	11981-11989	protocol	_
63-61	11989-11990	;	_
63-62	11991-11994	and	_
63-63	11995-11996	5	_
63-64	11996-11997	)	_
63-65	11998-12007	smoothing	_
63-66	12008-12011	the	_
63-67	12012-12023	unmodulated	_
63-68	12024-12028	gray	_
63-69	12029-12035	matter	_
63-70	12036-12042	images	_
63-71	12043-12047	with	_
63-72	12048-12049	a	_
63-73	12050-12058	Gaussian	_
63-74	12059-12065	kernel	_
63-75	12066-12068	of	_
63-76	12069-12070	8	_
63-77	12070-12071	-	_
63-78	12071-12073	mm	_
63-79	12074-12084	full-width	_
63-80	12085-12087	at	_
63-81	12088-12100	half-maximum	_
63-82	12101-12102	(	_
63-83	12102-12106	FWHM	_
63-84	12106-12107	)	_
63-85	12107-12108	.	_

#Text=Voxel-wise differences in the GMD in the intracerebral cortex were assessed using voxel-wise one way analysis of variance (ANOVA) across the three subject groups after controlling for age and gender(voxel wise p < 0.05 and cluster size >3554voxels).
64-1	12109-12119	Voxel-wise	_
64-2	12120-12131	differences	_
64-3	12132-12134	in	_
64-4	12135-12138	the	_
64-5	12139-12142	GMD	_
64-6	12143-12145	in	_
64-7	12146-12149	the	_
64-8	12150-12163	intracerebral	_
64-9	12164-12170	cortex	_
64-10	12171-12175	were	_
64-11	12176-12184	assessed	_
64-12	12185-12190	using	_
64-13	12191-12201	voxel-wise	_
64-14	12202-12205	one	_
64-15	12206-12209	way	_
64-16	12210-12218	analysis	_
64-17	12219-12221	of	_
64-18	12222-12230	variance	_
64-19	12231-12232	(	_
64-20	12232-12237	ANOVA	_
64-21	12237-12238	)	_
64-22	12239-12245	across	_
64-23	12246-12249	the	_
64-24	12250-12255	three	_
64-25	12256-12263	subject	_
64-26	12264-12270	groups	_
64-27	12271-12276	after	_
64-28	12277-12288	controlling	_
64-29	12289-12292	for	_
64-30	12293-12296	age	_
64-31	12297-12300	and	_
64-32	12301-12307	gender	_
64-33	12307-12308	(	_
64-34	12308-12313	voxel	_
64-35	12314-12318	wise	_
64-36	12319-12320	p	_
64-37	12321-12322	<	_
64-38	12323-12327	0.05	_
64-39	12328-12331	and	_
64-40	12332-12339	cluster	_
64-41	12340-12344	size	_
64-42	12345-12346	>	_
64-43	12346-12356	3554voxels	_
64-44	12356-12357	)	_
64-45	12357-12358	.	_

#Text=Multiple comparisons were corrected using Monte Carlo simulations in the Resting-State fMRI Data Analysis Toolkit (REST, http://rest.restfmri.net).
65-1	12359-12367	Multiple	_
65-2	12368-12379	comparisons	_
65-3	12380-12384	were	_
65-4	12385-12394	corrected	_
65-5	12395-12400	using	_
65-6	12401-12406	Monte	_
65-7	12407-12412	Carlo	_
65-8	12413-12424	simulations	_
65-9	12425-12427	in	_
65-10	12428-12431	the	_
65-11	12432-12445	Resting-State	_
65-12	12446-12450	fMRI	_
65-13	12451-12455	Data	_
65-14	12456-12464	Analysis	_
65-15	12465-12472	Toolkit	_
65-16	12473-12474	(	_
65-17	12474-12478	REST	_
65-18	12478-12479	,	_
65-19	12480-12484	http	_
65-20	12484-12485	:	_
65-21	12485-12486	/	_
65-22	12486-12487	/	_
65-23	12487-12504	rest.restfmri.net	_
65-24	12504-12505	)	_
65-25	12505-12506	.	_

#Text=Minimum cluster size was determined by AlphaSim.
66-1	12507-12514	Minimum	_
66-2	12515-12522	cluster	_
66-3	12523-12527	size	_
66-4	12528-12531	was	_
66-5	12532-12542	determined	_
66-6	12543-12545	by	_
66-7	12546-12554	AlphaSim	_
66-8	12554-12555	.	_

#Text=Restricted to the above voxels identified by ANOVA, between-group differences in gray matter densities were tested using post-hoc tests.
67-1	12556-12566	Restricted	_
67-2	12567-12569	to	_
67-3	12570-12573	the	_
67-4	12574-12579	above	_
67-5	12580-12586	voxels	_
67-6	12587-12597	identified	_
67-7	12598-12600	by	_
67-8	12601-12606	ANOVA	_
67-9	12606-12607	,	_
67-10	12608-12621	between-group	_
67-11	12622-12633	differences	_
67-12	12634-12636	in	_
67-13	12637-12641	gray	_
67-14	12642-12648	matter	_
67-15	12649-12658	densities	_
67-16	12659-12663	were	_
67-17	12664-12670	tested	_
67-18	12671-12676	using	_
67-19	12677-12685	post-hoc	_
67-20	12686-12691	tests	_
67-21	12691-12692	.	_

#Text=The same threshold adjustment method was used, SZ-CD and HCs (voxel size p < 0.05, cluster size > 3152voxels), SZ-NCD and HCs (voxel size p < 0.05, cluster size > 3369voxels), SZ-CD and SZ-NCD (voxel size p < 0.05, cluster size >3380 voxels), which were equivalent to an AlphaSim correction threshold of p < 0.05.
68-1	12693-12696	The	_
68-2	12697-12701	same	_
68-3	12702-12711	threshold	_
68-4	12712-12722	adjustment	_
68-5	12723-12729	method	_
68-6	12730-12733	was	_
68-7	12734-12738	used	_
68-8	12738-12739	,	_
68-9	12740-12745	SZ-CD	_
68-10	12746-12749	and	_
68-11	12750-12753	HCs	_
68-12	12754-12755	(	_
68-13	12755-12760	voxel	_
68-14	12761-12765	size	_
68-15	12766-12767	p	_
68-16	12768-12769	<	_
68-17	12770-12774	0.05	_
68-18	12774-12775	,	_
68-19	12776-12783	cluster	_
68-20	12784-12788	size	_
68-21	12789-12790	>	_
68-22	12791-12801	3152voxels	_
68-23	12801-12802	)	_
68-24	12802-12803	,	_
68-25	12804-12810	SZ-NCD	_
68-26	12811-12814	and	_
68-27	12815-12818	HCs	_
68-28	12819-12820	(	_
68-29	12820-12825	voxel	_
68-30	12826-12830	size	_
68-31	12831-12832	p	_
68-32	12833-12834	<	_
68-33	12835-12839	0.05	_
68-34	12839-12840	,	_
68-35	12841-12848	cluster	_
68-36	12849-12853	size	_
68-37	12854-12855	>	_
68-38	12856-12866	3369voxels	_
68-39	12866-12867	)	_
68-40	12867-12868	,	_
68-41	12869-12874	SZ-CD	_
68-42	12875-12878	and	_
68-43	12879-12885	SZ-NCD	_
68-44	12886-12887	(	_
68-45	12887-12892	voxel	_
68-46	12893-12897	size	_
68-47	12898-12899	p	_
68-48	12900-12901	<	_
68-49	12902-12906	0.05	_
68-50	12906-12907	,	_
68-51	12908-12915	cluster	_
68-52	12916-12920	size	_
68-53	12921-12922	>	_
68-54	12922-12926	3380	_
68-55	12927-12933	voxels	_
68-56	12933-12934	)	_
68-57	12934-12935	,	_
68-58	12936-12941	which	_
68-59	12942-12946	were	_
68-60	12947-12957	equivalent	_
68-61	12958-12960	to	_
68-62	12961-12963	an	_
68-63	12964-12972	AlphaSim	_
68-64	12973-12983	correction	_
68-65	12984-12993	threshold	_
68-66	12994-12996	of	_
68-67	12997-12998	p	_
68-68	12999-13000	<	_
68-69	13001-13005	0.05	_
68-70	13005-13006	.	_

#Text=For visual observation, the significant voxels were overlaid onto a high-definition T1-weighted brain template to show group differences.
69-1	13007-13010	For	_
69-2	13011-13017	visual	_
69-3	13018-13029	observation	_
69-4	13029-13030	,	_
69-5	13031-13034	the	_
69-6	13035-13046	significant	_
69-7	13047-13053	voxels	_
69-8	13054-13058	were	_
69-9	13059-13067	overlaid	_
69-10	13068-13072	onto	_
69-11	13073-13074	a	_
69-12	13075-13090	high-definition	_
69-13	13091-13093	T1	_
69-14	13093-13094	-	_
69-15	13094-13102	weighted	_
69-16	13103-13108	brain	_
69-17	13109-13117	template	_
69-18	13118-13120	to	_
69-19	13121-13125	show	_
69-20	13126-13131	group	_
69-21	13132-13143	differences	_
69-22	13143-13144	.	_

#Text=The average morphological anomalies in each significant cluster from both SZ patient groups and HCs were extracted.
70-1	13145-13148	The	_
70-2	13149-13156	average	_
70-3	13157-13170	morphological	_
70-4	13171-13180	anomalies	_
70-5	13181-13183	in	_
70-6	13184-13188	each	_
70-7	13189-13200	significant	_
70-8	13201-13208	cluster	_
70-9	13209-13213	from	_
70-10	13214-13218	both	_
70-11	13219-13221	SZ	_
70-12	13222-13229	patient	_
70-13	13230-13236	groups	_
70-14	13237-13240	and	_
70-15	13241-13244	HCs	_
70-16	13245-13249	were	_
70-17	13250-13259	extracted	_
70-18	13259-13260	.	_

#Text=GMD comparisons among the three groups and between each pair of groups were also assessed by ANOVA using IBM SPSS statistics (version 20.0).
71-1	13261-13264	GMD	_
71-2	13265-13276	comparisons	_
71-3	13277-13282	among	_
71-4	13283-13286	the	_
71-5	13287-13292	three	_
71-6	13293-13299	groups	_
71-7	13300-13303	and	_
71-8	13304-13311	between	_
71-9	13312-13316	each	_
71-10	13317-13321	pair	_
71-11	13322-13324	of	_
71-12	13325-13331	groups	_
71-13	13332-13336	were	_
71-14	13337-13341	also	_
71-15	13342-13350	assessed	_
71-16	13351-13353	by	_
71-17	13354-13359	ANOVA	_
71-18	13360-13365	using	_
71-19	13366-13369	IBM	_
71-20	13370-13374	SPSS	_
71-21	13375-13385	statistics	_
71-22	13386-13387	(	_
71-23	13387-13394	version	_
71-24	13395-13399	20.0	_
71-25	13399-13400	)	_
71-26	13400-13401	.	_

#Text=Receive operation curve (ROC) could illustrate the diagnostic ability of a binary classifier system when different discrimination threshold was set, which was usually used to differentiate the patients from the healthy controls or between subgroups.
72-1	13402-13409	Receive	_
72-2	13410-13419	operation	_
72-3	13420-13425	curve	_
72-4	13426-13427	(	_
72-5	13427-13430	ROC	_
72-6	13430-13431	)	_
72-7	13432-13437	could	_
72-8	13438-13448	illustrate	_
72-9	13449-13452	the	_
72-10	13453-13463	diagnostic	_
72-11	13464-13471	ability	_
72-12	13472-13474	of	_
72-13	13475-13476	a	_
72-14	13477-13483	binary	_
72-15	13484-13494	classifier	_
72-16	13495-13501	system	_
72-17	13502-13506	when	_
72-18	13507-13516	different	_
72-19	13517-13531	discrimination	_
72-20	13532-13541	threshold	_
72-21	13542-13545	was	_
72-22	13546-13549	set	_
72-23	13549-13550	,	_
72-24	13551-13556	which	_
72-25	13557-13560	was	_
72-26	13561-13568	usually	_
72-27	13569-13573	used	_
72-28	13574-13576	to	_
72-29	13577-13590	differentiate	_
72-30	13591-13594	the	_
72-31	13595-13603	patients	_
72-32	13604-13608	from	_
72-33	13609-13612	the	_
72-34	13613-13620	healthy	_
72-35	13621-13629	controls	_
72-36	13630-13632	or	_
72-37	13633-13640	between	_
72-38	13641-13650	subgroups	_
72-39	13650-13651	.	_

#Text=Furthermore, we plotted ROC to explore whether the GMD values in each significant cluster could differentiate the patients from the healthy controls or between subgroups.
73-1	13652-13663	Furthermore	_
73-2	13663-13664	,	_
73-3	13665-13667	we	_
73-4	13668-13675	plotted	_
73-5	13676-13679	ROC	_
73-6	13680-13682	to	_
73-7	13683-13690	explore	_
73-8	13691-13698	whether	_
73-9	13699-13702	the	_
73-10	13703-13706	GMD	_
73-11	13707-13713	values	_
73-12	13714-13716	in	_
73-13	13717-13721	each	_
73-14	13722-13733	significant	_
73-15	13734-13741	cluster	_
73-16	13742-13747	could	_
73-17	13748-13761	differentiate	_
73-18	13762-13765	the	_
73-19	13766-13774	patients	_
73-20	13775-13779	from	_
73-21	13780-13783	the	_
73-22	13784-13791	healthy	_
73-23	13792-13800	controls	_
73-24	13801-13803	or	_
73-25	13804-13811	between	_
73-26	13812-13821	subgroups	_
73-27	13821-13822	.	_

#Text=Voxel–wise Pearson correlation coefficients were calculated between the GMD values of significant clusters and N-back performance scores, duration of illness and medication doses to examine potential associations between morphological deficits and clinical symptoms in the combined SZ-CD and SZ-NCD groups after controlling age and sex.
74-1	13823-13833	Voxel–wise	_
74-2	13834-13841	Pearson	_
74-3	13842-13853	correlation	_
74-4	13854-13866	coefficients	_
74-5	13867-13871	were	_
74-6	13872-13882	calculated	_
74-7	13883-13890	between	_
74-8	13891-13894	the	_
74-9	13895-13898	GMD	_
74-10	13899-13905	values	_
74-11	13906-13908	of	_
74-12	13909-13920	significant	_
74-13	13921-13929	clusters	_
74-14	13930-13933	and	_
74-15	13934-13940	N-back	_
74-16	13941-13952	performance	_
74-17	13953-13959	scores	_
74-18	13959-13960	,	_
74-19	13961-13969	duration	_
74-20	13970-13972	of	_
74-21	13973-13980	illness	_
74-22	13981-13984	and	_
74-23	13985-13995	medication	_
74-24	13996-14001	doses	_
74-25	14002-14004	to	_
74-26	14005-14012	examine	_
74-27	14013-14022	potential	_
74-28	14023-14035	associations	_
74-29	14036-14043	between	_
74-30	14044-14057	morphological	_
74-31	14058-14066	deficits	_
74-32	14067-14070	and	_
74-33	14071-14079	clinical	_
74-34	14080-14088	symptoms	_
74-35	14089-14091	in	_
74-36	14092-14095	the	_
74-37	14096-14104	combined	_
74-38	14105-14110	SZ-CD	_
74-39	14111-14114	and	_
74-40	14115-14121	SZ-NCD	_
74-41	14122-14128	groups	_
74-42	14129-14134	after	_
74-43	14135-14146	controlling	_
74-44	14147-14150	age	_
74-45	14151-14154	and	_
74-46	14155-14158	sex	_
74-47	14158-14159	.	_

#Text=Correlation analyses were performed in the Resting-State fMRI Data Analysis Toolkit with a corrected p < 0.05 (p < 0.05, cluster size >4484mm3).
75-1	14160-14171	Correlation	_
75-2	14172-14180	analyses	_
75-3	14181-14185	were	_
75-4	14186-14195	performed	_
75-5	14196-14198	in	_
75-6	14199-14202	the	_
75-7	14203-14216	Resting-State	_
75-8	14217-14221	fMRI	_
75-9	14222-14226	Data	_
75-10	14227-14235	Analysis	_
75-11	14236-14243	Toolkit	_
75-12	14244-14248	with	_
75-13	14249-14250	a	_
75-14	14251-14260	corrected	_
75-15	14261-14262	p	_
75-16	14263-14264	<	_
75-17	14265-14269	0.05	_
75-18	14270-14271	(	_
75-19	14271-14272	p	_
75-20	14273-14274	<	_
75-21	14275-14279	0.05	_
75-22	14279-14280	,	_
75-23	14281-14288	cluster	_
75-24	14289-14293	size	_
75-25	14294-14295	>	_
75-26	14295-14302	4484mm3	_
75-27	14302-14303	)	_
75-28	14303-14304	.	_

#Text=Results
#Text=Demographic and clinical characteristics
#Text=Among the three participant groups, no significant differences in age, years of education, or gender were found by ANOVA or chi-square tests (Table 1).
76-1	14305-14312	Results	_
76-2	14313-14324	Demographic	_
76-3	14325-14328	and	_
76-4	14329-14337	clinical	_
76-5	14338-14353	characteristics	_
76-6	14354-14359	Among	_
76-7	14360-14363	the	_
76-8	14364-14369	three	_
76-9	14370-14381	participant	_
76-10	14382-14388	groups	_
76-11	14388-14389	,	_
76-12	14390-14392	no	_
76-13	14393-14404	significant	_
76-14	14405-14416	differences	_
76-15	14417-14419	in	_
76-16	14420-14423	age	_
76-17	14423-14424	,	_
76-18	14425-14430	years	_
76-19	14431-14433	of	_
76-20	14434-14443	education	_
76-21	14443-14444	,	_
76-22	14445-14447	or	_
76-23	14448-14454	gender	_
76-24	14455-14459	were	_
76-25	14460-14465	found	_
76-26	14466-14468	by	_
76-27	14469-14474	ANOVA	_
76-28	14475-14477	or	_
76-29	14478-14488	chi-square	_
76-30	14489-14494	tests	_
76-31	14495-14496	(	_
76-32	14496-14501	Table	_
76-33	14502-14503	1	_
76-34	14503-14504	)	_
76-35	14504-14505	.	_

#Text=There were also no significant differences in the duration of illness, medication dosage, SANS, or SAPS between the SZ-CD and SZ-NCD patient groups.
77-1	14506-14511	There	_
77-2	14512-14516	were	_
77-3	14517-14521	also	_
77-4	14522-14524	no	_
77-5	14525-14536	significant	_
77-6	14537-14548	differences	_
77-7	14549-14551	in	_
77-8	14552-14555	the	_
77-9	14556-14564	duration	_
77-10	14565-14567	of	_
77-11	14568-14575	illness	_
77-12	14575-14576	,	_
77-13	14577-14587	medication	_
77-14	14588-14594	dosage	_
77-15	14594-14595	,	_
77-16	14596-14600	SANS	_
77-17	14600-14601	,	_
77-18	14602-14604	or	_
77-19	14605-14609	SAPS	_
77-20	14610-14617	between	_
77-21	14618-14621	the	_
77-22	14622-14627	SZ-CD	_
77-23	14628-14631	and	_
77-24	14632-14638	SZ-NCD	_
77-25	14639-14646	patient	_
77-26	14647-14653	groups	_
77-27	14653-14654	.	_

#Text=By contrast, a two-sample t-test showed that both information processing speed and verbal comprehension differed significantly between the SZ-CD and SZ-NCD groups.
78-1	14655-14657	By	_
78-2	14658-14666	contrast	_
78-3	14666-14667	,	_
78-4	14668-14669	a	_
78-5	14670-14680	two-sample	_
78-6	14681-14687	t-test	_
78-7	14688-14694	showed	_
78-8	14695-14699	that	_
78-9	14700-14704	both	_
78-10	14705-14716	information	_
78-11	14717-14727	processing	_
78-12	14728-14733	speed	_
78-13	14734-14737	and	_
78-14	14738-14744	verbal	_
78-15	14745-14758	comprehension	_
78-16	14759-14767	differed	_
78-17	14768-14781	significantly	_
78-18	14782-14789	between	_
78-19	14790-14793	the	_
78-20	14794-14799	SZ-CD	_
78-21	14800-14803	and	_
78-22	14804-14810	SZ-NCD	_
78-23	14811-14817	groups	_
78-24	14817-14818	.	_

#Text=Brain structural differences
#Text=Significant group differences among the three groups are shown.
79-1	14819-14824	Brain	_
79-2	14825-14835	structural	_
79-3	14836-14847	differences	_
79-4	14848-14859	Significant	_
79-5	14860-14865	group	_
79-6	14866-14877	differences	_
79-7	14878-14883	among	_
79-8	14884-14887	the	_
79-9	14888-14893	three	_
79-10	14894-14900	groups	_
79-11	14901-14904	are	_
79-12	14905-14910	shown	_
79-13	14910-14911	.	_

#Text=These significant regions are shown as color-coded statistical F-values superimposed on 3D slices of the human brain
#Text=Regions showing gray matter density among SZ-NCD, SZ-CD, and control group
#Text=\tMNI coordinates(mm, mm, mm)\t \tCluster size\tBrain regions\tF value\tZ value\tX\tY\tZ\t \t8659\tCerebellum\t14.79\t4.28\t−47\t−59\t−54\t \t2259\tRight MFG\t14.37\t4.22\t33\t20\t41\t \t8143\tLeft CL\t13.36\t4.07\t−11\t21\t−2\t \tLeft PHG\t10.38\t3.58\t−21\t−5\t−27\t \t3883\tLeft SMA\t10.39\t3.58\t−6\t−20\t59\t \tRight PreCG\t6.21\t2.66\t21\t−21\t66\t \t6256\tRight MOG\t7.75\t3.04\t42\t−68\t5\t \tRight SOG\t6.97\t2.85\t24\t−72\t27\t \t
#Text=X, Y, Z, coordinates of peak locations in the MNI space; F, Z, statistical value of peak voxel showing gray matter density differences among the three groups
#Text=
#Text=MFG middle frontal gyrus, CL caudate lobe, PHG parahippocampal gyrus, SMA supplementary motor area, PreCG precentral gyrus, MOG middle occipital gyrus, SOG superior occipital gyrus.
80-1	14912-14917	These	_
80-2	14918-14929	significant	_
80-3	14930-14937	regions	_
80-4	14938-14941	are	_
80-5	14942-14947	shown	_
80-6	14948-14950	as	_
80-7	14951-14962	color-coded	_
80-8	14963-14974	statistical	_
80-9	14975-14983	F-values	_
80-10	14984-14996	superimposed	_
80-11	14997-14999	on	_
80-12	15000-15002	3D	_
80-13	15003-15009	slices	_
80-14	15010-15012	of	_
80-15	15013-15016	the	_
80-16	15017-15022	human	_
80-17	15023-15028	brain	_
80-18	15029-15036	Regions	_
80-19	15037-15044	showing	_
80-20	15045-15049	gray	_
80-21	15050-15056	matter	_
80-22	15057-15064	density	_
80-23	15065-15070	among	_
80-24	15071-15077	SZ-NCD	_
80-25	15077-15078	,	_
80-26	15079-15084	SZ-CD	_
80-27	15084-15085	,	_
80-28	15086-15089	and	_
80-29	15090-15097	control	_
80-30	15098-15103	group	_
80-31	15105-15108	MNI	_
80-32	15109-15120	coordinates	_
80-33	15120-15121	(	_
80-34	15121-15123	mm	_
80-35	15123-15124	,	_
80-36	15125-15127	mm	_
80-37	15127-15128	,	_
80-38	15129-15131	mm	_
80-39	15131-15132	)	_
80-40	15135-15142	Cluster	_
80-41	15143-15147	size	_
80-42	15148-15153	Brain	_
80-43	15154-15161	regions	_
80-44	15162-15163	F	_
80-45	15164-15169	value	_
80-46	15170-15171	Z	_
80-47	15172-15177	value	_
80-48	15178-15179	X	_
80-49	15180-15181	Y	_
80-50	15182-15183	Z	_
80-51	15186-15190	8659	_
80-52	15191-15201	Cerebellum	_
80-53	15202-15207	14.79	_
80-54	15208-15212	4.28	_
80-55	15213-15214	−	_
80-56	15214-15216	47	_
80-57	15217-15218	−	_
80-58	15218-15220	59	_
80-59	15221-15222	−	_
80-60	15222-15224	54	_
80-61	15227-15231	2259	_
80-62	15232-15237	Right	_
80-63	15238-15241	MFG	_
80-64	15242-15247	14.37	_
80-65	15248-15252	4.22	_
80-66	15253-15255	33	_
80-67	15256-15258	20	_
80-68	15259-15261	41	_
80-69	15264-15268	8143	_
80-70	15269-15273	Left	_
80-71	15274-15276	CL	_
80-72	15277-15282	13.36	_
80-73	15283-15287	4.07	_
80-74	15288-15289	−	_
80-75	15289-15291	11	_
80-76	15292-15294	21	_
80-77	15295-15296	−	_
80-78	15296-15297	2	_
80-79	15300-15304	Left	_
80-80	15305-15308	PHG	_
80-81	15309-15314	10.38	_
80-82	15315-15319	3.58	_
80-83	15320-15321	−	_
80-84	15321-15323	21	_
80-85	15324-15325	−	_
80-86	15325-15326	5	_
80-87	15327-15328	−	_
80-88	15328-15330	27	_
80-89	15333-15337	3883	_
80-90	15338-15342	Left	_
80-91	15343-15346	SMA	_
80-92	15347-15352	10.39	_
80-93	15353-15357	3.58	_
80-94	15358-15359	−	_
80-95	15359-15360	6	_
80-96	15361-15362	−	_
80-97	15362-15364	20	_
80-98	15365-15367	59	_
80-99	15370-15375	Right	_
80-100	15376-15381	PreCG	_
80-101	15382-15386	6.21	_
80-102	15387-15391	2.66	_
80-103	15392-15394	21	_
80-104	15395-15396	−	_
80-105	15396-15398	21	_
80-106	15399-15401	66	_
80-107	15404-15408	6256	_
80-108	15409-15414	Right	_
80-109	15415-15418	MOG	_
80-110	15419-15423	7.75	_
80-111	15424-15428	3.04	_
80-112	15429-15431	42	_
80-113	15432-15433	−	_
80-114	15433-15435	68	_
80-115	15436-15437	5	_
80-116	15440-15445	Right	_
80-117	15446-15449	SOG	_
80-118	15450-15454	6.97	_
80-119	15455-15459	2.85	_
80-120	15460-15462	24	_
80-121	15463-15464	−	_
80-122	15464-15466	72	_
80-123	15467-15469	27	_
80-124	15473-15474	X	_
80-125	15474-15475	,	_
80-126	15476-15477	Y	_
80-127	15477-15478	,	_
80-128	15479-15480	Z	_
80-129	15480-15481	,	_
80-130	15482-15493	coordinates	_
80-131	15494-15496	of	_
80-132	15497-15501	peak	_
80-133	15502-15511	locations	_
80-134	15512-15514	in	_
80-135	15515-15518	the	_
80-136	15519-15522	MNI	_
80-137	15523-15528	space	_
80-138	15528-15529	;	_
80-139	15530-15531	F	_
80-140	15531-15532	,	_
80-141	15533-15534	Z	_
80-142	15534-15535	,	_
80-143	15536-15547	statistical	_
80-144	15548-15553	value	_
80-145	15554-15556	of	_
80-146	15557-15561	peak	_
80-147	15562-15567	voxel	_
80-148	15568-15575	showing	_
80-149	15576-15580	gray	_
80-150	15581-15587	matter	_
80-151	15588-15595	density	_
80-152	15596-15607	differences	_
80-153	15608-15613	among	_
80-154	15614-15617	the	_
80-155	15618-15623	three	_
80-156	15624-15630	groups	_
80-157	15632-15635	MFG	_
80-158	15636-15642	middle	_
80-159	15643-15650	frontal	_
80-160	15651-15656	gyrus	_
80-161	15656-15657	,	_
80-162	15658-15660	CL	_
80-163	15661-15668	caudate	_
80-164	15669-15673	lobe	_
80-165	15673-15674	,	_
80-166	15675-15678	PHG	_
80-167	15679-15694	parahippocampal	_
80-168	15695-15700	gyrus	_
80-169	15700-15701	,	_
80-170	15702-15705	SMA	_
80-171	15706-15719	supplementary	_
80-172	15720-15725	motor	_
80-173	15726-15730	area	_
80-174	15730-15731	,	_
80-175	15732-15737	PreCG	_
80-176	15738-15748	precentral	_
80-177	15749-15754	gyrus	_
80-178	15754-15755	,	_
80-179	15756-15759	MOG	_
80-180	15760-15766	middle	_
80-181	15767-15776	occipital	_
80-182	15777-15782	gyrus	_
80-183	15782-15783	,	_
80-184	15784-15787	SOG	_
80-185	15788-15796	superior	_
80-186	15797-15806	occipital	_
80-187	15807-15812	gyrus	_
80-188	15812-15813	.	_

#Text=P < 0.05, corrected for multiple comparisons, cluster size >3554 voxels
#Text=Significant group differences of two patients groups compared to healthy controls were identified. a Patients with cognitive deficits vs healthy controls, P < 0.05, corrected for multiple comparisons, cluster size >3152 voxels and. b Patients without cognitive deficits vs healthy controls.
81-1	15814-15815	P	_
81-2	15816-15817	<	_
81-3	15818-15822	0.05	_
81-4	15822-15823	,	_
81-5	15824-15833	corrected	_
81-6	15834-15837	for	_
81-7	15838-15846	multiple	_
81-8	15847-15858	comparisons	_
81-9	15858-15859	,	_
81-10	15860-15867	cluster	_
81-11	15868-15872	size	_
81-12	15873-15874	>	_
81-13	15874-15878	3554	_
81-14	15879-15885	voxels	_
81-15	15886-15897	Significant	_
81-16	15898-15903	group	_
81-17	15904-15915	differences	_
81-18	15916-15918	of	_
81-19	15919-15922	two	_
81-20	15923-15931	patients	_
81-21	15932-15938	groups	_
81-22	15939-15947	compared	_
81-23	15948-15950	to	_
81-24	15951-15958	healthy	_
81-25	15959-15967	controls	_
81-26	15968-15972	were	_
81-27	15973-15983	identified	_
81-28	15983-15984	.	_
81-29	15985-15986	a	_
81-30	15987-15995	Patients	_
81-31	15996-16000	with	_
81-32	16001-16010	cognitive	_
81-33	16011-16019	deficits	_
81-34	16020-16022	vs	_
81-35	16023-16030	healthy	_
81-36	16031-16039	controls	_
81-37	16039-16040	,	_
81-38	16041-16042	P	_
81-39	16043-16044	<	_
81-40	16045-16049	0.05	_
81-41	16049-16050	,	_
81-42	16051-16060	corrected	_
81-43	16061-16064	for	_
81-44	16065-16073	multiple	_
81-45	16074-16085	comparisons	_
81-46	16085-16086	,	_
81-47	16087-16094	cluster	_
81-48	16095-16099	size	_
81-49	16100-16101	>	_
81-50	16101-16105	3152	_
81-51	16106-16112	voxels	_
81-52	16113-16116	and	_
81-53	16116-16117	.	_
81-54	16118-16119	b	_
81-55	16120-16128	Patients	_
81-56	16129-16136	without	_
81-57	16137-16146	cognitive	_
81-58	16147-16155	deficits	_
81-59	16156-16158	vs	_
81-60	16159-16166	healthy	_
81-61	16167-16175	controls	_
81-62	16175-16176	.	_

#Text=P < 0.05, corrected for multiple comparisons, cluster size >3369 voxels. c Patients with cognitive deficits vs Patients without cognitive deficits.
82-1	16177-16178	P	_
82-2	16179-16180	<	_
82-3	16181-16185	0.05	_
82-4	16185-16186	,	_
82-5	16187-16196	corrected	_
82-6	16197-16200	for	_
82-7	16201-16209	multiple	_
82-8	16210-16221	comparisons	_
82-9	16221-16222	,	_
82-10	16223-16230	cluster	_
82-11	16231-16235	size	_
82-12	16236-16237	>	_
82-13	16237-16241	3369	_
82-14	16242-16248	voxels	_
82-15	16248-16249	.	_
82-16	16250-16251	c	_
82-17	16252-16260	Patients	_
82-18	16261-16265	with	_
82-19	16266-16275	cognitive	_
82-20	16276-16284	deficits	_
82-21	16285-16287	vs	_
82-22	16288-16296	Patients	_
82-23	16297-16304	without	_
82-24	16305-16314	cognitive	_
82-25	16315-16323	deficits	_
82-26	16323-16324	.	_

#Text=P < 0.05, corrected for multiple comparisons, cluster size >3380 voxels
#Text=Significantly different clusters of gray matter density identified by post hoc analysis between SZ-CD, SZ-NCD, and HCs
#Text=\tMNI coordinates(mm, mm, mm)\t \tContrasts\tCluster size\tBrain regions\tT value\tZ value\tX\tY\tZ\t \tSZ-CDvsHCs\t25,102\tCerebellumvermis, tonsil\t4.43\t4.04\t−11\t−57\t−70\t \t3598\tRight STG\t3.29\t3.11\t68\t−8\t6\t \tLeft PUT\t2.97\t2.84\t−26\t8\t2\t \tSZ-NCD vsHCs\t8879\tLeft CL\t5.02\t4.49\t−11\t21\t−2\t \tLeft PHG\t4.34\t3.97\t−21\t−5\t−27\t \t5924\tLeft Cerebellum\t3.41\t3.22\t−42\t−59\t−48\t \tSZ-CDvsSZ-NCD\t8113\tLeft SMA\t4.54\t4.13\t−6\t−20\t59\t \tLeft PreCG\t3.4\t3.21\t−26\t−18\t60\t \tRight PreCG\t4.0\t3.7\t41\t−15\t36\t \t3383\tCerebellumvermis, tonsil\t3.67\t3.44\t8\t−44\t−2\t \t
#Text=X, Y, Z, coordinates of peak locations in the MNI space
#Text=
#Text=STG superior temporal gyrus, PUT putamen, CL caudate lobe, PHG parahippocampal gyrus, SMA, supplementary motor area, PreCG precentral gyrus, MNI Montreal Neurological Institute, SZ-CD schizophrenia with cognitive deficits, SZ-NCD schizophrenia with no cognitive deficits
#Text=P < 0.05, corrected for multiple comparisons, cluster size >3152 voxels (SZ-CD vs HCs), cluster size >3369 voxels (SZ-NCD vs HCs), cluster size > 3380 voxels (SZ-CD vs SZ-NCD)
#Text=ANOVA analyses showed significant group differences in the vermis, tonsil and horizontal fissure of cerebellum, right middle frontal gyrus, left caudate lobe, left supplementary motor area, and right middle occipital gyrus (Fig. 1).
83-1	16325-16326	P	_
83-2	16327-16328	<	_
83-3	16329-16333	0.05	_
83-4	16333-16334	,	_
83-5	16335-16344	corrected	_
83-6	16345-16348	for	_
83-7	16349-16357	multiple	_
83-8	16358-16369	comparisons	_
83-9	16369-16370	,	_
83-10	16371-16378	cluster	_
83-11	16379-16383	size	_
83-12	16384-16385	>	_
83-13	16385-16389	3380	_
83-14	16390-16396	voxels	_
83-15	16397-16410	Significantly	_
83-16	16411-16420	different	_
83-17	16421-16429	clusters	_
83-18	16430-16432	of	_
83-19	16433-16437	gray	_
83-20	16438-16444	matter	_
83-21	16445-16452	density	_
83-22	16453-16463	identified	_
83-23	16464-16466	by	_
83-24	16467-16471	post	_
83-25	16472-16475	hoc	_
83-26	16476-16484	analysis	_
83-27	16485-16492	between	_
83-28	16493-16498	SZ-CD	_
83-29	16498-16499	,	_
83-30	16500-16506	SZ-NCD	_
83-31	16506-16507	,	_
83-32	16508-16511	and	_
83-33	16512-16515	HCs	_
83-34	16517-16520	MNI	_
83-35	16521-16532	coordinates	_
83-36	16532-16533	(	_
83-37	16533-16535	mm	_
83-38	16535-16536	,	_
83-39	16537-16539	mm	_
83-40	16539-16540	,	_
83-41	16541-16543	mm	_
83-42	16543-16544	)	_
83-43	16547-16556	Contrasts	_
83-44	16557-16564	Cluster	_
83-45	16565-16569	size	_
83-46	16570-16575	Brain	_
83-47	16576-16583	regions	_
83-48	16584-16585	T	_
83-49	16586-16591	value	_
83-50	16592-16593	Z	_
83-51	16594-16599	value	_
83-52	16600-16601	X	_
83-53	16602-16603	Y	_
83-54	16604-16605	Z	_
83-55	16608-16618	SZ-CDvsHCs	_
83-56	16619-16625	25,102	_
83-57	16626-16642	Cerebellumvermis	_
83-58	16642-16643	,	_
83-59	16644-16650	tonsil	_
83-60	16651-16655	4.43	_
83-61	16656-16660	4.04	_
83-62	16661-16662	−	_
83-63	16662-16664	11	_
83-64	16665-16666	−	_
83-65	16666-16668	57	_
83-66	16669-16670	−	_
83-67	16670-16672	70	_
83-68	16675-16679	3598	_
83-69	16680-16685	Right	_
83-70	16686-16689	STG	_
83-71	16690-16694	3.29	_
83-72	16695-16699	3.11	_
83-73	16700-16702	68	_
83-74	16703-16704	−	_
83-75	16704-16705	8	_
83-76	16706-16707	6	_
83-77	16710-16714	Left	_
83-78	16715-16718	PUT	_
83-79	16719-16723	2.97	_
83-80	16724-16728	2.84	_
83-81	16729-16730	−	_
83-82	16730-16732	26	_
83-83	16733-16734	8	_
83-84	16735-16736	2	_
83-85	16739-16745	SZ-NCD	_
83-86	16746-16751	vsHCs	_
83-87	16752-16756	8879	_
83-88	16757-16761	Left	_
83-89	16762-16764	CL	_
83-90	16765-16769	5.02	_
83-91	16770-16774	4.49	_
83-92	16775-16776	−	_
83-93	16776-16778	11	_
83-94	16779-16781	21	_
83-95	16782-16783	−	_
83-96	16783-16784	2	_
83-97	16787-16791	Left	_
83-98	16792-16795	PHG	_
83-99	16796-16800	4.34	_
83-100	16801-16805	3.97	_
83-101	16806-16807	−	_
83-102	16807-16809	21	_
83-103	16810-16811	−	_
83-104	16811-16812	5	_
83-105	16813-16814	−	_
83-106	16814-16816	27	_
83-107	16819-16823	5924	_
83-108	16824-16828	Left	_
83-109	16829-16839	Cerebellum	_
83-110	16840-16844	3.41	_
83-111	16845-16849	3.22	_
83-112	16850-16851	−	_
83-113	16851-16853	42	_
83-114	16854-16855	−	_
83-115	16855-16857	59	_
83-116	16858-16859	−	_
83-117	16859-16861	48	_
83-118	16864-16877	SZ-CDvsSZ-NCD	_
83-119	16878-16882	8113	_
83-120	16883-16887	Left	_
83-121	16888-16891	SMA	_
83-122	16892-16896	4.54	_
83-123	16897-16901	4.13	_
83-124	16902-16903	−	_
83-125	16903-16904	6	_
83-126	16905-16906	−	_
83-127	16906-16908	20	_
83-128	16909-16911	59	_
83-129	16914-16918	Left	_
83-130	16919-16924	PreCG	_
83-131	16925-16928	3.4	_
83-132	16929-16933	3.21	_
83-133	16934-16935	−	_
83-134	16935-16937	26	_
83-135	16938-16939	−	_
83-136	16939-16941	18	_
83-137	16942-16944	60	_
83-138	16947-16952	Right	_
83-139	16953-16958	PreCG	_
83-140	16959-16962	4.0	_
83-141	16963-16966	3.7	_
83-142	16967-16969	41	_
83-143	16970-16971	−	_
83-144	16971-16973	15	_
83-145	16974-16976	36	_
83-146	16979-16983	3383	_
83-147	16984-17000	Cerebellumvermis	_
83-148	17000-17001	,	_
83-149	17002-17008	tonsil	_
83-150	17009-17013	3.67	_
83-151	17014-17018	3.44	_
83-152	17019-17020	8	_
83-153	17021-17022	−	_
83-154	17022-17024	44	_
83-155	17025-17026	−	_
83-156	17026-17027	2	_
83-157	17031-17032	X	_
83-158	17032-17033	,	_
83-159	17034-17035	Y	_
83-160	17035-17036	,	_
83-161	17037-17038	Z	_
83-162	17038-17039	,	_
83-163	17040-17051	coordinates	_
83-164	17052-17054	of	_
83-165	17055-17059	peak	_
83-166	17060-17069	locations	_
83-167	17070-17072	in	_
83-168	17073-17076	the	_
83-169	17077-17080	MNI	_
83-170	17081-17086	space	_
83-171	17088-17091	STG	_
83-172	17092-17100	superior	_
83-173	17101-17109	temporal	_
83-174	17110-17115	gyrus	_
83-175	17115-17116	,	_
83-176	17117-17120	PUT	_
83-177	17121-17128	putamen	_
83-178	17128-17129	,	_
83-179	17130-17132	CL	_
83-180	17133-17140	caudate	_
83-181	17141-17145	lobe	_
83-182	17145-17146	,	_
83-183	17147-17150	PHG	_
83-184	17151-17166	parahippocampal	_
83-185	17167-17172	gyrus	_
83-186	17172-17173	,	_
83-187	17174-17177	SMA	_
83-188	17177-17178	,	_
83-189	17179-17192	supplementary	_
83-190	17193-17198	motor	_
83-191	17199-17203	area	_
83-192	17203-17204	,	_
83-193	17205-17210	PreCG	_
83-194	17211-17221	precentral	_
83-195	17222-17227	gyrus	_
83-196	17227-17228	,	_
83-197	17229-17232	MNI	_
83-198	17233-17241	Montreal	_
83-199	17242-17254	Neurological	_
83-200	17255-17264	Institute	_
83-201	17264-17265	,	_
83-202	17266-17271	SZ-CD	_
83-203	17272-17285	schizophrenia	_
83-204	17286-17290	with	_
83-205	17291-17300	cognitive	_
83-206	17301-17309	deficits	_
83-207	17309-17310	,	_
83-208	17311-17317	SZ-NCD	_
83-209	17318-17331	schizophrenia	_
83-210	17332-17336	with	_
83-211	17337-17339	no	_
83-212	17340-17349	cognitive	_
83-213	17350-17358	deficits	_
83-214	17359-17360	P	_
83-215	17361-17362	<	_
83-216	17363-17367	0.05	_
83-217	17367-17368	,	_
83-218	17369-17378	corrected	_
83-219	17379-17382	for	_
83-220	17383-17391	multiple	_
83-221	17392-17403	comparisons	_
83-222	17403-17404	,	_
83-223	17405-17412	cluster	_
83-224	17413-17417	size	_
83-225	17418-17419	>	_
83-226	17419-17423	3152	_
83-227	17424-17430	voxels	_
83-228	17431-17432	(	_
83-229	17432-17437	SZ-CD	_
83-230	17438-17440	vs	_
83-231	17441-17444	HCs	_
83-232	17444-17445	)	_
83-233	17445-17446	,	_
83-234	17447-17454	cluster	_
83-235	17455-17459	size	_
83-236	17460-17461	>	_
83-237	17461-17465	3369	_
83-238	17466-17472	voxels	_
83-239	17473-17474	(	_
83-240	17474-17480	SZ-NCD	_
83-241	17481-17483	vs	_
83-242	17484-17487	HCs	_
83-243	17487-17488	)	_
83-244	17488-17489	,	_
83-245	17490-17497	cluster	_
83-246	17498-17502	size	_
83-247	17503-17504	>	_
83-248	17505-17509	3380	_
83-249	17510-17516	voxels	_
83-250	17517-17518	(	_
83-251	17518-17523	SZ-CD	_
83-252	17524-17526	vs	_
83-253	17527-17533	SZ-NCD	_
83-254	17533-17534	)	_
83-255	17535-17540	ANOVA	_
83-256	17541-17549	analyses	_
83-257	17550-17556	showed	_
83-258	17557-17568	significant	_
83-259	17569-17574	group	_
83-260	17575-17586	differences	_
83-261	17587-17589	in	_
83-262	17590-17593	the	_
83-263	17594-17600	vermis	_
83-264	17600-17601	,	_
83-265	17602-17608	tonsil	_
83-266	17609-17612	and	_
83-267	17613-17623	horizontal	_
83-268	17624-17631	fissure	_
83-269	17632-17634	of	_
83-270	17635-17645	cerebellum	_
83-271	17645-17646	,	_
83-272	17647-17652	right	_
83-273	17653-17659	middle	_
83-274	17660-17667	frontal	_
83-275	17668-17673	gyrus	_
83-276	17673-17674	,	_
83-277	17675-17679	left	_
83-278	17680-17687	caudate	_
83-279	17688-17692	lobe	_
83-280	17692-17693	,	_
83-281	17694-17698	left	_
83-282	17699-17712	supplementary	_
83-283	17713-17718	motor	_
83-284	17719-17723	area	_
83-285	17723-17724	,	_
83-286	17725-17728	and	_
83-287	17729-17734	right	_
83-288	17735-17741	middle	_
83-289	17742-17751	occipital	_
83-290	17752-17757	gyrus	_
83-291	17758-17759	(	_
83-292	17759-17762	Fig	_
83-293	17762-17763	.	_
83-294	17763-17764	 	_
83-295	17764-17765	1	_
83-296	17765-17766	)	_
83-297	17766-17767	.	_

#Text=The cluster size, F score, Z score, and coordinates of peak voxels for these clusters were listed in Table 2.
84-1	17768-17771	The	_
84-2	17772-17779	cluster	_
84-3	17780-17784	size	_
84-4	17784-17785	,	_
84-5	17786-17787	F	_
84-6	17788-17793	score	_
84-7	17793-17794	,	_
84-8	17795-17796	Z	_
84-9	17797-17802	score	_
84-10	17802-17803	,	_
84-11	17804-17807	and	_
84-12	17808-17819	coordinates	_
84-13	17820-17822	of	_
84-14	17823-17827	peak	_
84-15	17828-17834	voxels	_
84-16	17835-17838	for	_
84-17	17839-17844	these	_
84-18	17845-17853	clusters	_
84-19	17854-17858	were	_
84-20	17859-17865	listed	_
84-21	17866-17868	in	_
84-22	17869-17874	Table	_
84-23	17874-17875	 	_
84-24	17875-17876	2	_
84-25	17876-17877	.	_

#Text=Post hoc comparisons showed that the part of gray matter of the cerebellum, left putamen, hippocampus, parahippocampal gyrus, and bilateral caudate nucleus were all significantly reduced in the SZ-CD and the SZ-NCD patients, compared with that in the HCs, and that patients with cognitive deficits were found to have reduced gray matter density in the vermis and tonsil of cerebellum, left supplementary motor area, bilateral precentral gyrus compared with patients without cognitive deficits (Fig. 2).
85-1	17878-17882	Post	_
85-2	17883-17886	hoc	_
85-3	17887-17898	comparisons	_
85-4	17899-17905	showed	_
85-5	17906-17910	that	_
85-6	17911-17914	the	_
85-7	17915-17919	part	_
85-8	17920-17922	of	_
85-9	17923-17927	gray	_
85-10	17928-17934	matter	_
85-11	17935-17937	of	_
85-12	17938-17941	the	_
85-13	17942-17952	cerebellum	_
85-14	17952-17953	,	_
85-15	17954-17958	left	_
85-16	17959-17966	putamen	_
85-17	17966-17967	,	_
85-18	17968-17979	hippocampus	_
85-19	17979-17980	,	_
85-20	17981-17996	parahippocampal	_
85-21	17997-18002	gyrus	_
85-22	18002-18003	,	_
85-23	18004-18007	and	_
85-24	18008-18017	bilateral	_
85-25	18018-18025	caudate	_
85-26	18026-18033	nucleus	_
85-27	18034-18038	were	_
85-28	18039-18042	all	_
85-29	18043-18056	significantly	_
85-30	18057-18064	reduced	_
85-31	18065-18067	in	_
85-32	18068-18071	the	_
85-33	18072-18077	SZ-CD	_
85-34	18078-18081	and	_
85-35	18082-18085	the	_
85-36	18086-18092	SZ-NCD	_
85-37	18093-18101	patients	_
85-38	18101-18102	,	_
85-39	18103-18111	compared	_
85-40	18112-18116	with	_
85-41	18117-18121	that	_
85-42	18122-18124	in	_
85-43	18125-18128	the	_
85-44	18129-18132	HCs	_
85-45	18132-18133	,	_
85-46	18134-18137	and	_
85-47	18138-18142	that	_
85-48	18143-18151	patients	_
85-49	18152-18156	with	_
85-50	18157-18166	cognitive	_
85-51	18167-18175	deficits	_
85-52	18176-18180	were	_
85-53	18181-18186	found	_
85-54	18187-18189	to	_
85-55	18190-18194	have	_
85-56	18195-18202	reduced	_
85-57	18203-18207	gray	_
85-58	18208-18214	matter	_
85-59	18215-18222	density	_
85-60	18223-18225	in	_
85-61	18226-18229	the	_
85-62	18230-18236	vermis	_
85-63	18237-18240	and	_
85-64	18241-18247	tonsil	_
85-65	18248-18250	of	_
85-66	18251-18261	cerebellum	_
85-67	18261-18262	,	_
85-68	18263-18267	left	_
85-69	18268-18281	supplementary	_
85-70	18282-18287	motor	_
85-71	18288-18292	area	_
85-72	18292-18293	,	_
85-73	18294-18303	bilateral	_
85-74	18304-18314	precentral	_
85-75	18315-18320	gyrus	_
85-76	18321-18329	compared	_
85-77	18330-18334	with	_
85-78	18335-18343	patients	_
85-79	18344-18351	without	_
85-80	18352-18361	cognitive	_
85-81	18362-18370	deficits	_
85-82	18371-18372	(	_
85-83	18372-18375	Fig	_
85-84	18375-18376	.	_
85-85	18376-18377	 	_
85-86	18377-18378	2	_
85-87	18378-18379	)	_
85-88	18379-18380	.	_

#Text=Decreased GMD in vermis and tonsil of bilateral cerebellum were found in SZ-CD group, while anterior and posterior lobe of left cerebellum in SZ-NCD group.
86-1	18381-18390	Decreased	_
86-2	18391-18394	GMD	_
86-3	18395-18397	in	_
86-4	18398-18404	vermis	_
86-5	18405-18408	and	_
86-6	18409-18415	tonsil	_
86-7	18416-18418	of	_
86-8	18419-18428	bilateral	_
86-9	18429-18439	cerebellum	_
86-10	18440-18444	were	_
86-11	18445-18450	found	_
86-12	18451-18453	in	_
86-13	18454-18459	SZ-CD	_
86-14	18460-18465	group	_
86-15	18465-18466	,	_
86-16	18467-18472	while	_
86-17	18473-18481	anterior	_
86-18	18482-18485	and	_
86-19	18486-18495	posterior	_
86-20	18496-18500	lobe	_
86-21	18501-18503	of	_
86-22	18504-18508	left	_
86-23	18509-18519	cerebellum	_
86-24	18520-18522	in	_
86-25	18523-18529	SZ-NCD	_
86-26	18530-18535	group	_
86-27	18535-18536	.	_

#Text=The peak voxel details of these clusters were listed in Table 3.
87-1	18537-18540	The	_
87-2	18541-18545	peak	_
87-3	18546-18551	voxel	_
87-4	18552-18559	details	_
87-5	18560-18562	of	_
87-6	18563-18568	these	_
87-7	18569-18577	clusters	_
87-8	18578-18582	were	_
87-9	18583-18589	listed	_
87-10	18590-18592	in	_
87-11	18593-18598	Table	_
87-12	18598-18599	 	_
87-13	18599-18600	3	_
87-14	18600-18601	.	_

#Text=Significant differences of GMD in each cluster and receiver operating characteristic (ROC) curve for each pair of groups.
88-1	18606-18617	Significant	_
88-2	18618-18629	differences	_
88-3	18630-18632	of	_
88-4	18633-18636	GMD	_
88-5	18637-18639	in	_
88-6	18640-18644	each	_
88-7	18645-18652	cluster	_
88-8	18653-18656	and	_
88-9	18657-18665	receiver	_
88-10	18666-18675	operating	_
88-11	18676-18690	characteristic	_
88-12	18691-18692	(	_
88-13	18692-18695	ROC	_
88-14	18695-18696	)	_
88-15	18697-18702	curve	_
88-16	18703-18706	for	_
88-17	18707-18711	each	_
88-18	18712-18716	pair	_
88-19	18717-18719	of	_
88-20	18720-18726	groups	_
88-21	18726-18727	.	_

#Text=Classifier results showed GMD of cerebellar vermis tonsil cluster in SZ-CD vs HCs could differentiate SZ-CD from controls (sensitivity,92.5%;specificity75%, a), the left cerebellum cluster (anterior lobe and posterior lobe) in SZ-NCD vs HCs could distinguish between SZ-NCD vs controls(sensitivity,90.5%;specificity,77.8%, b) and all SZ versus all controls (sensitivity,90.5%,specificity70.6%, b), left supplementary motor area (SMA)cluster(left SMA, bilateral precentral gyrus) in SZ-CD vs SZ-NCD could differentiate SZ-CD from SZ-NCD (sensitivity,83.3%;specificity,81.2%, c), GMD of cerebellar vermis tonsil cluster in SZ-CD vs SZ-NCD could differentiate SZ-CD from controls (sensitivity,92.5%;specificity75%, d) GMD, gray matter density; SZ-CD, schizophrenia with cognitive deficits; SZ-NCD, schizophrenia without cognitive deficits; HCs, healthy controls
#Text=For further quantitative analysis, we compared the mean GMD in significant clusters among the three groups and between each pair of groups.
89-1	18728-18738	Classifier	_
89-2	18739-18746	results	_
89-3	18747-18753	showed	_
89-4	18754-18757	GMD	_
89-5	18758-18760	of	_
89-6	18761-18771	cerebellar	_
89-7	18772-18778	vermis	_
89-8	18779-18785	tonsil	_
89-9	18786-18793	cluster	_
89-10	18794-18796	in	_
89-11	18797-18802	SZ-CD	_
89-12	18803-18805	vs	_
89-13	18806-18809	HCs	_
89-14	18810-18815	could	_
89-15	18816-18829	differentiate	_
89-16	18830-18835	SZ-CD	_
89-17	18836-18840	from	_
89-18	18841-18849	controls	_
89-19	18850-18851	(	_
89-20	18851-18862	sensitivity	_
89-21	18862-18863	,	_
89-22	18863-18868	92.5%	_
89-23	18868-18869	;	_
89-24	18869-18883	specificity75%	_
89-25	18883-18884	,	_
89-26	18885-18886	a	_
89-27	18886-18887	)	_
89-28	18887-18888	,	_
89-29	18889-18892	the	_
89-30	18893-18897	left	_
89-31	18898-18908	cerebellum	_
89-32	18909-18916	cluster	_
89-33	18917-18918	(	_
89-34	18918-18926	anterior	_
89-35	18927-18931	lobe	_
89-36	18932-18935	and	_
89-37	18936-18945	posterior	_
89-38	18946-18950	lobe	_
89-39	18950-18951	)	_
89-40	18952-18954	in	_
89-41	18955-18961	SZ-NCD	_
89-42	18962-18964	vs	_
89-43	18965-18968	HCs	_
89-44	18969-18974	could	_
89-45	18975-18986	distinguish	_
89-46	18987-18994	between	_
89-47	18995-19001	SZ-NCD	_
89-48	19002-19004	vs	_
89-49	19005-19013	controls	_
89-50	19013-19014	(	_
89-51	19014-19025	sensitivity	_
89-52	19025-19026	,	_
89-53	19026-19031	90.5%	_
89-54	19031-19032	;	_
89-55	19032-19043	specificity	_
89-56	19043-19044	,	_
89-57	19044-19049	77.8%	_
89-58	19049-19050	,	_
89-59	19051-19052	b	_
89-60	19052-19053	)	_
89-61	19054-19057	and	_
89-62	19058-19061	all	_
89-63	19062-19064	SZ	_
89-64	19065-19071	versus	_
89-65	19072-19075	all	_
89-66	19076-19084	controls	_
89-67	19085-19086	(	_
89-68	19086-19097	sensitivity	_
89-69	19097-19098	,	_
89-70	19098-19103	90.5%	_
89-71	19103-19104	,	_
89-72	19104-19120	specificity70.6%	_
89-73	19120-19121	,	_
89-74	19122-19123	b	_
89-75	19123-19124	)	_
89-76	19124-19125	,	_
89-77	19126-19130	left	_
89-78	19131-19144	supplementary	_
89-79	19145-19150	motor	_
89-80	19151-19155	area	_
89-81	19156-19157	(	_
89-82	19157-19160	SMA	_
89-83	19160-19161	)	_
89-84	19161-19168	cluster	_
89-85	19168-19169	(	_
89-86	19169-19173	left	_
89-87	19174-19177	SMA	_
89-88	19177-19178	,	_
89-89	19179-19188	bilateral	_
89-90	19189-19199	precentral	_
89-91	19200-19205	gyrus	_
89-92	19205-19206	)	_
89-93	19207-19209	in	_
89-94	19210-19215	SZ-CD	_
89-95	19216-19218	vs	_
89-96	19219-19225	SZ-NCD	_
89-97	19226-19231	could	_
89-98	19232-19245	differentiate	_
89-99	19246-19251	SZ-CD	_
89-100	19252-19256	from	_
89-101	19257-19263	SZ-NCD	_
89-102	19264-19265	(	_
89-103	19265-19276	sensitivity	_
89-104	19276-19277	,	_
89-105	19277-19282	83.3%	_
89-106	19282-19283	;	_
89-107	19283-19294	specificity	_
89-108	19294-19295	,	_
89-109	19295-19300	81.2%	_
89-110	19300-19301	,	_
89-111	19302-19303	c	_
89-112	19303-19304	)	_
89-113	19304-19305	,	_
89-114	19306-19309	GMD	_
89-115	19310-19312	of	_
89-116	19313-19323	cerebellar	_
89-117	19324-19330	vermis	_
89-118	19331-19337	tonsil	_
89-119	19338-19345	cluster	_
89-120	19346-19348	in	_
89-121	19349-19354	SZ-CD	_
89-122	19355-19357	vs	_
89-123	19358-19364	SZ-NCD	_
89-124	19365-19370	could	_
89-125	19371-19384	differentiate	_
89-126	19385-19390	SZ-CD	_
89-127	19391-19395	from	_
89-128	19396-19404	controls	_
89-129	19405-19406	(	_
89-130	19406-19417	sensitivity	_
89-131	19417-19418	,	_
89-132	19418-19423	92.5%	_
89-133	19423-19424	;	_
89-134	19424-19438	specificity75%	_
89-135	19438-19439	,	_
89-136	19440-19441	d	_
89-137	19441-19442	)	_
89-138	19443-19446	GMD	_
89-139	19446-19447	,	_
89-140	19448-19452	gray	_
89-141	19453-19459	matter	_
89-142	19460-19467	density	_
89-143	19467-19468	;	_
89-144	19469-19474	SZ-CD	_
89-145	19474-19475	,	_
89-146	19476-19489	schizophrenia	_
89-147	19490-19494	with	_
89-148	19495-19504	cognitive	_
89-149	19505-19513	deficits	_
89-150	19513-19514	;	_
89-151	19515-19521	SZ-NCD	_
89-152	19521-19522	,	_
89-153	19523-19536	schizophrenia	_
89-154	19537-19544	without	_
89-155	19545-19554	cognitive	_
89-156	19555-19563	deficits	_
89-157	19563-19564	;	_
89-158	19565-19568	HCs	_
89-159	19568-19569	,	_
89-160	19570-19577	healthy	_
89-161	19578-19586	controls	_
89-162	19587-19590	For	_
89-163	19591-19598	further	_
89-164	19599-19611	quantitative	_
89-165	19612-19620	analysis	_
89-166	19620-19621	,	_
89-167	19622-19624	we	_
89-168	19625-19633	compared	_
89-169	19634-19637	the	_
89-170	19638-19642	mean	_
89-171	19643-19646	GMD	_
89-172	19647-19649	in	_
89-173	19650-19661	significant	_
89-174	19662-19670	clusters	_
89-175	19671-19676	among	_
89-176	19677-19680	the	_
89-177	19681-19686	three	_
89-178	19687-19693	groups	_
89-179	19694-19697	and	_
89-180	19698-19705	between	_
89-181	19706-19710	each	_
89-182	19711-19715	pair	_
89-183	19716-19718	of	_
89-184	19719-19725	groups	_
89-185	19725-19726	.	_

#Text=ANOVA results showed that the mean GMD of the cerebellar vermis cluster in SZ-CD vs HCs had a significant decrease in SZ-CD group compared with HCs group (T = 4.43, P < 0.001); left cerebellum cluster in SZ-NCD vs HCs, a significant decrease in SZ-NCD group (T = 3.41,P < 0.001); left SMA cluster in SZ-NCD vs SZ-CD, a significant decrease in SZ-CD group (T = 4.54,P < 0.001); cerebellar vermis cluster in SZ-NCD vs SZ-CD, a significant decrease in SZ-CD group (T = 3.67,P = 0.003).
90-1	19727-19732	ANOVA	_
90-2	19733-19740	results	_
90-3	19741-19747	showed	_
90-4	19748-19752	that	_
90-5	19753-19756	the	_
90-6	19757-19761	mean	_
90-7	19762-19765	GMD	_
90-8	19766-19768	of	_
90-9	19769-19772	the	_
90-10	19773-19783	cerebellar	_
90-11	19784-19790	vermis	_
90-12	19791-19798	cluster	_
90-13	19799-19801	in	_
90-14	19802-19807	SZ-CD	_
90-15	19808-19810	vs	_
90-16	19811-19814	HCs	_
90-17	19815-19818	had	_
90-18	19819-19820	a	_
90-19	19821-19832	significant	_
90-20	19833-19841	decrease	_
90-21	19842-19844	in	_
90-22	19845-19850	SZ-CD	_
90-23	19851-19856	group	_
90-24	19857-19865	compared	_
90-25	19866-19870	with	_
90-26	19871-19874	HCs	_
90-27	19875-19880	group	_
90-28	19881-19882	(	_
90-29	19882-19883	T	_
90-30	19884-19885	=	_
90-31	19886-19890	4.43	_
90-32	19890-19891	,	_
90-33	19892-19893	P	_
90-34	19894-19895	<	_
90-35	19896-19901	0.001	_
90-36	19901-19902	)	_
90-37	19902-19903	;	_
90-38	19904-19908	left	_
90-39	19909-19919	cerebellum	_
90-40	19920-19927	cluster	_
90-41	19928-19930	in	_
90-42	19931-19937	SZ-NCD	_
90-43	19938-19940	vs	_
90-44	19941-19944	HCs	_
90-45	19944-19945	,	_
90-46	19946-19947	a	_
90-47	19948-19959	significant	_
90-48	19960-19968	decrease	_
90-49	19969-19971	in	_
90-50	19972-19978	SZ-NCD	_
90-51	19979-19984	group	_
90-52	19985-19986	(	_
90-53	19986-19987	T	_
90-54	19988-19989	=	_
90-55	19990-19994	3.41	_
90-56	19994-19995	,	_
90-57	19995-19996	P	_
90-58	19997-19998	<	_
90-59	19999-20004	0.001	_
90-60	20004-20005	)	_
90-61	20005-20006	;	_
90-62	20007-20011	left	_
90-63	20012-20015	SMA	_
90-64	20016-20023	cluster	_
90-65	20024-20026	in	_
90-66	20027-20033	SZ-NCD	_
90-67	20034-20036	vs	_
90-68	20037-20042	SZ-CD	_
90-69	20042-20043	,	_
90-70	20044-20045	a	_
90-71	20046-20057	significant	_
90-72	20058-20066	decrease	_
90-73	20067-20069	in	_
90-74	20070-20075	SZ-CD	_
90-75	20076-20081	group	_
90-76	20082-20083	(	_
90-77	20083-20084	T	_
90-78	20085-20086	=	_
90-79	20087-20091	4.54	_
90-80	20091-20092	,	_
90-81	20092-20093	P	_
90-82	20094-20095	<	_
90-83	20096-20101	0.001	_
90-84	20101-20102	)	_
90-85	20102-20103	;	_
90-86	20104-20114	cerebellar	_
90-87	20115-20121	vermis	_
90-88	20122-20129	cluster	_
90-89	20130-20132	in	_
90-90	20133-20139	SZ-NCD	_
90-91	20140-20142	vs	_
90-92	20143-20148	SZ-CD	_
90-93	20148-20149	,	_
90-94	20150-20151	a	_
90-95	20152-20163	significant	_
90-96	20164-20172	decrease	_
90-97	20173-20175	in	_
90-98	20176-20181	SZ-CD	_
90-99	20182-20187	group	_
90-100	20188-20189	(	_
90-101	20189-20190	T	_
90-102	20191-20192	=	_
90-103	20193-20197	3.67	_
90-104	20197-20198	,	_
90-105	20198-20199	P	_
90-106	20200-20201	=	_
90-107	20202-20207	0.003	_
90-108	20207-20208	)	_
90-109	20208-20209	.	_

#Text=Furthermore, ROC showed GMD of cerebellar vermis tonsil cluster could differentiate SZ-CD from controls with a sensitivity of 92.5% and specificity of 75%, the left cerebellum cluster (anterior lobe and posterior lobe) could distinguish between SZ-NCD vs controls with a sensitivity of 90.5% and specificity of 77.8%, and all SZ versus all controls with a sensitivity of 90.5% and specificity of 70.6%,, left SMAcluster(left SMA, bilateral precentral gyrus) could differentiate SZ-CD from SZ-NCD with a sensitivity of 83.3% and specificity of 81.2% (Fig. 3).
91-1	20210-20221	Furthermore	_
91-2	20221-20222	,	_
91-3	20223-20226	ROC	_
91-4	20227-20233	showed	_
91-5	20234-20237	GMD	_
91-6	20238-20240	of	_
91-7	20241-20251	cerebellar	_
91-8	20252-20258	vermis	_
91-9	20259-20265	tonsil	_
91-10	20266-20273	cluster	_
91-11	20274-20279	could	_
91-12	20280-20293	differentiate	_
91-13	20294-20299	SZ-CD	_
91-14	20300-20304	from	_
91-15	20305-20313	controls	_
91-16	20314-20318	with	_
91-17	20319-20320	a	_
91-18	20321-20332	sensitivity	_
91-19	20333-20335	of	_
91-20	20336-20341	92.5%	_
91-21	20342-20345	and	_
91-22	20346-20357	specificity	_
91-23	20358-20360	of	_
91-24	20361-20364	75%	_
91-25	20364-20365	,	_
91-26	20366-20369	the	_
91-27	20370-20374	left	_
91-28	20375-20385	cerebellum	_
91-29	20386-20393	cluster	_
91-30	20394-20395	(	_
91-31	20395-20403	anterior	_
91-32	20404-20408	lobe	_
91-33	20409-20412	and	_
91-34	20413-20422	posterior	_
91-35	20423-20427	lobe	_
91-36	20427-20428	)	_
91-37	20429-20434	could	_
91-38	20435-20446	distinguish	_
91-39	20447-20454	between	_
91-40	20455-20461	SZ-NCD	_
91-41	20462-20464	vs	_
91-42	20465-20473	controls	_
91-43	20474-20478	with	_
91-44	20479-20480	a	_
91-45	20481-20492	sensitivity	_
91-46	20493-20495	of	_
91-47	20496-20501	90.5%	_
91-48	20502-20505	and	_
91-49	20506-20517	specificity	_
91-50	20518-20520	of	_
91-51	20521-20526	77.8%	_
91-52	20526-20527	,	_
91-53	20528-20531	and	_
91-54	20532-20535	all	_
91-55	20536-20538	SZ	_
91-56	20539-20545	versus	_
91-57	20546-20549	all	_
91-58	20550-20558	controls	_
91-59	20559-20563	with	_
91-60	20564-20565	a	_
91-61	20566-20577	sensitivity	_
91-62	20578-20580	of	_
91-63	20581-20586	90.5%	_
91-64	20587-20590	and	_
91-65	20591-20602	specificity	_
91-66	20603-20605	of	_
91-67	20606-20611	70.6%	_
91-68	20611-20612	,	_
91-69	20612-20613	,	_
91-70	20614-20618	left	_
91-71	20619-20629	SMAcluster	_
91-72	20629-20630	(	_
91-73	20630-20634	left	_
91-74	20635-20638	SMA	_
91-75	20638-20639	,	_
91-76	20640-20649	bilateral	_
91-77	20650-20660	precentral	_
91-78	20661-20666	gyrus	_
91-79	20666-20667	)	_
91-80	20668-20673	could	_
91-81	20674-20687	differentiate	_
91-82	20688-20693	SZ-CD	_
91-83	20694-20698	from	_
91-84	20699-20705	SZ-NCD	_
91-85	20706-20710	with	_
91-86	20711-20712	a	_
91-87	20713-20724	sensitivity	_
91-88	20725-20727	of	_
91-89	20728-20733	83.3%	_
91-90	20734-20737	and	_
91-91	20738-20749	specificity	_
91-92	20750-20752	of	_
91-93	20753-20758	81.2%	_
91-94	20759-20760	(	_
91-95	20760-20763	Fig	_
91-96	20763-20764	.	_
91-97	20765-20766	3	_
91-98	20766-20767	)	_
91-99	20767-20768	.	_

#Text=Correlation between the alterations in gray matter density and clinical symptom severity
#Text=
#Text=a Correlation maps of task accuracy and gray matter density for patients groups.
92-1	20770-20781	Correlation	_
92-2	20782-20789	between	_
92-3	20790-20793	the	_
92-4	20794-20805	alterations	_
92-5	20806-20808	in	_
92-6	20809-20813	gray	_
92-7	20814-20820	matter	_
92-8	20821-20828	density	_
92-9	20829-20832	and	_
92-10	20833-20841	clinical	_
92-11	20842-20849	symptom	_
92-12	20850-20858	severity	_
92-13	20860-20861	a	_
92-14	20862-20873	Correlation	_
92-15	20874-20878	maps	_
92-16	20879-20881	of	_
92-17	20882-20886	task	_
92-18	20887-20895	accuracy	_
92-19	20896-20899	and	_
92-20	20900-20904	gray	_
92-21	20905-20911	matter	_
92-22	20912-20919	density	_
92-23	20920-20923	for	_
92-24	20924-20932	patients	_
92-25	20933-20939	groups	_
92-26	20939-20940	.	_

#Text=Significant positive correlations were found in right precentral gyrus, posterior central gyrus, middle frontal gyrus, superior frontal gyrus, bilateral vermis and 8,9 of cerebellum. b The scatter plots between significant cluster in cerebellum and task accuracy (r = 0.46, p = 0.01), as assessed by 2 back task
#Text=In the combined patient groups, voxel–wise Pearson correlation maps showed positive correlations found in right superior frontal gyrus, vermis and tonsil of bilateral cerebellum, right precentral gyrus with task accuracy.
93-1	20941-20952	Significant	_
93-2	20953-20961	positive	_
93-3	20962-20974	correlations	_
93-4	20975-20979	were	_
93-5	20980-20985	found	_
93-6	20986-20988	in	_
93-7	20989-20994	right	_
93-8	20995-21005	precentral	_
93-9	21006-21011	gyrus	_
93-10	21011-21012	,	_
93-11	21013-21022	posterior	_
93-12	21023-21030	central	_
93-13	21031-21036	gyrus	_
93-14	21036-21037	,	_
93-15	21038-21044	middle	_
93-16	21045-21052	frontal	_
93-17	21053-21058	gyrus	_
93-18	21058-21059	,	_
93-19	21060-21068	superior	_
93-20	21069-21076	frontal	_
93-21	21077-21082	gyrus	_
93-22	21082-21083	,	_
93-23	21084-21093	bilateral	_
93-24	21094-21100	vermis	_
93-25	21101-21104	and	_
93-26	21105-21108	8,9	_
93-27	21109-21111	of	_
93-28	21112-21122	cerebellum	_
93-29	21122-21123	.	_
93-30	21124-21125	b	_
93-31	21126-21129	The	_
93-32	21130-21137	scatter	_
93-33	21138-21143	plots	_
93-34	21144-21151	between	_
93-35	21152-21163	significant	_
93-36	21164-21171	cluster	_
93-37	21172-21174	in	_
93-38	21175-21185	cerebellum	_
93-39	21186-21189	and	_
93-40	21190-21194	task	_
93-41	21195-21203	accuracy	_
93-42	21204-21205	(	_
93-43	21205-21206	r	_
93-44	21207-21208	=	_
93-45	21209-21213	0.46	_
93-46	21213-21214	,	_
93-47	21215-21216	p	_
93-48	21217-21218	=	_
93-49	21219-21223	0.01	_
93-50	21223-21224	)	_
93-51	21224-21225	,	_
93-52	21226-21228	as	_
93-53	21229-21237	assessed	_
93-54	21238-21240	by	_
93-55	21241-21242	2	_
93-56	21243-21247	back	_
93-57	21248-21252	task	_
93-58	21253-21255	In	_
93-59	21256-21259	the	_
93-60	21260-21268	combined	_
93-61	21269-21276	patient	_
93-62	21277-21283	groups	_
93-63	21283-21284	,	_
93-64	21285-21295	voxel–wise	_
93-65	21296-21303	Pearson	_
93-66	21304-21315	correlation	_
93-67	21316-21320	maps	_
93-68	21321-21327	showed	_
93-69	21328-21336	positive	_
93-70	21337-21349	correlations	_
93-71	21350-21355	found	_
93-72	21356-21358	in	_
93-73	21359-21364	right	_
93-74	21365-21373	superior	_
93-75	21374-21381	frontal	_
93-76	21382-21387	gyrus	_
93-77	21387-21388	,	_
93-78	21389-21395	vermis	_
93-79	21396-21399	and	_
93-80	21400-21406	tonsil	_
93-81	21407-21409	of	_
93-82	21410-21419	bilateral	_
93-83	21420-21430	cerebellum	_
93-84	21430-21431	,	_
93-85	21432-21437	right	_
93-86	21438-21448	precentral	_
93-87	21449-21454	gyrus	_
93-88	21455-21459	with	_
93-89	21460-21464	task	_
93-90	21465-21473	accuracy	_
93-91	21473-21474	.	_

#Text=GMD in bilateral cerebellum vermis cluster was positively correlated with task accuracy (r = 0.46, p = 0.014) (Fig. 4).
94-1	21475-21478	GMD	_
94-2	21479-21481	in	_
94-3	21482-21491	bilateral	_
94-4	21492-21502	cerebellum	_
94-5	21503-21509	vermis	_
94-6	21510-21517	cluster	_
94-7	21518-21521	was	_
94-8	21522-21532	positively	_
94-9	21533-21543	correlated	_
94-10	21544-21548	with	_
94-11	21549-21553	task	_
94-12	21554-21562	accuracy	_
94-13	21563-21564	(	_
94-14	21564-21565	r	_
94-15	21566-21567	=	_
94-16	21568-21572	0.46	_
94-17	21572-21573	,	_
94-18	21574-21575	p	_
94-19	21576-21577	=	_
94-20	21578-21583	0.014	_
94-21	21583-21584	)	_
94-22	21585-21586	(	_
94-23	21586-21589	Fig	_
94-24	21589-21590	.	_
94-25	21590-21591	 	_
94-26	21591-21592	4	_
94-27	21592-21593	)	_
94-28	21593-21594	.	_

#Text=Discussion
#Text=Based on VBM analysis, the present study found that first-episode SZ-CD had lower GMD in the vermis and tonsil of cerebellum than either SZ-NCD, or healthy controls and decreased GMD in left SMA cluster compared with SZ-NCD.
95-1	21596-21606	Discussion	_
95-2	21607-21612	Based	_
95-3	21613-21615	on	_
95-4	21616-21619	VBM	_
95-5	21620-21628	analysis	_
95-6	21628-21629	,	_
95-7	21630-21633	the	_
95-8	21634-21641	present	_
95-9	21642-21647	study	_
95-10	21648-21653	found	_
95-11	21654-21658	that	_
95-12	21659-21672	first-episode	_
95-13	21673-21678	SZ-CD	_
95-14	21679-21682	had	_
95-15	21683-21688	lower	_
95-16	21689-21692	GMD	_
95-17	21693-21695	in	_
95-18	21696-21699	the	_
95-19	21700-21706	vermis	_
95-20	21707-21710	and	_
95-21	21711-21717	tonsil	_
95-22	21718-21720	of	_
95-23	21721-21731	cerebellum	_
95-24	21732-21736	than	_
95-25	21737-21743	either	_
95-26	21744-21750	SZ-NCD	_
95-27	21750-21751	,	_
95-28	21752-21754	or	_
95-29	21755-21762	healthy	_
95-30	21763-21771	controls	_
95-31	21772-21775	and	_
95-32	21776-21785	decreased	_
95-33	21786-21789	GMD	_
95-34	21790-21792	in	_
95-35	21793-21797	left	_
95-36	21798-21801	SMA	_
95-37	21802-21809	cluster	_
95-38	21810-21818	compared	_
95-39	21819-21823	with	_
95-40	21824-21830	SZ-NCD	_
95-41	21830-21831	.	_

#Text=Classification method revealed that the GMD of this cerebellum vermis cluster can be applied to differentiate SZ-CD patients from healthy controls and left SMA cluster differentiate SZ-CD group from SZ-NCD group with a high sensitivity and specificity.
96-1	21832-21846	Classification	_
96-2	21847-21853	method	_
96-3	21854-21862	revealed	_
96-4	21863-21867	that	_
96-5	21868-21871	the	_
96-6	21872-21875	GMD	_
96-7	21876-21878	of	_
96-8	21879-21883	this	_
96-9	21884-21894	cerebellum	_
96-10	21895-21901	vermis	_
96-11	21902-21909	cluster	_
96-12	21910-21913	can	_
96-13	21914-21916	be	_
96-14	21917-21924	applied	_
96-15	21925-21927	to	_
96-16	21928-21941	differentiate	_
96-17	21942-21947	SZ-CD	_
96-18	21948-21956	patients	_
96-19	21957-21961	from	_
96-20	21962-21969	healthy	_
96-21	21970-21978	controls	_
96-22	21979-21982	and	_
96-23	21983-21987	left	_
96-24	21988-21991	SMA	_
96-25	21992-21999	cluster	_
96-26	22000-22013	differentiate	_
96-27	22014-22019	SZ-CD	_
96-28	22020-22025	group	_
96-29	22026-22030	from	_
96-30	22031-22037	SZ-NCD	_
96-31	22038-22043	group	_
96-32	22044-22048	with	_
96-33	22049-22050	a	_
96-34	22051-22055	high	_
96-35	22056-22067	sensitivity	_
96-36	22068-22071	and	_
96-37	22072-22083	specificity	_
96-38	22083-22084	.	_

#Text=Further significant positive correlation was found between the GMD of this cerebellum vermis cluster and task accuracy.
97-1	22085-22092	Further	_
97-2	22093-22104	significant	_
97-3	22105-22113	positive	_
97-4	22114-22125	correlation	_
97-5	22126-22129	was	_
97-6	22130-22135	found	_
97-7	22136-22143	between	_
97-8	22144-22147	the	_
97-9	22148-22151	GMD	_
97-10	22152-22154	of	_
97-11	22155-22159	this	_
97-12	22160-22170	cerebellum	_
97-13	22171-22177	vermis	_
97-14	22178-22185	cluster	_
97-15	22186-22189	and	_
97-16	22190-22194	task	_
97-17	22195-22203	accuracy	_
97-18	22203-22204	.	_

#Text=In spite of the traditional viewpoint that the cerebellum only plays a role in motor-related function, recent studies have revealed that it contributes to cognitive processing and emotional control.
98-1	22205-22207	In	_
98-2	22208-22213	spite	_
98-3	22214-22216	of	_
98-4	22217-22220	the	_
98-5	22221-22232	traditional	_
98-6	22233-22242	viewpoint	_
98-7	22243-22247	that	_
98-8	22248-22251	the	_
98-9	22252-22262	cerebellum	_
98-10	22263-22267	only	_
98-11	22268-22273	plays	_
98-12	22274-22275	a	_
98-13	22276-22280	role	_
98-14	22281-22283	in	_
98-15	22284-22297	motor-related	_
98-16	22298-22306	function	_
98-17	22306-22307	,	_
98-18	22308-22314	recent	_
98-19	22315-22322	studies	_
98-20	22323-22327	have	_
98-21	22328-22336	revealed	_
98-22	22337-22341	that	_
98-23	22342-22344	it	_
98-24	22345-22356	contributes	_
98-25	22357-22359	to	_
98-26	22360-22369	cognitive	_
98-27	22370-22380	processing	_
98-28	22381-22384	and	_
98-29	22385-22394	emotional	_
98-30	22395-22402	control	_
98-31	22402-22403	.	_

#Text=The cerebellum is anatomically connected to frontal and parietal cortex by a cortico-cerebellar-thalamic-cortical circuit, and have been proven to have an important role in both motor and cognitive tasks through different connections depending on the demands of the task.
99-1	22404-22407	The	_
99-2	22408-22418	cerebellum	_
99-3	22419-22421	is	_
99-4	22422-22434	anatomically	_
99-5	22435-22444	connected	_
99-6	22445-22447	to	_
99-7	22448-22455	frontal	_
99-8	22456-22459	and	_
99-9	22460-22468	parietal	_
99-10	22469-22475	cortex	_
99-11	22476-22478	by	_
99-12	22479-22480	a	_
99-13	22481-22517	cortico-cerebellar-thalamic-cortical	_
99-14	22518-22525	circuit	_
99-15	22525-22526	,	_
99-16	22527-22530	and	_
99-17	22531-22535	have	_
99-18	22536-22540	been	_
99-19	22541-22547	proven	_
99-20	22548-22550	to	_
99-21	22551-22555	have	_
99-22	22556-22558	an	_
99-23	22559-22568	important	_
99-24	22569-22573	role	_
99-25	22574-22576	in	_
99-26	22577-22581	both	_
99-27	22582-22587	motor	_
99-28	22588-22591	and	_
99-29	22592-22601	cognitive	_
99-30	22602-22607	tasks	_
99-31	22608-22615	through	_
99-32	22616-22625	different	_
99-33	22626-22637	connections	_
99-34	22638-22647	depending	_
99-35	22648-22650	on	_
99-36	22651-22654	the	_
99-37	22655-22662	demands	_
99-38	22663-22665	of	_
99-39	22666-22669	the	_
99-40	22670-22674	task	_
99-41	22674-22675	.	_

#Text=Cerebellar dysfunction, particularly in the vermis, has been proposed to lead to “cognitive dysmetria” in schizophrenia via the cortico-cerebellar-thalamic-cortical circuit.Reduced activation has been found in the cerebellar vermis during verbal working memory in schizophrenia.Although inconsistent findings of increased or decreased size or no change in vermis structure in schizophrenia patients, volumetric alterations in the vermis have been associated with deficits in cognitive and executive function.Given the evidence that has begun to accumulate, the significantly abnormal GMD reported here in the vermis of SZ-CD patients compared with SZ-NCD patients and HCs is not surprising.
100-1	22676-22686	Cerebellar	_
100-2	22687-22698	dysfunction	_
100-3	22698-22699	,	_
100-4	22700-22712	particularly	_
100-5	22713-22715	in	_
100-6	22716-22719	the	_
100-7	22720-22726	vermis	_
100-8	22726-22727	,	_
100-9	22728-22731	has	_
100-10	22732-22736	been	_
100-11	22737-22745	proposed	_
100-12	22746-22748	to	_
100-13	22749-22753	lead	_
100-14	22754-22756	to	_
100-15	22757-22758	“	_
100-16	22758-22767	cognitive	_
100-17	22768-22777	dysmetria	_
100-18	22777-22778	”	_
100-19	22779-22781	in	_
100-20	22782-22795	schizophrenia	_
100-21	22796-22799	via	_
100-22	22800-22803	the	_
100-23	22804-22840	cortico-cerebellar-thalamic-cortical	_
100-24	22841-22856	circuit.Reduced	_
100-25	22857-22867	activation	_
100-26	22868-22871	has	_
100-27	22872-22876	been	_
100-28	22877-22882	found	_
100-29	22883-22885	in	_
100-30	22886-22889	the	_
100-31	22890-22900	cerebellar	_
100-32	22901-22907	vermis	_
100-33	22908-22914	during	_
100-34	22915-22921	verbal	_
100-35	22922-22929	working	_
100-36	22930-22936	memory	_
100-37	22937-22939	in	_
100-38	22940-22962	schizophrenia.Although	_
100-39	22963-22975	inconsistent	_
100-40	22976-22984	findings	_
100-41	22985-22987	of	_
100-42	22988-22997	increased	_
100-43	22998-23000	or	_
100-44	23001-23010	decreased	_
100-45	23011-23015	size	_
100-46	23016-23018	or	_
100-47	23019-23021	no	_
100-48	23022-23028	change	_
100-49	23029-23031	in	_
100-50	23032-23038	vermis	_
100-51	23039-23048	structure	_
100-52	23049-23051	in	_
100-53	23052-23065	schizophrenia	_
100-54	23066-23074	patients	_
100-55	23074-23075	,	_
100-56	23076-23086	volumetric	_
100-57	23087-23098	alterations	_
100-58	23099-23101	in	_
100-59	23102-23105	the	_
100-60	23106-23112	vermis	_
100-61	23113-23117	have	_
100-62	23118-23122	been	_
100-63	23123-23133	associated	_
100-64	23134-23138	with	_
100-65	23139-23147	deficits	_
100-66	23148-23150	in	_
100-67	23151-23160	cognitive	_
100-68	23161-23164	and	_
100-69	23165-23174	executive	_
100-70	23175-23189	function.Given	_
100-71	23190-23193	the	_
100-72	23194-23202	evidence	_
100-73	23203-23207	that	_
100-74	23208-23211	has	_
100-75	23212-23217	begun	_
100-76	23218-23220	to	_
100-77	23221-23231	accumulate	_
100-78	23231-23232	,	_
100-79	23233-23236	the	_
100-80	23237-23250	significantly	_
100-81	23251-23259	abnormal	_
100-82	23260-23263	GMD	_
100-83	23264-23272	reported	_
100-84	23273-23277	here	_
100-85	23278-23280	in	_
100-86	23281-23284	the	_
100-87	23285-23291	vermis	_
100-88	23292-23294	of	_
100-89	23295-23300	SZ-CD	_
100-90	23301-23309	patients	_
100-91	23310-23318	compared	_
100-92	23319-23323	with	_
100-93	23324-23330	SZ-NCD	_
100-94	23331-23339	patients	_
100-95	23340-23343	and	_
100-96	23344-23347	HCs	_
100-97	23348-23350	is	_
100-98	23351-23354	not	_
100-99	23355-23365	surprising	_
100-100	23365-23366	.	_

#Text=A recent two-photon calcium imaging showed that cerebellar granule cells encode the expectation of reward, providing further important implications for cognitive processing in the cerebellum.Based on the fact that reduced GMD may be related to the loss of neurons, we speculate that cerebellar granule cells may be significantly disrupted in SZ-CD patients.
101-1	23367-23368	A	_
101-2	23369-23375	recent	_
101-3	23376-23386	two-photon	_
101-4	23387-23394	calcium	_
101-5	23395-23402	imaging	_
101-6	23403-23409	showed	_
101-7	23410-23414	that	_
101-8	23415-23425	cerebellar	_
101-9	23426-23433	granule	_
101-10	23434-23439	cells	_
101-11	23440-23446	encode	_
101-12	23447-23450	the	_
101-13	23451-23462	expectation	_
101-14	23463-23465	of	_
101-15	23466-23472	reward	_
101-16	23472-23473	,	_
101-17	23474-23483	providing	_
101-18	23484-23491	further	_
101-19	23492-23501	important	_
101-20	23502-23514	implications	_
101-21	23515-23518	for	_
101-22	23519-23528	cognitive	_
101-23	23529-23539	processing	_
101-24	23540-23542	in	_
101-25	23543-23546	the	_
101-26	23547-23563	cerebellum.Based	_
101-27	23564-23566	on	_
101-28	23567-23570	the	_
101-29	23571-23575	fact	_
101-30	23576-23580	that	_
101-31	23581-23588	reduced	_
101-32	23589-23592	GMD	_
101-33	23593-23596	may	_
101-34	23597-23599	be	_
101-35	23600-23607	related	_
101-36	23608-23610	to	_
101-37	23611-23614	the	_
101-38	23615-23619	loss	_
101-39	23620-23622	of	_
101-40	23623-23630	neurons	_
101-41	23630-23631	,	_
101-42	23632-23634	we	_
101-43	23635-23644	speculate	_
101-44	23645-23649	that	_
101-45	23650-23660	cerebellar	_
101-46	23661-23668	granule	_
101-47	23669-23674	cells	_
101-48	23675-23678	may	_
101-49	23679-23681	be	_
101-50	23682-23695	significantly	_
101-51	23696-23705	disrupted	_
101-52	23706-23708	in	_
101-53	23709-23714	SZ-CD	_
101-54	23715-23723	patients	_
101-55	23723-23724	.	_

#Text=The relationship between the early changes of GMD in patient groups and clinical outcomes is of clinical importance.
102-1	23725-23728	The	_
102-2	23729-23741	relationship	_
102-3	23742-23749	between	_
102-4	23750-23753	the	_
102-5	23754-23759	early	_
102-6	23760-23767	changes	_
102-7	23768-23770	of	_
102-8	23771-23774	GMD	_
102-9	23775-23777	in	_
102-10	23778-23785	patient	_
102-11	23786-23792	groups	_
102-12	23793-23796	and	_
102-13	23797-23805	clinical	_
102-14	23806-23814	outcomes	_
102-15	23815-23817	is	_
102-16	23818-23820	of	_
102-17	23821-23829	clinical	_
102-18	23830-23840	importance	_
102-19	23840-23841	.	_

#Text=Reduced gray matter density of vermis was found to be positively related to the task accuracy in first-episode schizophrenia.
103-1	23842-23849	Reduced	_
103-2	23850-23854	gray	_
103-3	23855-23861	matter	_
103-4	23862-23869	density	_
103-5	23870-23872	of	_
103-6	23873-23879	vermis	_
103-7	23880-23883	was	_
103-8	23884-23889	found	_
103-9	23890-23892	to	_
103-10	23893-23895	be	_
103-11	23896-23906	positively	_
103-12	23907-23914	related	_
103-13	23915-23917	to	_
103-14	23918-23921	the	_
103-15	23922-23926	task	_
103-16	23927-23935	accuracy	_
103-17	23936-23938	in	_
103-18	23939-23952	first-episode	_
103-19	23953-23966	schizophrenia	_
103-20	23966-23967	.	_

#Text=The smaller the GMD the vermis, the more severely the patient’s cognitive ability is affected.
104-1	23968-23971	The	_
104-2	23972-23979	smaller	_
104-3	23980-23983	the	_
104-4	23984-23987	GMD	_
104-5	23988-23991	the	_
104-6	23992-23998	vermis	_
104-7	23998-23999	,	_
104-8	24000-24003	the	_
104-9	24004-24008	more	_
104-10	24009-24017	severely	_
104-11	24018-24021	the	_
104-12	24022-24029	patient	_
104-13	24029-24030	’	_
104-14	24030-24031	s	_
104-15	24032-24041	cognitive	_
104-16	24042-24049	ability	_
104-17	24050-24052	is	_
104-18	24053-24061	affected	_
104-19	24061-24062	.	_

#Text=As a classified variable, GMD of the vermis could differentiate the SZ-CD patients from healthy controls.
105-1	24063-24065	As	_
105-2	24066-24067	a	_
105-3	24068-24078	classified	_
105-4	24079-24087	variable	_
105-5	24087-24088	,	_
105-6	24089-24092	GMD	_
105-7	24093-24095	of	_
105-8	24096-24099	the	_
105-9	24100-24106	vermis	_
105-10	24107-24112	could	_
105-11	24113-24126	differentiate	_
105-12	24127-24130	the	_
105-13	24131-24136	SZ-CD	_
105-14	24137-24145	patients	_
105-15	24146-24150	from	_
105-16	24151-24158	healthy	_
105-17	24159-24167	controls	_
105-18	24167-24168	.	_

#Text=The specific relationship between the reduced GMD in the vermis and cognitive impairment suggests that GMD changes in the vermis during the early stage of schizophrenia could sever as candidate biomarker for SZ-CD.
106-1	24169-24172	The	_
106-2	24173-24181	specific	_
106-3	24182-24194	relationship	_
106-4	24195-24202	between	_
106-5	24203-24206	the	_
106-6	24207-24214	reduced	_
106-7	24215-24218	GMD	_
106-8	24219-24221	in	_
106-9	24222-24225	the	_
106-10	24226-24232	vermis	_
106-11	24233-24236	and	_
106-12	24237-24246	cognitive	_
106-13	24247-24257	impairment	_
106-14	24258-24266	suggests	_
106-15	24267-24271	that	_
106-16	24272-24275	GMD	_
106-17	24276-24283	changes	_
106-18	24284-24286	in	_
106-19	24287-24290	the	_
106-20	24291-24297	vermis	_
106-21	24298-24304	during	_
106-22	24305-24308	the	_
106-23	24309-24314	early	_
106-24	24315-24320	stage	_
106-25	24321-24323	of	_
106-26	24324-24337	schizophrenia	_
106-27	24338-24343	could	_
106-28	24344-24349	sever	_
106-29	24350-24352	as	_
106-30	24353-24362	candidate	_
106-31	24363-24372	biomarker	_
106-32	24373-24376	for	_
106-33	24377-24382	SZ-CD	_
106-34	24382-24383	.	_

#Text=Our results also showed reduced GMD of superior temporal gyrus in SZ-CD group.
107-1	24384-24387	Our	_
107-2	24388-24395	results	_
107-3	24396-24400	also	_
107-4	24401-24407	showed	_
107-5	24408-24415	reduced	_
107-6	24416-24419	GMD	_
107-7	24420-24422	of	_
107-8	24423-24431	superior	_
107-9	24432-24440	temporal	_
107-10	24441-24446	gyrus	_
107-11	24447-24449	in	_
107-12	24450-24455	SZ-CD	_
107-13	24456-24461	group	_
107-14	24461-24462	.	_

#Text=Superior temporal gyrus was associated with auditory and speech comprehension.
108-1	24463-24471	Superior	_
108-2	24472-24480	temporal	_
108-3	24481-24486	gyrus	_
108-4	24487-24490	was	_
108-5	24491-24501	associated	_
108-6	24502-24506	with	_
108-7	24507-24515	auditory	_
108-8	24516-24519	and	_
108-9	24520-24526	speech	_
108-10	24527-24540	comprehension	_
108-11	24540-24541	.	_

#Text=Decreased cortical thickness in superior temporal gyrus had been found in multiple sclerosis patients, which was correlated with cognitive performance.
109-1	24542-24551	Decreased	_
109-2	24552-24560	cortical	_
109-3	24561-24570	thickness	_
109-4	24571-24573	in	_
109-5	24574-24582	superior	_
109-6	24583-24591	temporal	_
109-7	24592-24597	gyrus	_
109-8	24598-24601	had	_
109-9	24602-24606	been	_
109-10	24607-24612	found	_
109-11	24613-24615	in	_
109-12	24616-24624	multiple	_
109-13	24625-24634	sclerosis	_
109-14	24635-24643	patients	_
109-15	24643-24644	,	_
109-16	24645-24650	which	_
109-17	24651-24654	was	_
109-18	24655-24665	correlated	_
109-19	24666-24670	with	_
109-20	24671-24680	cognitive	_
109-21	24681-24692	performance	_
109-22	24692-24693	.	_

#Text=In silent cerebral infarction patients, decreased gray matter volume was found and positively correlated with the MoCA scale.
110-1	24694-24696	In	_
110-2	24697-24703	silent	_
110-3	24704-24712	cerebral	_
110-4	24713-24723	infarction	_
110-5	24724-24732	patients	_
110-6	24732-24733	,	_
110-7	24734-24743	decreased	_
110-8	24744-24748	gray	_
110-9	24749-24755	matter	_
110-10	24756-24762	volume	_
110-11	24763-24766	was	_
110-12	24767-24772	found	_
110-13	24773-24776	and	_
110-14	24777-24787	positively	_
110-15	24788-24798	correlated	_
110-16	24799-24803	with	_
110-17	24804-24807	the	_
110-18	24808-24812	MoCA	_
110-19	24813-24818	scale	_
110-20	24818-24819	.	_

#Text=In spite of different diseases, the relationships between structural abnormalities and cognitive impairment showed superior temporal gyrus was involved in cognitive function.
111-1	24820-24822	In	_
111-2	24823-24828	spite	_
111-3	24829-24831	of	_
111-4	24832-24841	different	_
111-5	24842-24850	diseases	_
111-6	24850-24851	,	_
111-7	24852-24855	the	_
111-8	24856-24869	relationships	_
111-9	24870-24877	between	_
111-10	24878-24888	structural	_
111-11	24889-24902	abnormalities	_
111-12	24903-24906	and	_
111-13	24907-24916	cognitive	_
111-14	24917-24927	impairment	_
111-15	24928-24934	showed	_
111-16	24935-24943	superior	_
111-17	24944-24952	temporal	_
111-18	24953-24958	gyrus	_
111-19	24959-24962	was	_
111-20	24963-24971	involved	_
111-21	24972-24974	in	_
111-22	24975-24984	cognitive	_
111-23	24985-24993	function	_
111-24	24993-24994	.	_

#Text=In addition, reduced GMD was also observed in the parahippocampal gyrus, left cerebellar posterior lobe in SZ-NCD patients group.
112-1	24995-24997	In	_
112-2	24998-25006	addition	_
112-3	25006-25007	,	_
112-4	25008-25015	reduced	_
112-5	25016-25019	GMD	_
112-6	25020-25023	was	_
112-7	25024-25028	also	_
112-8	25029-25037	observed	_
112-9	25038-25040	in	_
112-10	25041-25044	the	_
112-11	25045-25060	parahippocampal	_
112-12	25061-25066	gyrus	_
112-13	25066-25067	,	_
112-14	25068-25072	left	_
112-15	25073-25083	cerebellar	_
112-16	25084-25093	posterior	_
112-17	25094-25098	lobe	_
112-18	25099-25101	in	_
112-19	25102-25108	SZ-NCD	_
112-20	25109-25117	patients	_
112-21	25118-25123	group	_
112-22	25123-25124	.	_

#Text=The parahippocampal gyrus plays an important role in memory encoding and retrieval.
113-1	25125-25128	The	_
113-2	25129-25144	parahippocampal	_
113-3	25145-25150	gyrus	_
113-4	25151-25156	plays	_
113-5	25157-25159	an	_
113-6	25160-25169	important	_
113-7	25170-25174	role	_
113-8	25175-25177	in	_
113-9	25178-25184	memory	_
113-10	25185-25193	encoding	_
113-11	25194-25197	and	_
113-12	25198-25207	retrieval	_
113-13	25207-25208	.	_

#Text=A reduced GMD of the parahippocampal gyrus has also been found in other first-episode schizophrenia studies.
114-1	25209-25210	A	_
114-2	25211-25218	reduced	_
114-3	25219-25222	GMD	_
114-4	25223-25225	of	_
114-5	25226-25229	the	_
114-6	25230-25245	parahippocampal	_
114-7	25246-25251	gyrus	_
114-8	25252-25255	has	_
114-9	25256-25260	also	_
114-10	25261-25265	been	_
114-11	25266-25271	found	_
114-12	25272-25274	in	_
114-13	25275-25280	other	_
114-14	25281-25294	first-episode	_
114-15	25295-25308	schizophrenia	_
114-16	25309-25316	studies	_
114-17	25316-25317	.	_

#Text=Another two morphological indexes, cortical thickness and gyrification have also be shown to be disturbed in the parahippocampal gyrus of first-episode schizophrenia and chronically hallucinating schizophrenic patients.
115-1	25318-25325	Another	_
115-2	25326-25329	two	_
115-3	25330-25343	morphological	_
115-4	25344-25351	indexes	_
115-5	25351-25352	,	_
115-6	25353-25361	cortical	_
115-7	25362-25371	thickness	_
115-8	25372-25375	and	_
115-9	25376-25388	gyrification	_
115-10	25389-25393	have	_
115-11	25394-25398	also	_
115-12	25399-25401	be	_
115-13	25402-25407	shown	_
115-14	25408-25410	to	_
115-15	25411-25413	be	_
115-16	25414-25423	disturbed	_
115-17	25424-25426	in	_
115-18	25427-25430	the	_
115-19	25431-25446	parahippocampal	_
115-20	25447-25452	gyrus	_
115-21	25453-25455	of	_
115-22	25456-25469	first-episode	_
115-23	25470-25483	schizophrenia	_
115-24	25484-25487	and	_
115-25	25488-25499	chronically	_
115-26	25500-25513	hallucinating	_
115-27	25514-25527	schizophrenic	_
115-28	25528-25536	patients	_
115-29	25536-25537	.	_

#Text=Decreased GMD of left cerebellar posterior lobe was found in first-episode schizophrenia patients.Compared with previous studies, our study showed consistent results in first-episode schizophrenia patients.
116-1	25538-25547	Decreased	_
116-2	25548-25551	GMD	_
116-3	25552-25554	of	_
116-4	25555-25559	left	_
116-5	25560-25570	cerebellar	_
116-6	25571-25580	posterior	_
116-7	25581-25585	lobe	_
116-8	25586-25589	was	_
116-9	25590-25595	found	_
116-10	25596-25598	in	_
116-11	25599-25612	first-episode	_
116-12	25613-25626	schizophrenia	_
116-13	25627-25644	patients.Compared	_
116-14	25645-25649	with	_
116-15	25650-25658	previous	_
116-16	25659-25666	studies	_
116-17	25666-25667	,	_
116-18	25668-25671	our	_
116-19	25672-25677	study	_
116-20	25678-25684	showed	_
116-21	25685-25695	consistent	_
116-22	25696-25703	results	_
116-23	25704-25706	in	_
116-24	25707-25720	first-episode	_
116-25	25721-25734	schizophrenia	_
116-26	25735-25743	patients	_
116-27	25743-25744	.	_

#Text=Interestingly, much higher GMD value in left SMA cluster were found in SZ-NCD group than SZ-CD group and healthy controls, but no significant difference between SZ-CD and healthy controls.
117-1	25745-25758	Interestingly	_
117-2	25758-25759	,	_
117-3	25760-25764	much	_
117-4	25765-25771	higher	_
117-5	25772-25775	GMD	_
117-6	25776-25781	value	_
117-7	25782-25784	in	_
117-8	25785-25789	left	_
117-9	25790-25793	SMA	_
117-10	25794-25801	cluster	_
117-11	25802-25806	were	_
117-12	25807-25812	found	_
117-13	25813-25815	in	_
117-14	25816-25822	SZ-NCD	_
117-15	25823-25828	group	_
117-16	25829-25833	than	_
117-17	25834-25839	SZ-CD	_
117-18	25840-25845	group	_
117-19	25846-25849	and	_
117-20	25850-25857	healthy	_
117-21	25858-25866	controls	_
117-22	25866-25867	,	_
117-23	25868-25871	but	_
117-24	25872-25874	no	_
117-25	25875-25886	significant	_
117-26	25887-25897	difference	_
117-27	25898-25905	between	_
117-28	25906-25911	SZ-CD	_
117-29	25912-25915	and	_
117-30	25916-25923	healthy	_
117-31	25924-25932	controls	_
117-32	25932-25933	.	_

#Text=Meanwhile, left SMA cluster could distinguish SZ-CD group from SZ-NCD group.
118-1	25934-25943	Meanwhile	_
118-2	25943-25944	,	_
118-3	25945-25949	left	_
118-4	25950-25953	SMA	_
118-5	25954-25961	cluster	_
118-6	25962-25967	could	_
118-7	25968-25979	distinguish	_
118-8	25980-25985	SZ-CD	_
118-9	25986-25991	group	_
118-10	25992-25996	from	_
118-11	25997-26003	SZ-NCD	_
118-12	26004-26009	group	_
118-13	26009-26010	.	_

#Text=Researches had also reported that increased gray matter in SMA were found after aerobic exercise training, and which was associated with cognitive function.We speculated that increased GMD in SMA cluster might uncover structural compensation for cognitive function in SZ-NCD group.
119-1	26011-26021	Researches	_
119-2	26022-26025	had	_
119-3	26026-26030	also	_
119-4	26031-26039	reported	_
119-5	26040-26044	that	_
119-6	26045-26054	increased	_
119-7	26055-26059	gray	_
119-8	26060-26066	matter	_
119-9	26067-26069	in	_
119-10	26070-26073	SMA	_
119-11	26074-26078	were	_
119-12	26079-26084	found	_
119-13	26085-26090	after	_
119-14	26091-26098	aerobic	_
119-15	26099-26107	exercise	_
119-16	26108-26116	training	_
119-17	26116-26117	,	_
119-18	26118-26121	and	_
119-19	26122-26127	which	_
119-20	26128-26131	was	_
119-21	26132-26142	associated	_
119-22	26143-26147	with	_
119-23	26148-26157	cognitive	_
119-24	26158-26169	function.We	_
119-25	26170-26180	speculated	_
119-26	26181-26185	that	_
119-27	26186-26195	increased	_
119-28	26196-26199	GMD	_
119-29	26200-26202	in	_
119-30	26203-26206	SMA	_
119-31	26207-26214	cluster	_
119-32	26215-26220	might	_
119-33	26221-26228	uncover	_
119-34	26229-26239	structural	_
119-35	26240-26252	compensation	_
119-36	26253-26256	for	_
119-37	26257-26266	cognitive	_
119-38	26267-26275	function	_
119-39	26276-26278	in	_
119-40	26279-26285	SZ-NCD	_
119-41	26286-26291	group	_
119-42	26291-26292	.	_

#Text=Several limitations to our study should be considered.
120-1	26293-26300	Several	_
120-2	26301-26312	limitations	_
120-3	26313-26315	to	_
120-4	26316-26319	our	_
120-5	26320-26325	study	_
120-6	26326-26332	should	_
120-7	26333-26335	be	_
120-8	26336-26346	considered	_
120-9	26346-26347	.	_

#Text=First, after dividing patients into subgroups based on their cognitive ability, there was a relatively small sample size of participants in each patient group.
121-1	26348-26353	First	_
121-2	26353-26354	,	_
121-3	26355-26360	after	_
121-4	26361-26369	dividing	_
121-5	26370-26378	patients	_
121-6	26379-26383	into	_
121-7	26384-26393	subgroups	_
121-8	26394-26399	based	_
121-9	26400-26402	on	_
121-10	26403-26408	their	_
121-11	26409-26418	cognitive	_
121-12	26419-26426	ability	_
121-13	26426-26427	,	_
121-14	26428-26433	there	_
121-15	26434-26437	was	_
121-16	26438-26439	a	_
121-17	26440-26450	relatively	_
121-18	26451-26456	small	_
121-19	26457-26463	sample	_
121-20	26464-26468	size	_
121-21	26469-26471	of	_
121-22	26472-26484	participants	_
121-23	26485-26487	in	_
121-24	26488-26492	each	_
121-25	26493-26500	patient	_
121-26	26501-26506	group	_
121-27	26506-26507	.	_

#Text=Further larger studies are required to replicate the current results.
122-1	26508-26515	Further	_
122-2	26516-26522	larger	_
122-3	26523-26530	studies	_
122-4	26531-26534	are	_
122-5	26535-26543	required	_
122-6	26544-26546	to	_
122-7	26547-26556	replicate	_
122-8	26557-26560	the	_
122-9	26561-26568	current	_
122-10	26569-26576	results	_
122-11	26576-26577	.	_

#Text=Second, the classification criterion was the mean accuracy in the N-back task.
123-1	26578-26584	Second	_
123-2	26584-26585	,	_
123-3	26586-26589	the	_
123-4	26590-26604	classification	_
123-5	26605-26614	criterion	_
123-6	26615-26618	was	_
123-7	26619-26622	the	_
123-8	26623-26627	mean	_
123-9	26628-26636	accuracy	_
123-10	26637-26639	in	_
123-11	26640-26643	the	_
123-12	26644-26650	N-back	_
123-13	26651-26655	task	_
123-14	26655-26656	.	_

#Text=This task may not comprehensively represent one’s cognitive ability, although we added two other behavioral indicators to confirm our subgroup classification.
124-1	26657-26661	This	_
124-2	26662-26666	task	_
124-3	26667-26670	may	_
124-4	26671-26674	not	_
124-5	26675-26690	comprehensively	_
124-6	26691-26700	represent	_
124-7	26701-26704	one	_
124-8	26704-26705	’	_
124-9	26705-26706	s	_
124-10	26707-26716	cognitive	_
124-11	26717-26724	ability	_
124-12	26724-26725	,	_
124-13	26726-26734	although	_
124-14	26735-26737	we	_
124-15	26738-26743	added	_
124-16	26744-26747	two	_
124-17	26748-26753	other	_
124-18	26754-26764	behavioral	_
124-19	26765-26775	indicators	_
124-20	26776-26778	to	_
124-21	26779-26786	confirm	_
124-22	26787-26790	our	_
124-23	26791-26799	subgroup	_
124-24	26800-26814	classification	_
124-25	26814-26815	.	_

#Text=Third, DSST and WAIS score of control group were did not estimated.
125-1	26816-26821	Third	_
125-2	26821-26822	,	_
125-3	26823-26827	DSST	_
125-4	26828-26831	and	_
125-5	26832-26836	WAIS	_
125-6	26837-26842	score	_
125-7	26843-26845	of	_
125-8	26846-26853	control	_
125-9	26854-26859	group	_
125-10	26860-26864	were	_
125-11	26865-26868	did	_
125-12	26869-26872	not	_
125-13	26873-26882	estimated	_
125-14	26882-26883	.	_

#Text=Conclusions
#Text=The results of the present study provided new in vivo evidence for an early maturational deficit of the vermis in schizophrenia.
126-1	26884-26895	Conclusions	_
126-2	26896-26899	The	_
126-3	26900-26907	results	_
126-4	26908-26910	of	_
126-5	26911-26914	the	_
126-6	26915-26922	present	_
126-7	26923-26928	study	_
126-8	26929-26937	provided	_
126-9	26938-26941	new	_
126-10	26942-26944	in	_
126-11	26945-26949	vivo	_
126-12	26950-26958	evidence	_
126-13	26959-26962	for	_
126-14	26963-26965	an	_
126-15	26966-26971	early	_
126-16	26972-26984	maturational	_
126-17	26985-26992	deficit	_
126-18	26993-26995	of	_
126-19	26996-26999	the	_
126-20	27000-27006	vermis	_
126-21	27007-27009	in	_
126-22	27010-27023	schizophrenia	_
126-23	27023-27024	.	_

#Text=We further found that reduced GMD in the vermis are correlated with cognitive deficits in first-episode schizophrenia.
127-1	27025-27027	We	_
127-2	27028-27035	further	_
127-3	27036-27041	found	_
127-4	27042-27046	that	_
127-5	27047-27054	reduced	_
127-6	27055-27058	GMD	_
127-7	27059-27061	in	_
127-8	27062-27065	the	_
127-9	27066-27072	vermis	_
127-10	27073-27076	are	_
127-11	27077-27087	correlated	_
127-12	27088-27092	with	_
127-13	27093-27102	cognitive	_
127-14	27103-27111	deficits	_
127-15	27112-27114	in	_
127-16	27115-27128	first-episode	_
127-17	27129-27142	schizophrenia	_
127-18	27142-27143	.	_

#Text=However, any inferences drawn from the present study require confirmation from further investigations in a larger sample size.
128-1	27144-27151	However	_
128-2	27151-27152	,	_
128-3	27153-27156	any	_
128-4	27157-27167	inferences	_
128-5	27168-27173	drawn	_
128-6	27174-27178	from	_
128-7	27179-27182	the	_
128-8	27183-27190	present	_
128-9	27191-27196	study	_
128-10	27197-27204	require	_
128-11	27205-27217	confirmation	_
128-12	27218-27222	from	_
128-13	27223-27230	further	_
128-14	27231-27245	investigations	_
128-15	27246-27248	in	_
128-16	27249-27250	a	_
128-17	27251-27257	larger	_
128-18	27258-27264	sample	_
128-19	27265-27269	size	_
128-20	27269-27270	.	_

#Text=Abbreviations
#Text=ANOVA
#Text=One-way analysis of variance
#Text=CPZ
#Text=Chlorpromazine
#Text=DSM-IV
#Text=Diagnostic and Statistical Manual for Mental Disorders Fourth Edition
#Text=DSST
#Text=Digital Symbol Substitution Test
#Text=FWHM
#Text=Full-width at half-maximum
#Text=GMD
#Text=Gray matter density
#Text=HCs
#Text=Healthy controls
#Text=SANS
#Text=Scale for the Assessment of Negative Symptoms
#Text=SAPS
#Text=Scale for Assessment of Positive Symptoms
#Text=SCID-I/P
#Text=Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition
#Text=SD
#Text=Standard deviation
#Text=SPM8
#Text=Statistical Parametric Mapping 8
#Text=SZ-CD
#Text=Schizophrenia patients with cognitive deficits
#Text=SZ-NCD
#Text=Schizophrenia patients with no cognitive deficits
#Text=VBM
#Text=Voxel-based morphometry
#Text=WAIS_Digit
#Text=The Digit Symbol Substitution Test of the Wechsler Adult Intelligence Scale
#Text=WAIS-CR
#Text=Wechsler Adult Intelligence Scale Chinese Revised
#Text=WAIS-Information
#Text=The information subscale of the Wechsler Adult Intelligence Scale
#Text=Authors’ contributions
#Text=ZL and JL made a substantial contribution to the conception and design of this study.
129-1	27271-27284	Abbreviations	_
129-2	27285-27290	ANOVA	_
129-3	27291-27298	One-way	_
129-4	27299-27307	analysis	_
129-5	27308-27310	of	_
129-6	27311-27319	variance	_
129-7	27320-27323	CPZ	_
129-8	27324-27338	Chlorpromazine	_
129-9	27339-27345	DSM-IV	_
129-10	27346-27356	Diagnostic	_
129-11	27357-27360	and	_
129-12	27361-27372	Statistical	_
129-13	27373-27379	Manual	_
129-14	27380-27383	for	_
129-15	27384-27390	Mental	_
129-16	27391-27400	Disorders	_
129-17	27401-27407	Fourth	_
129-18	27408-27415	Edition	_
129-19	27416-27420	DSST	_
129-20	27421-27428	Digital	_
129-21	27429-27435	Symbol	_
129-22	27436-27448	Substitution	_
129-23	27449-27453	Test	_
129-24	27454-27458	FWHM	_
129-25	27459-27469	Full-width	_
129-26	27470-27472	at	_
129-27	27473-27485	half-maximum	_
129-28	27486-27489	GMD	_
129-29	27490-27494	Gray	_
129-30	27495-27501	matter	_
129-31	27502-27509	density	_
129-32	27510-27513	HCs	_
129-33	27514-27521	Healthy	_
129-34	27522-27530	controls	_
129-35	27531-27535	SANS	_
129-36	27536-27541	Scale	_
129-37	27542-27545	for	_
129-38	27546-27549	the	_
129-39	27550-27560	Assessment	_
129-40	27561-27563	of	_
129-41	27564-27572	Negative	_
129-42	27573-27581	Symptoms	_
129-43	27582-27586	SAPS	_
129-44	27587-27592	Scale	_
129-45	27593-27596	for	_
129-46	27597-27607	Assessment	_
129-47	27608-27610	of	_
129-48	27611-27619	Positive	_
129-49	27620-27628	Symptoms	_
129-50	27629-27635	SCID-I	_
129-51	27635-27636	/	_
129-52	27636-27637	P	_
129-53	27638-27648	Structured	_
129-54	27649-27657	Clinical	_
129-55	27658-27667	Interview	_
129-56	27668-27671	for	_
129-57	27672-27678	DSM-IV	_
129-58	27679-27683	Axis	_
129-59	27684-27685	I	_
129-60	27686-27695	Disorders	_
129-61	27695-27696	,	_
129-62	27697-27704	Patient	_
129-63	27705-27712	Edition	_
129-64	27713-27715	SD	_
129-65	27716-27724	Standard	_
129-66	27725-27734	deviation	_
129-67	27735-27739	SPM8	_
129-68	27740-27751	Statistical	_
129-69	27752-27762	Parametric	_
129-70	27763-27770	Mapping	_
129-71	27771-27772	8	_
129-72	27773-27778	SZ-CD	_
129-73	27779-27792	Schizophrenia	_
129-74	27793-27801	patients	_
129-75	27802-27806	with	_
129-76	27807-27816	cognitive	_
129-77	27817-27825	deficits	_
129-78	27826-27832	SZ-NCD	_
129-79	27833-27846	Schizophrenia	_
129-80	27847-27855	patients	_
129-81	27856-27860	with	_
129-82	27861-27863	no	_
129-83	27864-27873	cognitive	_
129-84	27874-27882	deficits	_
129-85	27883-27886	VBM	_
129-86	27887-27898	Voxel-based	_
129-87	27899-27910	morphometry	_
129-88	27911-27921	WAIS_Digit	_
129-89	27922-27925	The	_
129-90	27926-27931	Digit	_
129-91	27932-27938	Symbol	_
129-92	27939-27951	Substitution	_
129-93	27952-27956	Test	_
129-94	27957-27959	of	_
129-95	27960-27963	the	_
129-96	27964-27972	Wechsler	_
129-97	27973-27978	Adult	_
129-98	27979-27991	Intelligence	_
129-99	27992-27997	Scale	_
129-100	27998-28005	WAIS-CR	_
129-101	28006-28014	Wechsler	_
129-102	28015-28020	Adult	_
129-103	28021-28033	Intelligence	_
129-104	28034-28039	Scale	_
129-105	28040-28047	Chinese	_
129-106	28048-28055	Revised	_
129-107	28056-28072	WAIS-Information	_
129-108	28073-28076	The	_
129-109	28077-28088	information	_
129-110	28089-28097	subscale	_
129-111	28098-28100	of	_
129-112	28101-28104	the	_
129-113	28105-28113	Wechsler	_
129-114	28114-28119	Adult	_
129-115	28120-28132	Intelligence	_
129-116	28133-28138	Scale	_
129-117	28139-28146	Authors	_
129-118	28146-28147	’	_
129-119	28148-28161	contributions	_
129-120	28162-28164	ZL	_
129-121	28165-28168	and	_
129-122	28169-28171	JL	_
129-123	28172-28176	made	_
129-124	28177-28178	a	_
129-125	28179-28190	substantial	_
129-126	28191-28203	contribution	_
129-127	28204-28206	to	_
129-128	28207-28210	the	_
129-129	28211-28221	conception	_
129-130	28222-28225	and	_
129-131	28226-28232	design	_
129-132	28233-28235	of	_
129-133	28236-28240	this	_
129-134	28241-28246	study	_
129-135	28246-28247	.	_

#Text=CC, LZ and JW recruited the participants and completed the clinical assessment.
130-1	28248-28250	CC	_
130-2	28250-28251	,	_
130-3	28252-28254	LZ	_
130-4	28255-28258	and	_
130-5	28259-28261	JW	_
130-6	28262-28271	recruited	_
130-7	28272-28275	the	_
130-8	28276-28288	participants	_
130-9	28289-28292	and	_
130-10	28293-28302	completed	_
130-11	28303-28306	the	_
130-12	28307-28315	clinical	_
130-13	28316-28326	assessment	_
130-14	28326-28327	.	_

#Text=JW managed the data analysis and wrote the first draft of the manuscript.
131-1	28328-28330	JW	_
131-2	28331-28338	managed	_
131-3	28339-28342	the	_
131-4	28343-28347	data	_
131-5	28348-28356	analysis	_
131-6	28357-28360	and	_
131-7	28361-28366	wrote	_
131-8	28367-28370	the	_
131-9	28371-28376	first	_
131-10	28377-28382	draft	_
131-11	28383-28385	of	_
131-12	28386-28389	the	_
131-13	28390-28400	manuscript	_
131-14	28400-28401	.	_

#Text=All authors read and approved the final manuscript.
132-1	28402-28405	All	_
132-2	28406-28413	authors	_
132-3	28414-28418	read	_
132-4	28419-28422	and	_
132-5	28423-28431	approved	_
132-6	28432-28435	the	_
132-7	28436-28441	final	_
132-8	28442-28452	manuscript	_
132-9	28452-28453	.	_

#Text=Ethics approval and consent to participate
#Text=This study required written informed consent from all participants.
133-1	28454-28460	Ethics	_
133-2	28461-28469	approval	_
133-3	28470-28473	and	_
133-4	28474-28481	consent	_
133-5	28482-28484	to	_
133-6	28485-28496	participate	_
133-7	28497-28501	This	_
133-8	28502-28507	study	_
133-9	28508-28516	required	_
133-10	28517-28524	written	_
133-11	28525-28533	informed	_
133-12	28534-28541	consent	_
133-13	28542-28546	from	_
133-14	28547-28550	all	_
133-15	28551-28563	participants	_
133-16	28563-28564	.	_

#Text=Ethics approval was granted by the ethics committee of the Second Xiangya Hospital, Central South University, Hunan, China.
134-1	28565-28571	Ethics	_
134-2	28572-28580	approval	_
134-3	28581-28584	was	_
134-4	28585-28592	granted	_
134-5	28593-28595	by	_
134-6	28596-28599	the	_
134-7	28600-28606	ethics	_
134-8	28607-28616	committee	_
134-9	28617-28619	of	_
134-10	28620-28623	the	_
134-11	28624-28630	Second	_
134-12	28631-28638	Xiangya	_
134-13	28639-28647	Hospital	_
134-14	28647-28648	,	_
134-15	28649-28656	Central	_
134-16	28657-28662	South	_
134-17	28663-28673	University	_
134-18	28673-28674	,	_
134-19	28675-28680	Hunan	_
134-20	28680-28681	,	_
134-21	28682-28687	China	_
134-22	28687-28688	.	_

#Text=Consent for publication
#Text=Not applicable.
135-1	28689-28696	Consent	_
135-2	28697-28700	for	_
135-3	28701-28712	publication	_
135-4	28713-28716	Not	_
135-5	28717-28727	applicable	_
135-6	28727-28728	.	_

#Text=Competing interests
#Text=The authors declare that they have no competing interests.
136-1	28729-28738	Competing	_
136-2	28739-28748	interests	_
136-3	28749-28752	The	_
136-4	28753-28760	authors	_
136-5	28761-28768	declare	_
136-6	28769-28773	that	_
136-7	28774-28778	they	_
136-8	28779-28783	have	_
136-9	28784-28786	no	_
136-10	28787-28796	competing	_
136-11	28797-28806	interests	_
136-12	28806-28807	.	_

#Text=Publisher’s Note
#Text=Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
137-1	28808-28817	Publisher	_
137-2	28817-28818	’	_
137-3	28818-28819	s	_
137-4	28820-28824	Note	_
137-5	28825-28833	Springer	_
137-6	28834-28840	Nature	_
137-7	28841-28848	remains	_
137-8	28849-28856	neutral	_
137-9	28857-28861	with	_
137-10	28862-28868	regard	_
137-11	28869-28871	to	_
137-12	28872-28886	jurisdictional	_
137-13	28887-28893	claims	_
137-14	28894-28896	in	_
137-15	28897-28906	published	_
137-16	28907-28911	maps	_
137-17	28912-28915	and	_
137-18	28916-28929	institutional	_
137-19	28930-28942	affiliations	_
137-20	28942-28943	.	_

#Text=References
#Text=Rethinking schizophrenia
#Text=Cognitive effects of adjunctive N-acetyl cysteine in psychosis
#Text=Neural mechanisms of mismatch negativity (MMN) dysfunction in schizophrenia
#Text=Functional implications of neuropsychological normality and symptom remission in older outpatients diagnosed with schizophrenia: a cross-sectional study
#Text=Neuropsychological near normality and brain structure abnormality in schizophrenia
#Text=Neural correlates of cognitive impairment in schizophrenia
#Text=White matter integrity and cognitive impairment in first-episode psychosis
#Text=Mapping gray matter reductions in schizophrenia: an anatomical likelihood estimation analysis of voxel-based morphometry studies
#Text=Brain structure biomarkers in the psychosis biotypes: findings from the bipolar-schizophrenia network for intermediate phenotypes
#Text=Effective connectivity of the posterior cingulate and medial prefrontal cortices relates to working memory impairment in schizophrenic and bipolar patients
#Text=Ineffecient DMN suppression in schizophrenia patients with impaired cognitive function but not patients with preserved cognitive function
#Text=Mwansisya TE, Wang Z, Tao HJ, Zhang HR, Hu AM, Guo SX et al.
138-1	28944-28954	References	_
138-2	28955-28965	Rethinking	_
138-3	28966-28979	schizophrenia	_
138-4	28980-28989	Cognitive	_
138-5	28990-28997	effects	_
138-6	28998-29000	of	_
138-7	29001-29011	adjunctive	_
138-8	29012-29020	N-acetyl	_
138-9	29021-29029	cysteine	_
138-10	29030-29032	in	_
138-11	29033-29042	psychosis	_
138-12	29043-29049	Neural	_
138-13	29050-29060	mechanisms	_
138-14	29061-29063	of	_
138-15	29064-29072	mismatch	_
138-16	29073-29083	negativity	_
138-17	29084-29085	(	_
138-18	29085-29088	MMN	_
138-19	29088-29089	)	_
138-20	29090-29101	dysfunction	_
138-21	29102-29104	in	_
138-22	29105-29118	schizophrenia	_
138-23	29119-29129	Functional	_
138-24	29130-29142	implications	_
138-25	29143-29145	of	_
138-26	29146-29164	neuropsychological	_
138-27	29165-29174	normality	_
138-28	29175-29178	and	_
138-29	29179-29186	symptom	_
138-30	29187-29196	remission	_
138-31	29197-29199	in	_
138-32	29200-29205	older	_
138-33	29206-29217	outpatients	_
138-34	29218-29227	diagnosed	_
138-35	29228-29232	with	_
138-36	29233-29246	schizophrenia	_
138-37	29246-29247	:	_
138-38	29248-29249	a	_
138-39	29250-29265	cross-sectional	_
138-40	29266-29271	study	_
138-41	29272-29290	Neuropsychological	_
138-42	29291-29295	near	_
138-43	29296-29305	normality	_
138-44	29306-29309	and	_
138-45	29310-29315	brain	_
138-46	29316-29325	structure	_
138-47	29326-29337	abnormality	_
138-48	29338-29340	in	_
138-49	29341-29354	schizophrenia	_
138-50	29355-29361	Neural	_
138-51	29362-29372	correlates	_
138-52	29373-29375	of	_
138-53	29376-29385	cognitive	_
138-54	29386-29396	impairment	_
138-55	29397-29399	in	_
138-56	29400-29413	schizophrenia	_
138-57	29414-29419	White	_
138-58	29420-29426	matter	_
138-59	29427-29436	integrity	_
138-60	29437-29440	and	_
138-61	29441-29450	cognitive	_
138-62	29451-29461	impairment	_
138-63	29462-29464	in	_
138-64	29465-29478	first-episode	_
138-65	29479-29488	psychosis	_
138-66	29489-29496	Mapping	_
138-67	29497-29501	gray	_
138-68	29502-29508	matter	_
138-69	29509-29519	reductions	_
138-70	29520-29522	in	_
138-71	29523-29536	schizophrenia	_
138-72	29536-29537	:	_
138-73	29538-29540	an	_
138-74	29541-29551	anatomical	_
138-75	29552-29562	likelihood	_
138-76	29563-29573	estimation	_
138-77	29574-29582	analysis	_
138-78	29583-29585	of	_
138-79	29586-29597	voxel-based	_
138-80	29598-29609	morphometry	_
138-81	29610-29617	studies	_
138-82	29618-29623	Brain	_
138-83	29624-29633	structure	_
138-84	29634-29644	biomarkers	_
138-85	29645-29647	in	_
138-86	29648-29651	the	_
138-87	29652-29661	psychosis	_
138-88	29662-29670	biotypes	_
138-89	29670-29671	:	_
138-90	29672-29680	findings	_
138-91	29681-29685	from	_
138-92	29686-29689	the	_
138-93	29690-29711	bipolar-schizophrenia	_
138-94	29712-29719	network	_
138-95	29720-29723	for	_
138-96	29724-29736	intermediate	_
138-97	29737-29747	phenotypes	_
138-98	29748-29757	Effective	_
138-99	29758-29770	connectivity	_
138-100	29771-29773	of	_
138-101	29774-29777	the	_
138-102	29778-29787	posterior	_
138-103	29788-29797	cingulate	_
138-104	29798-29801	and	_
138-105	29802-29808	medial	_
138-106	29809-29819	prefrontal	_
138-107	29820-29828	cortices	_
138-108	29829-29836	relates	_
138-109	29837-29839	to	_
138-110	29840-29847	working	_
138-111	29848-29854	memory	_
138-112	29855-29865	impairment	_
138-113	29866-29868	in	_
138-114	29869-29882	schizophrenic	_
138-115	29883-29886	and	_
138-116	29887-29894	bipolar	_
138-117	29895-29903	patients	_
138-118	29904-29915	Ineffecient	_
138-119	29916-29919	DMN	_
138-120	29920-29931	suppression	_
138-121	29932-29934	in	_
138-122	29935-29948	schizophrenia	_
138-123	29949-29957	patients	_
138-124	29958-29962	with	_
138-125	29963-29971	impaired	_
138-126	29972-29981	cognitive	_
138-127	29982-29990	function	_
138-128	29991-29994	but	_
138-129	29995-29998	not	_
138-130	29999-30007	patients	_
138-131	30008-30012	with	_
138-132	30013-30022	preserved	_
138-133	30023-30032	cognitive	_
138-134	30033-30041	function	_
138-135	30042-30051	Mwansisya	_
138-136	30052-30054	TE	_
138-137	30054-30055	,	_
138-138	30056-30060	Wang	_
138-139	30061-30062	Z	_
138-140	30062-30063	,	_
138-141	30064-30067	Tao	_
138-142	30068-30070	HJ	_
138-143	30070-30071	,	_
138-144	30072-30077	Zhang	_
138-145	30078-30080	HR	_
138-146	30080-30081	,	_
138-147	30082-30084	Hu	_
138-148	30085-30087	AM	_
138-149	30087-30088	,	_
138-150	30089-30092	Guo	_
138-151	30093-30095	SX	_
138-152	30096-30098	et	_
138-153	30099-30101	al	_
138-154	30101-30102	.	_

#Text=The diminished interhemispheric connectivity correlates with negative symptoms and cognitive impairment in first-episode schizophrenia.
139-1	30103-30106	The	_
139-2	30107-30117	diminished	_
139-3	30118-30134	interhemispheric	_
139-4	30135-30147	connectivity	_
139-5	30148-30158	correlates	_
139-6	30159-30163	with	_
139-7	30164-30172	negative	_
139-8	30173-30181	symptoms	_
139-9	30182-30185	and	_
139-10	30186-30195	cognitive	_
139-11	30196-30206	impairment	_
139-12	30207-30209	in	_
139-13	30210-30223	first-episode	_
139-14	30224-30237	schizophrenia	_
139-15	30237-30238	.	_

#Text=Schizophr Res. 2013;150(1):144-50.
140-1	30239-30248	Schizophr	_
140-2	30249-30252	Res	_
140-3	30252-30253	.	_
140-4	30254-30258	2013	_
140-5	30258-30259	;	_
140-6	30259-30262	150	_
140-7	30262-30263	(	_
140-8	30263-30264	1	_
140-9	30264-30265	)	_
140-10	30265-30266	:	_
140-11	30266-30269	144	_
140-12	30269-30270	-	_
140-13	30270-30272	50	_
140-14	30272-30273	.	_

#Text=Stoodley CJ, Valera EM, Schmahmann JD.
141-1	30274-30282	Stoodley	_
141-2	30283-30285	CJ	_
141-3	30285-30286	,	_
141-4	30287-30293	Valera	_
141-5	30294-30296	EM	_
141-6	30296-30297	,	_
141-7	30298-30308	Schmahmann	_
141-8	30309-30311	JD	_
141-9	30311-30312	.	_

#Text=Functional topography of the cerebellum for motor and cognitive tasks:an fMRI study.
142-1	30313-30323	Functional	_
142-2	30324-30334	topography	_
142-3	30335-30337	of	_
142-4	30338-30341	the	_
142-5	30342-30352	cerebellum	_
142-6	30353-30356	for	_
142-7	30357-30362	motor	_
142-8	30363-30366	and	_
142-9	30367-30376	cognitive	_
142-10	30377-30382	tasks	_
142-11	30382-30383	:	_
142-12	30383-30385	an	_
142-13	30386-30390	fMRI	_
142-14	30391-30396	study	_
142-15	30396-30397	.	_

#Text=Neuroimage. 2012;59(2):1560–70.
143-1	30398-30408	Neuroimage	_
143-2	30408-30409	.	_
143-3	30410-30414	2012	_
143-4	30414-30415	;	_
143-5	30415-30417	59	_
143-6	30417-30418	(	_
143-7	30418-30419	2	_
143-8	30419-30420	)	_
143-9	30420-30421	:	_
143-10	30421-30425	1560	_
143-11	30425-30426	–	_
143-12	30426-30428	70	_
143-13	30428-30429	.	_

#Text=Schmahmann JD, Caplan D.
144-1	30430-30440	Schmahmann	_
144-2	30441-30443	JD	_
144-3	30443-30444	,	_
144-4	30445-30451	Caplan	_
144-5	30452-30453	D	_
144-6	30453-30454	.	_

#Text=Cognition, emotion and the cerebellum.
145-1	30455-30464	Cognition	_
145-2	30464-30465	,	_
145-3	30466-30473	emotion	_
145-4	30474-30477	and	_
145-5	30478-30481	the	_
145-6	30482-30492	cerebellum	_
145-7	30492-30493	.	_

#Text=Brain. 2006;129(2):290–2.
146-1	30494-30499	Brain	_
146-2	30499-30500	.	_
146-3	30501-30505	2006	_
146-4	30505-30506	;	_
146-5	30506-30509	129	_
146-6	30509-30510	(	_
146-7	30510-30511	2	_
146-8	30511-30512	)	_
146-9	30512-30513	:	_
146-10	30513-30516	290	_
146-11	30516-30517	–	_
146-12	30517-30518	2	_
146-13	30518-30519	.	_

#Text=The role of the cerebellum in schizophrenia
#Text=Cerebellar grey matter deficits in first-episode schizophrenia mapped using cortical pattern matching
#Text=Et al.Stable signatures of schizophrenia in the cortical–subcortical–cerebellar network using fMRI of verbal working memory
#Text=Sexual dimorphism of the cerebellar vermis in schizophrenia
#Text=Cerebellar deficits in schizophrenia are associated with executive dysfuntion
#Text=Cerebellar granule cells encode the expectation of reward
#Text=Superior temporal gyrus thickness correlates with cognitive performance in multiple sclerosis
#Text=Cognitive impairment and gray matter volume abnormalities in silent cerebral infarction
#Text=Structural gray matter differences between first-episode schizophrenics and normal controls using voxel-based morphometry
#Text=Sustained attention impairment correlates to gray matter decreases in first episode neuroleptic-naive schizophrenic patients
#Text=Cerebral grey, white matter and csf in never-medicated, first-episode schizophrenia
#Text=Meta-analysis of gray matter anomalies in schizophrenia: application of anatomic likelihood estimation and network analysis
#Text=Increased parahippocampal and lingual gyrification in first-episode schizophrenia
#Text=Grey matter morphological anomalies in the caudate head in first-episode psychosis patients with delusions of reference
#Text=Dynamic gray matter changes within cortex and striatum after short motor skill training are associated with their increased functional interaction
#Text=Acute aerobic exercise increases cortical activity during working memory: a functional MRI study in female college students
147-1	30520-30523	The	_
147-2	30524-30528	role	_
147-3	30529-30531	of	_
147-4	30532-30535	the	_
147-5	30536-30546	cerebellum	_
147-6	30547-30549	in	_
147-7	30550-30563	schizophrenia	_
147-8	30564-30574	Cerebellar	_
147-9	30575-30579	grey	_
147-10	30580-30586	matter	_
147-11	30587-30595	deficits	_
147-12	30596-30598	in	_
147-13	30599-30612	first-episode	_
147-14	30613-30626	schizophrenia	_
147-15	30627-30633	mapped	_
147-16	30634-30639	using	_
147-17	30640-30648	cortical	_
147-18	30649-30656	pattern	_
147-19	30657-30665	matching	_
147-20	30666-30668	Et	_
147-21	30669-30678	al.Stable	_
147-22	30679-30689	signatures	_
147-23	30690-30692	of	_
147-24	30693-30706	schizophrenia	_
147-25	30707-30709	in	_
147-26	30710-30713	the	_
147-27	30714-30745	cortical–subcortical–cerebellar	_
147-28	30746-30753	network	_
147-29	30754-30759	using	_
147-30	30760-30764	fMRI	_
147-31	30765-30767	of	_
147-32	30768-30774	verbal	_
147-33	30775-30782	working	_
147-34	30783-30789	memory	_
147-35	30790-30796	Sexual	_
147-36	30797-30807	dimorphism	_
147-37	30808-30810	of	_
147-38	30811-30814	the	_
147-39	30815-30825	cerebellar	_
147-40	30826-30832	vermis	_
147-41	30833-30835	in	_
147-42	30836-30849	schizophrenia	_
147-43	30850-30860	Cerebellar	_
147-44	30861-30869	deficits	_
147-45	30870-30872	in	_
147-46	30873-30886	schizophrenia	_
147-47	30887-30890	are	_
147-48	30891-30901	associated	_
147-49	30902-30906	with	_
147-50	30907-30916	executive	_
147-51	30917-30927	dysfuntion	_
147-52	30928-30938	Cerebellar	_
147-53	30939-30946	granule	_
147-54	30947-30952	cells	_
147-55	30953-30959	encode	_
147-56	30960-30963	the	_
147-57	30964-30975	expectation	_
147-58	30976-30978	of	_
147-59	30979-30985	reward	_
147-60	30986-30994	Superior	_
147-61	30995-31003	temporal	_
147-62	31004-31009	gyrus	_
147-63	31010-31019	thickness	_
147-64	31020-31030	correlates	_
147-65	31031-31035	with	_
147-66	31036-31045	cognitive	_
147-67	31046-31057	performance	_
147-68	31058-31060	in	_
147-69	31061-31069	multiple	_
147-70	31070-31079	sclerosis	_
147-71	31080-31089	Cognitive	_
147-72	31090-31100	impairment	_
147-73	31101-31104	and	_
147-74	31105-31109	gray	_
147-75	31110-31116	matter	_
147-76	31117-31123	volume	_
147-77	31124-31137	abnormalities	_
147-78	31138-31140	in	_
147-79	31141-31147	silent	_
147-80	31148-31156	cerebral	_
147-81	31157-31167	infarction	_
147-82	31168-31178	Structural	_
147-83	31179-31183	gray	_
147-84	31184-31190	matter	_
147-85	31191-31202	differences	_
147-86	31203-31210	between	_
147-87	31211-31224	first-episode	_
147-88	31225-31239	schizophrenics	_
147-89	31240-31243	and	_
147-90	31244-31250	normal	_
147-91	31251-31259	controls	_
147-92	31260-31265	using	_
147-93	31266-31277	voxel-based	_
147-94	31278-31289	morphometry	_
147-95	31290-31299	Sustained	_
147-96	31300-31309	attention	_
147-97	31310-31320	impairment	_
147-98	31321-31331	correlates	_
147-99	31332-31334	to	_
147-100	31335-31339	gray	_
147-101	31340-31346	matter	_
147-102	31347-31356	decreases	_
147-103	31357-31359	in	_
147-104	31360-31365	first	_
147-105	31366-31373	episode	_
147-106	31374-31391	neuroleptic-naive	_
147-107	31392-31405	schizophrenic	_
147-108	31406-31414	patients	_
147-109	31415-31423	Cerebral	_
147-110	31424-31428	grey	_
147-111	31428-31429	,	_
147-112	31430-31435	white	_
147-113	31436-31442	matter	_
147-114	31443-31446	and	_
147-115	31447-31450	csf	_
147-116	31451-31453	in	_
147-117	31454-31469	never-medicated	_
147-118	31469-31470	,	_
147-119	31471-31484	first-episode	_
147-120	31485-31498	schizophrenia	_
147-121	31499-31512	Meta-analysis	_
147-122	31513-31515	of	_
147-123	31516-31520	gray	_
147-124	31521-31527	matter	_
147-125	31528-31537	anomalies	_
147-126	31538-31540	in	_
147-127	31541-31554	schizophrenia	_
147-128	31554-31555	:	_
147-129	31556-31567	application	_
147-130	31568-31570	of	_
147-131	31571-31579	anatomic	_
147-132	31580-31590	likelihood	_
147-133	31591-31601	estimation	_
147-134	31602-31605	and	_
147-135	31606-31613	network	_
147-136	31614-31622	analysis	_
147-137	31623-31632	Increased	_
147-138	31633-31648	parahippocampal	_
147-139	31649-31652	and	_
147-140	31653-31660	lingual	_
147-141	31661-31673	gyrification	_
147-142	31674-31676	in	_
147-143	31677-31690	first-episode	_
147-144	31691-31704	schizophrenia	_
147-145	31705-31709	Grey	_
147-146	31710-31716	matter	_
147-147	31717-31730	morphological	_
147-148	31731-31740	anomalies	_
147-149	31741-31743	in	_
147-150	31744-31747	the	_
147-151	31748-31755	caudate	_
147-152	31756-31760	head	_
147-153	31761-31763	in	_
147-154	31764-31777	first-episode	_
147-155	31778-31787	psychosis	_
147-156	31788-31796	patients	_
147-157	31797-31801	with	_
147-158	31802-31811	delusions	_
147-159	31812-31814	of	_
147-160	31815-31824	reference	_
147-161	31825-31832	Dynamic	_
147-162	31833-31837	gray	_
147-163	31838-31844	matter	_
147-164	31845-31852	changes	_
147-165	31853-31859	within	_
147-166	31860-31866	cortex	_
147-167	31867-31870	and	_
147-168	31871-31879	striatum	_
147-169	31880-31885	after	_
147-170	31886-31891	short	_
147-171	31892-31897	motor	_
147-172	31898-31903	skill	_
147-173	31904-31912	training	_
147-174	31913-31916	are	_
147-175	31917-31927	associated	_
147-176	31928-31932	with	_
147-177	31933-31938	their	_
147-178	31939-31948	increased	_
147-179	31949-31959	functional	_
147-180	31960-31971	interaction	_
147-181	31972-31977	Acute	_
147-182	31978-31985	aerobic	_
147-183	31986-31994	exercise	_
147-184	31995-32004	increases	_
147-185	32005-32013	cortical	_
147-186	32014-32022	activity	_
147-187	32023-32029	during	_
147-188	32030-32037	working	_
147-189	32038-32044	memory	_
147-190	32044-32045	:	_
147-191	32046-32047	a	_
147-192	32048-32058	functional	_
147-193	32059-32062	MRI	_
147-194	32063-32068	study	_
147-195	32069-32071	in	_
147-196	32072-32078	female	_
147-197	32079-32086	college	_
147-198	32087-32095	students	_
